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Abstract 
The prevalence of diabetes is rising globally and, as a result, its associated complications 
are also rising. Painful diabetic neuropathy (PDN) is a well-known complication of 
diabetes and the most common cause of all neuropathic pain. About one-third of all 
diabetes patients suffer from PDN. The reported prevalence of PDN varies from 11% in 
Rochester, Minnesota, USA to 53.7% in the Middle East. One UK study, published in 
2011, reported that the prevalence of PDN was 21.5% in type 2 diabetes patients and 
13.4% in type 1 diabetes patients, resulting in an overall prevalence of 21%. Numerous 
studies have found cardiovascular risk factors—including increased age, longer duration 
of diabetes, higher weight, smoking, poor glycaemic control, renal impairment and high 
cholesterol—to be associated with PDN. This disorder has a huge effect on people’s daily 
lives both physically and mentally. Despite huge advances in medicine, the treatment of 
PDN is both challenging for physicians and distressing for patients. In this thesis, three 
studies were carried out on the following topics: prevalence and characteristics of painful 
diabetic neuropathy, PDN patients’ quality of life, and treatment employing lignocaine. 
This first study assessed the prevalence of painful diabetic neuropathy (PDN) and its 
relationship with various cardiovascular characteristics in diabetes subjects. This was 
done through an observational study of diabetes subjects in Northwest England, UK (n 
=204). The self-completed Leeds Assessment of Neuropathic Symptoms and Signs 
questionnaire was sent by post to the subjects and used to diagnose PDN. Consent for 
participation and access to blood results was given by the study participants. Ethical 
approval for the study was also granted by National Research Ethics Committee UK.  The 
results of the study showed that the crude prevalence of PDN among subjects was 30.3%. 
The prevalence of type 2 diabetes subjects was higher (33.1 %) than that of type 1 diabetes 
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subjects (14.1%).  There was a significant association of obesity, smoking and height in 
males with PDN compared to the non-PDN group (P <0.05). The results also showed a 
significant trend of increasing PDN prevalence with duration of diabetes, increasing 
HbA1c and increasing BMI (P<0.05). There was a trend of increasing prevalence with 
age as well (P>0.05); however, due to the small sample size, the data was not statistically 
significant. There was no relationship of PDN with systolic or diastolic blood pressure, 
nephropathy, alcohol intake or blood cholesterol (P>0.05). These results highlight the 
importance of better control of modifiable factors, including smoking, glycaemic control 
(HbA1c) and obesity. 
The second study assessed the impact of painful diabetic neuropathy on quality of life 
(QoL), mood and anxiety by comparing patients suffering from painful diabetic 
neuropathy (PDN group) with diabetes patients not known to have PDN (control group, 
C). The study used short form (SF) 36 and Hospital Anxiety and Depression Scale (HADS 
Scale) questionnaires. For the PDN group, 25 adult subjects (mean age 56, standard 
deviation (SD) +/- 11 years, male 15, female 10) were randomly selected from patients 
attending the painful diabetes neuropathy clinic at Chorley Hospital. For the control 
group, 25 adult diabetic subjects (mean age 56, SD +/- 14 years, male 14, female 9) were 
randomly selected from patients undergoing General Practitioner Surgery. Both groups 
completed the HADS and SF36 questionnaires. Subjects in the PDN group had 
significantly lower SF36 summary scores in both the physical health (P ˂0.0001) and 
mental health domains (P= 0.026) compared with the C group. HADS data showed that 
56% subjects in the PDN group could be diagnosed anxiety compared to only 20% in the 
C group (P=0.018); and 60% of the PDN group received the diagnosis of depression 
compare to 44% in the C group (P=0.396). The results also show that PDN was 
significantly associated with impaired QoL, both physically (p<0.0001) and mentally 
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(p<0.026). Anxiety was significantly associated with the PDN group compared to control 
(p<0.018), and depression was 16% more prevalent in PDN group than in the control 
group. 
The final study assessed the efficacy of lignocaine infusion as a treatment for PDN in 
challenging cases where conventional treatment had not helped. A total 11 patients 
participated; 7 patients were referred from the pain clinic (non-PDN group), and 4 were 
referred from the foot clinic (PDN group). All were given lignocaine infusion as a 
treatment for chronic pain. Participants from both groups were on multiple pain 
medications with minimal results. All participants gave consent for participation and 
filled out a McGill short form (SF) questionnaire before and after lignocaine infusion. 
The results showed a 33% reduction in the visual analogue pain score after lignocaine 
infusion in PDN group compared to an 11% reduction in the non-PDN group. The data 
were statistically significant (P<0.05). Similarly, there was significant (p<0.05) 
reduction of affective pain score: 41% after lignocaine infusion in PDN group, compared 
to 21% in non-PDN group.  In contrast, no significant difference was seen between groups 
for the sensory pain score reduction after lignocaine infusion: 23% in PDN group 
compared to 17% in non-PDN group (P>0.05). None of the 11 patients reported adverse 
effects from the treatment and their observations were within normal limits throughout 
the lignocaine infusion. Overall, the study showed that lignocaine infusion is effective 
and safe in reducing the chronic intractable pain when conventional treatments are 
intolerable or unhelpful. The treatment is also more effective for painful diabetic 
neuropathy than for other forms of chronic pain.   
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1.1 Diabetes Mellitus 
 
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycaemia 
due to either a lack of insulin or the presence of factors opposing insulin’s actions (Harris 
& Zimmet, 1997). DM is a common health condition worldwide, and there are currently 
about 2.9 million people diagnosed with diabetes in the UK. Its prevalence is also rising; 
in the UK in 2006, prevalence of DM was 3.54% and currently the figure is at 4.6%. It 
has been estimated that by the end of 2025, about 4 million people in the UK will be 
suffering from diabetes (Diabetes.uk.org, 2013). DM has huge impact on conferring 
increased risk for macrovascular complications such as cardiovascular disease 
(myocardial infarction, peripheral vascular disease & stroke) and microvascular 
complications such as neuropathy, nephropathy, retinopathy and erectile dysfunction 
(Turner & Wass, 2009) 
 
Diabetes was first described by Indian physicians in 1500 BC as “honey urine,” 
after they noted that ants were attract by the urine of these patients. The name Diabetes 
Mellitus was given by Greek physician Apollonius of Memphis, with diabetes meaning 
‘siphon’ (movement of fluid due to change in pressure) and mellitus meaning ‘sugar’. 
Together, these describe the hallmark symptoms of uncontrolled diabetes, including 
hyperglycaemia with osmotic symptoms of polyuria and polydipsia. Type 1 and type 2 
diabetes were first identified as a separate conditions in 400-500 CE by Indian physicians 
who noted the association of type 1 with young individuals and type 2 with middle aged 
obese (Poretsky, 2009). In the 18th century, Cawley linked diabetes with the pancreas 
(Cawley, 1788). In 1921, Banting and Best discovered insulin (Banting, 1942). After the 
discovery of insulin, the life expectancy of diabetes patients dramatically improved. Due 
to a better understanding of disease and advances in pharmacological treatments, diabetes 
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is now much better controlled. As a result people, are living longer with the long-term 
complications of diabetes, which include cardiovascular disease, nephropathy, 
retinopathy, erectile dysfunction and neuropathy. 
 
1.1.1 Type 1 and Type 2 Diabetes  
Type I, or Insulin-Dependent Diabetes Mellitus (IDDM), is caused by the deficiency of 
insulin. The onset of type 1 DM is typically during childhood and its pathogenesis 
involves environmental triggers that may activate autoimmune mechanisms in genetically 
susceptible individuals, leading to progressive loss of pancreatic islet  cells (Harrison et 
al., 1999). Islet cell antibodies are present in most patients and are a diagnostic criterion 
of type 1 DM; however, these disappear over time. Other antibodies to specific proteins 
have recently been identified: these include antibodies to glutamic acid decarboxylase 
and tyrosine phosphatase.  The presence of these antibodies in a non-diabetic individual 
indicates an 88% chance of developing diabetes within 10 years (Zimmet et al., 2001).   
Type 2, or Non-Insulin-Dependent Diabetes Mellitus (NIDDM), is associated 
with insulin resistance and obesity, in which target tissues fail to respond appropriately 
to insulin. Typically, the onset of this disease occurs in adulthood.  In some patients, the 
insulin receptor is abnormal, while in others, one or more aspects of insulin signalling are 
defective. And in another group of DM patients, no defect has been identified.  For most 
patients, insulin release is not usually impaired (at least initially) and insulin injections 
are therefore not useful for therapy. Rather, the disease is controlled through dietary 
therapy and hypoglycaemic agents (Harris & Zimmet, 1997; Moller, 2001; Zimmet et al., 
2001 ;  Kumar & Clark, 2002).  
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1.1.2 Sign and Symptoms 
The symptoms of diabetes mellitus are similar in both types of diabetes, including non-
specific symptoms such as tiredness, fatigue, and as well as more specific osmotic 
symptoms such as polyuria, polydipsia, and blurred vision. Because of the total lack of 
insulin in type 1 DM, symptoms progress rapidly and more severely with the presence of 
diabetic ketoacidosis (DKA) (Alterman, 1997; Kumar & Clark, 2002). Longstanding 
undiagnosed diabetes sometime present with the complications of DM, such as a 
cardiovascular event (ischaemic heart disease, stroke), renal failure (chronic kidney 
disease), visual impairment (retinopathy), erectile dysfunction, foot ulcers & pain in legs 
(neuropathy) (Kumar & Clark, 2002 ; Bracken et al., 2003 ; Fallow& Singh, 2004). 
 
1.1.3 Diagnosis of diabetes 
Traditionally, a fasting blood glucose (FBG) level above 7 mmol/litre, random blood 
glucose (RBG) above 11 mmol/litre, or a two-hour oral glucose tolerance test (OGTT) 
above 11mmol/litre have been used to diagnose diabetes (NICE, 2009 & SIGN 2010). In 
2011, the World Health Organization introduced HbA1c for the detection of DM, with a 
cut-off 48 mmol/mol.  To confirm the diagnoses of diabetes, the physician needs any two 
abnormal readings of FBG, RBG or HbA1c 2 weeks apart, or any one abnormal reading 
with osmotic symptoms of polyuria, polydipsia and visual disturbance.  
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1.1.4 Macrovascular complications of diabetes  
Diabetes mellitus is a major risk factor for the formation of atherosclerosis, which causes 
the narrowing and hardening of blood vessels and leads to the development of 
cardiovascular disease (CVD) including myocardial infarction, stroke and peripheral 
vascular disease. As a result, people with diabetes have an increased risk of cardiovascular 
disease compared to the general population. CVD is a major cause of death and disability 
in people with diabetes, accounting for 44% of fatalities in people with type 1 diabetes 
and 52% of deaths in people with type 2 diabetes (Diabetes.uk.org, 2013). Stroke is twice 
as likely to occur if a person has diabetes, and myocardial infarction is 3–5 times as likely. 
Peripheral vascular disease can lead to gangrene and amputation, and is 50 times more 
likely in a person with diabetes (Kumar & Clark, 2002). 
 
1.1.5 Chronic microvascular complications of diabetes  
Diabetes mellitus with chronic uncontrolled hyperglycaemia has a direct effect on small 
blood vessels. As a result, it causes microvascular complications with neuropathy, 
nephropathy, retinopathy and erectile dysfunction (Turner & Wass, 2009). 
Diabetes nephropathy is a well-known microvascular complication of diabetes 
and is the most common cause of end-stage renal disease requiring dialysis (Satirapoj, 
2012). The diagnosis of diabetic nephropathy relies on proteinuria. A urine spot albumin 
& creatinine ratio (ACR) above 2.5 mg/mmol in males and 3.5 mg/mmol in females 
classifies micro-albuminuria—the earliest sign of diabetic nephropathy. Urine proteinuria 
above 300 mg/day or urine spot ACR above 30 suggests a clear diagnosis of diabetic 
nephropathy (SIGN, 2010; CKS nephropathy, 2013). Research has shown a strong 
20 
 
correlation between micro-albuminuria and cardiovascular events (Viana et al., 2012).   A 
Cochrane review by Strippoli et al. (2006) showed that the angiotensin converting 
enzyme (ACE) inhibitor are the drugs of choice for preventing the progression of diabetic 
kidney disease. These drugs are also recommended by Scottish Intercollegiate Guidelines 
Network (SIGN) and National Institute for Health and Care Excellence (NICE) even with 
normal creatinine levels and eGFR. If there is evidence of micro or macro albuminuria, 
the patient needs to commence treatment with an ACE inhibitor as soon as possible. Also, 
as there is a strong relationship between micro-albuminuria and cardiovascular events. 
Blood pressure needs to be optimized at target levels of 130/80 mm of Hg.  
Diabetic retinopathy is another well-known microvascular complication of 
diabetes. It is estimated that, in England, there are 1,280 new cases of blindness every 
year, with 4,200 people are at risk for blindness caused by diabetic retinopathy (Diabetic 
eye screening UK, 2012). The United Kingdom Prospective Diabetes study (UKPDS) 
emphasized the importance of controlling both blood glucose and blood pressure in order 
to minimise the risk of developing sight-threatening retinopathy (Kohner, 2008).  
Diabetic neuropathy affects 8.3% to 60% (Shaw & Hodge 1998, Boru et al., 2004) 
of all diabetic patients. It presents as a feeling of numbness in symmetrical stocking-glove 
pattern, with the involvement of distal peripheral nerves. Because of the lack of sensation, 
subjects are not aware of stepping on sharp objects, having a cut or blister, or touching 
something too hot or cold. Complications of diabetic neuropathy include pain, ulcers, 
infections and amputation (Tesfaye and Boulton, 2009).  NICE (2009) and SIGN (2010) 
recommend feet examination upon diagnosis of diabetes and at least annually, including 
the 10-gram monofilament test for sensation, and searching for ulcers, calluses, 
deformities and pulses.  
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Erectile dysfunction is one of the microvascular complications that result from the 
neurovascular and autonomic neuropathy caused by diabetes. One study found that ED 
was three times more common in patients with diabetes mellitus. Erectile dysfunction in 
diabetes is strongly linked with macro-vascular diabetes complications (Watkins, 2003).  
This thesis focuses mainly on painful diabetic neuropathy (PDN). 
 
1.1.6 Management of diabetes  
The management of diabetes from initial assessment to further review should include the 
following components: 
1. Structured diabetes education 
2. Diet and lifestyle modification 
3. Glucose control 
4. Blood pressure control 
5. Assessment of need for lipid modification therapy 
6. Consideration of whether the person should be taking antithrombotic therapy 
 
 Structured diabetes education  
Structured diabetes education has been shown to lead to significant reduction in HbA1c 
and weight. The UK has in place a dedicated, well-structured programme called Diabetes 
Education and Self-Management for On-going and Newly-diagnosed Diabetes 
(DESMOND). Davies et al. (2008) demonstrated the DESMOND programme’s 
effectiveness in a cluster randomised controlled trial of 824 adults with a diagnosis of 
diabetes. The structured six-hour education programme delivered by two trained health 
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professionals was compared with usual care. At the end of a 12-month follow-up period, 
HbA1c had decreased by 1.49% in the intervention group compared with 1.21% in the 
control group. The programme group also showed a weight reduction of 2.98 Kg, 
compared with 1.86 Kg for controls (P=0.027). A positive association was also found 
between weight loss and a change in perceived personal responsibility at 12 months 
(P=0.008). In sum, the DESMOND programme led to greater improvements in weight 
loss, beliefs about the illness, and reduction in glycated haemoglobin (HbA1c) levels in 
newly diagnosed type 2 diabetes patients up to 12 months after diagnosis.  
Another structured educational programme for diabetes called “X-pert diabetes” 
consists of 6 sessions delivered weekly. The programme focuses on diabetes education, a 
patient-centred approach and self-empowerment. A randomized controlled trial showed 
significant improvement in clinical parameters, lifestyle and psychosocial well-being for 
programme participants with recent onset and long-term diabetes (Deakin et al., 2005).  
Another programme, Dose Adjustment For Normal Eating (DAFNE) is a 
structured diabetes type 1 education programme focused mainly on carbohydrate intake 
control and injected insulin dosage, along with hypoglycaemia awareness and general 
diabetes education. A follow-up study showed significant reduction of HbA1c in program 
participants, as well as improved quality of life at 12-month follow-up (Speight et al., 
2010).  
Diet and lifestyle modification 
Diet and lifestyle changes have been recommended by NICE (2009) and SIGN (2010) as 
the major element of diabetes management. Dyson et al. (2011) explained that lifestyle 
interventions are effective for weight loss, improving glycaemic control and reducing 
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cardiovascular risk in people with type 2 diabetes. Outside of pharmacological and 
surgical interventions, a combination of diet and physical activity is the standard and most 
successful route to achieving weight loss. NICE (2009) and SIGN (2010) recommend that 
people with type 2 DM should aim for 30 minutes of physical activity at least five days a 
week and be provided is the structured dietary advice that may help in the reduction of 
weight and better glycaemic control. Dietary options include simple caloric restriction, 
reducing fat intake, consumption of carbohydrates with low rather than high glycaemic 
index, and restricting the total amount of dietary carbohydrate (a maximum of 50 g per 
day appears safe for up to six months). 
Glucose control 
Glucose control is paramount in the management of diabetes. In type 1 diabetes, the main 
form of glucose control is the commencement of insulin treatment upon diagnosis. In type 
2 DM, the main treatment is oral medication or a combination of oral medications and 
insulin. When to initiate the treatment has been a controversial topic among national 
guidance organizations. NICE (2009) recommends diet and lifestyle modifications for the 
first 3 months, and if a target HbA1c of < 48 mmol/mol is not achieved then the oral 
medication, metformin, would be started. However, SIGN (2010) suggests offering 
pharmacological treatment from the time of diagnosis, along with diet and lifestyle 
changes. A 10-year follow-up UKPDS looked at 5,102 type 2 DM patients who were 
randomly assigned to either conventional treatment (dietary restriction only) or intensive 
treatment (metformin or sulfonylurea, plus insulin). The HbA1c differences initially seen 
were lost after 1 year of follow-up. In the sulfonylurea-insulin group, relative reductions 
in risk for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, 
P=0.001) persisted at 10 years. Furthermore reductions in risk for myocardial infarction 
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(15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time. In the 
metformin group, significant risk reductions persisted for all diabetes-related end points 
(21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, 
P=0.002). This study concluded that, despite an early loss of glycaemic differences, a 
continued reduction in microvascular risk and emergent risk reductions for myocardial 
infarction and death from any cause were observed during 10 years of post-trial follow-
up. A continued benefit of metformin therapy was evident among patients (Holman et al., 
2008). Therefore, better early control of glycaemia has a long-term effect in the 
prevention of micro- and macro-vascular disease.  
Blood pressure control 
Diabetes is itself a risk factor for cardiovascular events and the UKPDS risk calculator 
shows a direct relationship between hypertension and cardiovascular risks (Stevens et al., 
2001; Kothari et al., 2002). The UKPD study of long term follow-up after tight control of 
blood pressure in type 2 diabetes showed significant relative risk reductions during the 
trial for all diabetes-related end points, diabetes-related death, microvascular disease, and 
stroke in the group receiving tighter blood-pressure control. However, the benefit of 
previous blood pressure control was lost when blood pressure improvements in both 
groups were not sustained during the post-trial follow-up. Thus, the study demonstrated 
the significance of good control of blood pressure in the long term for prevention 
cardiovascular events (Holman et al., 2008). There are several antihypertensive 
medications available to control BP. A Cochrane review showed the effectiveness of ACE 
inhibitors and angiotensin II receptor antagonists for the prevention and the progression 
of diabetic kidney disease alongside the control of blood pressure (Strippoli, 2006). 
Hence, ACE inhibitors are the drugs of choice for treating hypertension in diabetes. 
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Lipid lowering medication 
Hypercholesterolemia is one of the known risk factors for cardiovascular disease (Stevens 
et al., 2001; Kothari et al., 2002). Hence, lowering the cholesterol levels should lower the 
cardiovascular risk. Both NICE (2009) and SIGN (2010) advise the anti-lipid treatment 
simvastatin 40 mg for pre-existing cardiovascular disease. If the patient is on anti-lipid 
treatment, the target is a total serum cholesterol of <4.0 mmol/litre and LDL of <2.0 
mmol/litre. According to SIGN (2010), for primary prevention, all diabetes patients above 
the age of 40 should be on statins. 
Antiplatelet therapy in diabetes  
Anti-platelet therapy has been shown to have clear benefits in reducing cardiovascular 
risk. Traditionally, it has been used both for primary and secondary prevention in 
diabetes. However, recent randomized controlled trials showed benefits only in secondary 
prevention; for primary prevention, the trials did not show a reduction of cardiovascular 
death. At the same time, there is increasing evidence of GI bleeding caused by aspirin. It 
has thus been concluded that aspirin is not effective in the primary prevention of 
cardiovascular disease (De Berardis et al., 2009; Sacco et al., 2003). SIGN 2010 also 
suggests not to use Aspirin for primary prevention in diabetes. 
As this thesis focuses mainly on PDN, the rest of this chapter will discuss the 
details of the pathogenesis and treatment of PDN. 
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1.2 Painful diabetic neuropathy (PDN) 
Diabetic Neuropathy (DN) is a well-known long-term complication of diabetes that can 
cause significant morbidity and mortality (Tapp and Shaw, 2009), and may affect up to 
50% of diabetic population (Vinik et al., 1994). DN encompasses variety of clinical and 
sub clinical presentations depending on the involvement of sensory, motor or autonomic 
nerve fibres of the peripheral nerves. Thomas (1997) proposed the classification of DN 
into generalized, focal, and multifocal. Generalized DN includes diabetic peripheral 
neuropathy, painful neuropathy and autonomic neuropathy. Focal and multifocal 
neuropathies include mononeuritis multiplex, amyotrphy radiculopathy and entrapment 
of the median nerve causing carpal tunnel syndrome (Fonseca, 2006). This chapter 
focuses mainly on PDN. 
Diabetes peripheral neuropathy is length dependent and manifests as a loss of 
sensation in a stocking pattern. Patients may present with the adverse consequences to the 
loss of sensation, such as plantar ulcers and arthropathy, mainly due to large fibre disease. 
One study on diabetic patients attending the diabetes clinic showed that 25% of patients 
exhibited symptoms of neuropathy and 50% were given a diagnosis of neuropathy after 
simple clinical tests such as the vibration perception test or ankle jerk (Larsen and 
Kronenberg, 2002).  
PDN is a common presentation of diabetic neuropathy and the most common 
cause of neuropathic pain in Europe (Chong and Hester, 2007). The reported prevalence 
of PDN varied from 11% in Rochester, Minnesota, USA, (Dyck et al, 1993) to 53.7 % in 
the Middle East (Jambart et al, 2011). One UK study published in 2011 reported that the 
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prevalence of PDN was 21.5% in type 2 diabetes patients and 13.4% in type 1 diabetes 
patients, resulting in an overall prevalence of 21%. (Abbott et al, 2011). In the large, 
prospective EURODIAB study in 16 European countries, almost one-quarter of type 1 
DM patients developed new onset PDN over a seven year period (Tesfaye et al. 1996). A 
prospective study in Finland followed newly diagnosed diabetes patients between the 
ages of 45 and 64 years for 10 years. It found a 6% prevalence at the time of diagnosis of 
diabetes and  a 26.4% prevalence at the 10-year follow (Partanen et al, 1995). In a large 
UK-based community diabetic population, Abbot et al. (Abbott et al, 2011) observed that 
increasing age was directly related to painful symptoms of neuropathy. Most studies 
found no significant difference in genders, however, Abbot et al. (Abbott et al, 2011) 
reported a slightly higher prevalence of painful symptoms of neuropathy in females (38%) 
than males (31%). The same study also found a higher prevalence of painful symptoms 
in South Asians (38%) compared to Europeans (32%). 
PDN symptoms exhibit a symmetrical “stocking and glove” distribution and are 
often associated with nocturnal exacerbation. It can present from a mild “pins and 
needles” sensation to stabbing, burning, unremitting or even unpleasant electric shock 
sensation. There can be allodynia in the form of cutaneous hypersensitivity leading to 
acute distress on contact with an external stimulus, such as clothing (Larsen and 
Kronenberg, 2002). The pain is often worse at night and disturbs sleep, causing tiredness 
during the day. Some patients present with distressing allodynia and severe pain in the 
legs. This may be so painful that it prevents them from performing their daily activities, 
thereby impacting their employment and social life. The constant, unremitting pain and 
withdrawal from social life often results in depression (Quattrini and Tesfaye, 1996). In 
extreme cases, patients lose their appetite and experience significant weight loss, which 
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is reported in the literature as “diabetic neuropathic cachexia” (Larsen and Kronenberg, 
2002).  
 
1.2.1 Physiology of pain 
Pain is the body’s perception of actual or potential damage to the nerve or tissue by 
noxious stimuli. The sensory afferent nerves carry sensations from the skin, joints and 
viscera via large and small fibres. Large fibres, such as A-alpha, are responsible for limb 
proprioception and A-beta fibres carry sensations of limb proprioception, pressure and 
vibration. Large A-delta myelinated fibres and small C unmyelinated fibres are mainly 
responsible for carrying nociceptive sensations. Superficial pain is often a sharp or 
pricking sensation and is transmitted by A-delta fibres. A deep seated, burning, itching, 
aching type of pain is often accompanied with hyper-algesia and allodynia and is 
transmitted via slow, unmyelinated C fibres. Tissue damage results in the release of 
inflammatory chemicals, such as prostaglandins, bradykinins and histamines, at the site 
of inflammation, which triggers the depolarization of nociceptors, thereby generating an 
action potential. The action potential transmits the nociceptive sensation, via the dorsal 
root ganglion (DRG), to the dorsal horn of the spinal cord. The release of glutamate and 
substance P results in the relay of nociceptive sensations to the spinothalamic tract, 
thalamus and, subsequently, the cortex, where pain is interpreted and perceived (Willis 
and Westlund, 1997). 
Nociceptive pain is the normal response to noxious insult or injury of tissues such as skin, 
muscles, visceral organs, joints, etc. Nociceptive pain usually subsides upon the healing 
of the tissue injury. On the other hand, neuropathic pain arises as a direct consequence of 
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a lesion or disease affecting the somatosensory system without any noxious stimuli. 
Neuropathic pain is caused by damage or pathological change and is characterised by the 
activation of abnormal pathways of pain at the peripheral nerves and posterior roots 
(peripheral neuropathic pain) or spinal cord and brain (central pain) (Treed et al, 2008). 
Neuropathic pain manifestation can be focal, multifocal or generalized depending on the 
involvement of peripheral or central origin and cause of the disease. A few examples of 
neuropathic pain are listed in Table 1.1.   
 
Table: 1.1: Examples of Neuropathic Pain 
 
 
Origin of Pain 
Structures Examples 
Peripheral Nervous 
System 
 
 
 
 
Nerve 
 
 
 
 
 
Dorsal Root 
 
Diabetic painful neuropathy 
Neuroma 
Phantom limb pain 
Trigeminal Neuralgia 
Lumbosacral plexopathy 
 
Post-herpetic neuralgia 
Brachial plexus avulsion 
 
 
Central Nervous System 
 
Spinal Cord 
 
 
 
Thalamus 
 
Spinal cord injury 
Spinal cord infarction 
Multiple sclerosis 
 
Infarct 
Tumour 
Parkinson disease 
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1.2.2 Neuropathic pain generation pathogenesis 
The origin of pain in PDN is not fully understood. The abnormalities in the peripheral or 
central nervous system could be related to hyperglycaemia, as this is the key metabolic 
abnormality of diabetes. There are many other conditions that produce pain similar to that 
of PDN and they may also aid our understanding of the pathophysiology of PDN. 
1.2.2.1 Ectopic electrical impulses 
Chronic hyperglycaemic (HG) damage to the nerves can cause regeneration of nerve 
sprouts, called neuromas, at the stump. The sprouting of the new nerves in all directions 
cause collateral damage of otherwise undamaged nerves and expands the sensitized area 
(Devor et al, 1994). Hyper-excitability in the neuroma generates ectopic impulses that 
affect neighbouring intact afferents and the cell bodies of the DRG. It leads to 
spontaneous, exaggerated, abnormal hyper-excited responses, along with increased 
sensitivity to a given stimulus (Study and Kral, 1996). This phenomenon is called 
peripheral sensitization. Electrical impulses from the axons of small fibres at the dorsal 
horn of the spinal cord are increased and, hence, it alters the “gate” (described below) and 
causes the release of substance P and glutamate. This causes a relay of the impulses to 
the ascending track, which is perceived as pain (Campbell et al, 1988). 
1.2.2.2 Change in Glucose flux and pain 
Treatment induced acute painful neuropathy due to rapid glycaemic control in the first 
month of the initiation of insulin or oral hypoglycaemic agents has been reported in the 
literature as ‘insulin neuritis’. In 1933, Caravati first described the observation that acute 
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painful neuropathy might follow a sudden change in glycaemia control, suggesting that 
blood glucose flux could precipitate pain. This observation was experimentally tested in 
rats by Kihara et al, in 1994. In their study, they infused insulin under non-hypoglycaemic 
conditions and evaluated its effect on endoneurial oxygen tension, nerve blood flow, and 
the oxy-haemoglobin dissociation curve of peripheral nerves in normal and diabetic rats. 
Their results showed that insulin administration caused a reduction in nerve nutritive 
blood flow and an increase in arterio-venous shunt flow. When the arterio-venous shunts 
were obliterated by the infusion of 5-hydroxytryptamine, endo-neurial oxygen reverted 
to normal. Sudden changes in glycaemia may induce relative hypoxia in nerve fibres, 
which contributes to the generation of impulses, thereby indicating that it is the 
combination of structural and functional changes in peripheral nerves that cause the pain. 
In 1996, Tesfaye et al observed neurovascular changes in vivo in five human 
diabetic patients with insulin neuritis. These patients presented with severe sensory 
symptoms but clinical examination and electrophysiological tests were normal, except in 
one subject who had severe autonomic neuropathy. On sural nerve exposure in vivo, 
epineural blood vessels showed severe structural abnormalities resembling the 
retinopathy changes normally seen in the retina, including arteriolar attenuation, 
tortuosity and arterio-venous shunting and the proliferation of newly formed vessels. 
They hypothesized that the structural abnormalities in epineural  blood vessels, together 
with the formation of new vessels, caused a steal effect and, hence, resulted in hypoxia 
and neuropathic pain. It can now be postulated that a sudden change in glycaemic control 
can cause flux effects that result in structural and functional changes in the epineural 
blood vessels of nerves, which, in turn, can lead to neuropathic pain or “insulin neuritis” 
(Boulton, 1992; Tesfaye et al, 1996) (see Figure: 1.1). Symptoms can be mild and often 
go unreported, but may present with severe, excruciating neuropathic pain. Symptoms 
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usually last up to six months and respond to treatment that is usually needed for up to six 
months (Larsen and Kronenberg, 2002). 
 
 
 
Figure 1.1: An image showing arteriolar attenuation (A), tortuosity (B), aterio-venous 
shunting (C) and proliferation of newly formed vessels (D) of the vasa nervosum seen in 
the sural nerve of a patient with insulin neuritis (Photo courtesy of Tesfaye and Boulton, 
1996). 
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1.2.2.3 Role of the dorsal root ganglion (DRG) in neuropathic pain 
The expression of voltage-gated sodium and calcium channels and voltage-independent 
potassium channels in the DRG has a significant role in the generation of nociceptive 
sensation and peripheral sensitization that leads to central sensitization. Hyper-excited 
ectopic impulses are generated by the expression of various voltage-gated sodium 
channels, such as Nav 1.3, Nav1.7 and Nav1.8 (Black et al, 2008). The voltage-gated 
sodium channel Nav1.3 probably plays a key role in the development of neuropathic pain 
(Cummins et al, 2001). Amir et al described after nerve injury, in the DRG, there is a 
sustained phasic discharge that results in repeated firing (Amir et al 1999). The voltage-
dependent sodium channel alternates with a voltage-independent potassium leak to 
oscillate membrane potentials. When these oscillations reach the threshold amplitude, 
they result in the generation of ectopic impulses and, hence, lead to sustained peripheral 
sensitization (Amir et al 2002). In addition to the voltage-gated sodium channels, the 
expression of voltage-gated calcium channels were also found in neuropathic pain 
(Mathews et al, 2001), specifically subtype Cav 3.2 is highly expressed in DRG neurons 
and showed strong correlation with allodynia (Bourinet et al, 2005). Calcium entry 
through voltage-gated calcium channels causes the release of substance P and glutamate, 
which results in the modulation of pain at the dorsal horn (White and Zimmermann, 
1988). The up-regulation of transient receptor potential expression is also found to be 
associated with neuropathic pain. Studies found a direct relationship between TRPV1 
(transient receptor potential vanilloid 1) and neuropathic pain. A few animal studies 
suggest that hyper-algesia does not develop in TRPV1-deficient mice and TRPV1 
antagonists reduce pain behaviour in mice  (Caterina et al, 2000; Hudson et al, 2001). 
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1.2.2.4 Methylglyoxal (MGO) and pain 
Methylglyoxal (MGO) is a reactive intracellular by-product of several metabolic 
pathways. However, the most important source of MGO is glycolysis and hyperglycaemia 
(Inoue and Kimura, 1995). Studies found that PDN patients had significantly higher 
concentration of plasma MGO (> 600 nM) compared to healthy controls or diabetes 
patients without pain (Bierhaus et al, 2012; Han et al, 2007). MGO depolarizes the 
sensory neuron by activating TRPV1 in the DRG (Andersson et al, 2013) and also induces 
post-translational modification of the voltage-gated sodium channel Nav 1.8 (Bierhaus et 
al, 2012). These changes are associated with increased electrical excitability and facilitate 
firing of nociceptive neurons.  
 
1.2.2.5 Sympathetic modulation of pain 
Nociceptive A-delta and C fibres are normally not directly connected to sympathetic 
nervous system. Several experiments using α-adrenoreceptor agonists found that it did 
not activate sympathetic neurons at nociceptor fibres under normal conditions (Elam et 
al, 2004; Zahn et al, 2004). It is widely accepted that the sympathetic nervous system does 
not activate the sensory nervous system under normal conditions. 
Neuropathy causes hypersensitivity in nerves as a result of an abnormal 
epinephrine-mediated transmission from one axon to another, this unusual connection is 
called ephaptic transmission or cross-talk (Janig et al, 1996). It was also noted that 
damaged nerves in the periphery also cause basket formation, called sympathetic 
sprouting in the DRG, which results in the release of noradrenaline (Kanno et al, 2010). 
Both sympathetic sprouting and ephaptic transmission release adrenaline and cause 
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sympathetic-sensory coupling. This leads to an increase in ectopic and spontaneous firing. 
This unusual connection is called sympathetically maintained pain. 
Several studies proved this hypothesis and showed dramatic improvement in pain 
relief after sympathetic blockage (Yoo et al, 2011), sympathetectomy (Sekiguchi et al, 
2008) or temporary blockage with α-adrenergic antagonists with intravenous 
phentolamine (Raja et al, 1991)   
 
1.2.2.6 Gate control theory 
In 1965, Melzak and Wall described, for the first time, that nervous connections from the 
peripheral to central nervous system and to the brain is not a seamless transmission of 
information. They described the gate mechanism at the dorsal horn of the spinal cord, 
which inhibits or facilitates the flow of afferent impulses from peripheral nerves to the 
spinal cord before it evokes pain perception. The activity at the gate is primarily 
dependent on the transmission of impulses along small or large nerve fibres. Small nerve 
fibres, unmyelinated C fibres, and myelinated A-delta fibres tend to open the gate and 
large A-beta fibres tend to close the gate. Opening and closing of the gate depends on the 
number of input impulses. Thus, if nociceptive input from C- and A-delta fibres exceeds 
A-beta fibre input, then the gate is open and nociceptive impulses ascend to the spinal 
cord. On the other hand, if A-beta fibre input (touch, vibration and pressure) exceeds that 
of C- and A-delta fibre input (pain), then gate is closed; nociceptive impulses only pass 
through when the gate is open (see figure 1.2). The classic example of this phenomenon 
is the rubbing of an injured site immediately after suffering from trauma, which results in 
gate closure (Melzack and Wall, 1965).   
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Figure 1.2: Visual description of Gate control theory Freudenrich C. "How Pain 
Works" (2007). HowStuffWorks.com. http://science.howstuffworks.com/life/inside-the-
mind/human-brain/pain4.htm. (Accessed on  06 August 2014) 
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1.2.2.7 Central sensitization 
Central sensitization was first described by Woolf in 1983. Non-noxious stimuli 
transmitted from the periphery with A-beta fibres (touch) was perceived as painful by 
patients with allodynia (Woolf, 1983). A-delta fibres and C fibres are innervated in 
laminae I-II and A-delta fibres also innervated in lamina V of the dorsal horn. The 
majority of spinal cord neurons that express the substance P receptor are located in lamina 
I, or have their cell bodies in laminae III-IV, but extend their dendrites to lamina I. The 
pain mediation of noxious stimuli occurs by releasing substance P, mainly in lamina I of 
the dorsal horn. A-beta fibres are innervated deep in laminae III to V and are responsible 
for touch mediation (Woolf et al, 1992; Koerber et al, 1994; Bouhassira, 1999). Peripheral 
sensitization and sustained hyper-excited impulses at the dorsal horn cause an increase in 
responsiveness to noxious and non-noxious stimulation. This was believed to be due to 
the structural plasticity of sprouting of A-beta fibres, which leads to “rewiring” of the 
dorsal horn laminae in the central nervous system (CNS) (Bouhassira, 1999). As a result, 
the CNS pathway, which is responsible for transmitting only non-noxious stimuli (touch), 
was replaced by sprouting A-beta fibres that transmit non-noxious impulses and release 
substance P in the dorsal horn, thereby mediating allodynia (Harris, 1999). This 
hypothesis was mainly based on experiments that showed that the uptake of the cholera 
toxin B (CTB) subunit, which is a selective tracer for large myelinated A-fibres, 
terminated in lamina II (Lekan et al, 1996). The selectivity of this toxin after peripheral 
nerve injury is somewhat controversial. Experiments demonstrated that uptake of the 
CTB tracer was not selective and that CTB was found in axons of all types including, A-
delta fibres and C fibres, and that the CTB tracer incorporated in C fibres that terminated 
in lamina II (Hughes et al, 2003). This contradicts the hypothesis of structural plasticity 
and A-beta fibres sprouting in lamina II. However, studies with immune-staining and 
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electrophysiological recordings have clearly established that peripheral nerve injury 
causes large myelinated fibres to begin to drive nociceptive neurons in superficial lamina 
(Bester et al, 2000; Woodbury et al 2008). The persistent incoming nerve impulses lead 
to activation of N-methyl-D-aspartate (NMDA) receptors on post-synaptic membranes in 
the dorsal horn of the spinal cord. This leads to the release and binding of glutamate (an 
excitatory neurotransmitter), which causes an influx of sodium and calcium and an efflux 
of potassium. This generates a larger post-synaptic action potential and augments the 
perception of normal stimuli, thereby resulting in allodynia (Chen and Huang, 1992). 
 
1.2.2.8 Central inhibition & Central facilitation  
Impulses from the brainstem nuclei descend to the spinal cord and influence the 
transmission of pain signals at the dorsal horn. The periaqueductal grey matter (PAG), 
locus coeruleus, the nucleus raphe magnus and several bulbar nuclei of reticular formation 
give rise to descending modulatory pathways. These pathways dampen or enhance the 
pain signal. Increased descending facilitation has been demonstrated in chronic pain 
models. The injection of lidocaine in to the rostral ventromedial medulla of rats with 
peripheral nerve injury abolished the enhance abnormal pain (Pertovaara et al, 1996). The 
projections from the nucleus raphe magnus to the spinal cord are the major source of 
serotonin in the spinal cord. Exogenous opioids imitate the endogenous opioids and 
induce analgesia by acting upon the PAG, reticular formation and the spinal dorsal horn 
(Willis and Westlund, 1997). The antidepressant serotonin and norepinephrine reuptake 
inhibitors (SNRIs) (Goldstein et al, 2005) and opioids (Harati, et al, 1998) have been 
found to be beneficial in the treatment of neuropathic pain as these medications increase 
the availability of these neurotransmitters and, hence, increase inhibition at the spinal 
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cord. Psychological factors, such as fear and anxiety, can influence the inhibitory 
mechanism through the modulatory system. Cognitive behavioural therapies are thought 
to be beneficial in modulating the pain by reducing the fear and anxiety (Otis et al, 2013). 
1.2.2.9 Thalamic abnormalities 
The nociceptive hyper-excited impulse generated within primary afferent nerves is not 
only modulated and amplified at the DRG-spinal cord level, but also at the thalamic 
ventral posterolateral (VPL) level, before being relayed to the cerebral cortex. This was 
experimentally proved in streptozotosin rat model with PDN. The experiment 
demonstrated hyper-excitability in thalamic VPL neurons, with increased responses to 
phasic brush, press, and pinch stimuli applied to peripheral receptive fields. VPL 
neurones from diabetic rats also displayed enhanced spontaneous activity, independent of 
ascending afferent impulses, and enlarged receptive fields (Fischer et al, 2009). 
Salverajah et al investigated this further in humans using a magnetic resonance (MR) 
perfusion scan in patients with PDN. This study demonstrated increased thalamic 
vascularity and sluggish blood flow (Salverajah et al, 2011). Similar vascular perfusion 
findings were also observed at the sural nerve in patients with PDN (Eaton et al, 2003). 
It was suggested that increased perfusion at thalamus VPL neurons in PDN patients 
causes an increase in neuronal activity and, hence, further modulates pain and central 
sensitization. 
 
1.2.2.10 Chronic neuropathic pain and plasticity of brain 
 
Neuroplasticity or plasticity of the brain is the term used to describe the adaptive change 
in structure, chemical balance and function of the brain in response to changes within the 
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body or in the external environment. In response to chronic neuropathic pain, 
neuroplasticity is associated with somatosensory cortex remodelling, reorganization and 
hyperexcitability in the absence of external stimuli. A study of patients with chronic 
neuropathic and non-neuropathic pain using functional and anatomical magnetic 
resonance imaging found cortical reorganization and changes in somatosensory cortex 
activity only in the neuropathic pain group (Gustin et al, 2012). Provoked pain and 
spontaneous stimuli may reverse the remodelling and reorganization at the somatosensory 
cortex. Other studies have also shown a beneficial effect of pain relief with transcranial 
magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), which 
suggests a reversal of plasticity (Knotkova and Cruciani, 2010; Treister et al, 2013).  
 
 1.2.3 Diagnosis of painful diabetic neuropathy 
Diagnosis of painful diabetic neuropathy is mainly based on a clinical history of pain. 
The classical description of PDN pain is that it usually begins distally from the feet 
bilaterally, or in both feet and hands in the “gloves and stockings” distribution, with 
progressive or spontaneous burning sensations, shooting pains similar to electric shock, 
stabbing, pins and needles, tingling, and hot or cold feelings with or without contact 
hypersensitivity (allodynia). In rare cases, it can focally affect the dermatome region. 
(Fonseca A, 2006) 
Sensory assessment using nerve conduction studies, vibration perception 
threshold tests, or the 10-gram monofilament test could be normal, as these tests assess 
only large A Beta fibres. As discussed earlier, pain is generated and mediated solely via 
small C fibres and large A delta fibres (Larsen and Kronenberg, 2002).  Quantitative 
sensory testing (QST) is the means of testing to assess the thermal pain thresholds to hot 
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(C fibre) and cold (A delta fibre) (Sorensen et al., 2006; Kelly et al., 2005). However, 
these assessments are known to be highly subjective and also not widely available; 
therefore, they are not commonly used in clinical practice. Direct examination of nerve 
fibres by punch biopsy found a loss of intra-epidermal nerve fibres (IENF) in the small 
fibres of patients with painful neuropathy. However, loss of IENF cannot explain pain 
in all cases, suggesting that different pain mechanisms trigger pain in neuropathy 
(Sorensen et al., 2006). So far there is no consensus supporting the use punch biopsy in 
clinical practice, and it would be difficult to do this invasive procedure in all patients. 
There have, however, been advancements in the detection of pain using functional 
Magnetic Resonance Imaging (fMRI), which measures the changes in brain in the form 
of a pain matrix after painful stimulus. This method can help in quantifying the intensity 
and location of pain (Melzac, 1999). However, further studies are needed before this 
mode of imaging can be fully utilized in clinical practice.  
1.2.3.1 Scales available to aid the diagnosis of neuropathic pain 
There are several validated neuropathic pain scales available to aid the diagnosis of 
neuropathic pain, such as the Neuropathic Symptom Score (NSS), the neuropathic pain 
scale (NPS),  the Douleur Neruopathicque en 4 Questions (DN4), the Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS) scale, and the Self completed LANSS 
(S-LANSS). These scales have been used in clinical practice to diagnose painful 
diabetic neuropathy (Jambart et al., 2011; Abbott et al., 2011; Erbas et al., 2011, 
Liberman et al., 2014; Gu et al., 2012; Yunus and Rajbhandari, 2011). The visual 
analogue score is widely used in monitoring the pain (Athanasakis et al., 2013). The 
McGill pain questionnaire has been used to assess the severity of the symptoms of 
neuropathic pain (Melzack, 1975); however, it is not widely used in clinical practice. 
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The brief pain inventory (BPI) has been used to assess the severity of pain, response to 
medications, and the physical and psychological impact of pain. The BPI has been 
shown to be effective in evaluating painful diabetic neuropathy (Zelman et al., 2005). 
1.2.4 Management of painful diabetic neuropathy 
There are several pharmacological and non-pharmacological therapies that have been 
proven to alleviate neuropathic pain, but not a single therapy restores nerve function. The 
main aim of treatment is symptomatic relief. Table 1.2 display the various 
pharmacological treatments and adverse reactions. Figure 1.3 displays the various 
pharmacological treatments with modes of action (see Figure 1.3 and Table 1.2) 
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Table: 1.2: Pharmacological therapies for the treatment of PDN 
Drug Classes Examples Adverse reactions 
 
Tricyclic antidepressants 
 
 
 
 
Serotonin norepinephrine 
reuptake inhibitor (SNRI) 
antidepressants 
 
 
 
Anticonvulsants  
 
 
 
 
 
 
Topical Anaesthetic  
 
 
Opioids 
 
Amitriptyline 
Nortriptyline 
 
 
 
Duloxetine 
 
 
 
 
 
Pregabalin 
Gabapentin 
 
Carbamazepine 
 
 
 
Lidocaine patch 5% 
 
 
Tramadol 
Morphine 
Oxycodone 
 
Agitation, anxiety, ataxia, 
confusion, dry mouth, 
arrhythmia 
 
Nausea 
Somnolence, headache, 
dizziness, insomnia, diarrhoea, 
constipation, decreased appetite 
 
Oedema, somnolence, 
dizziness, ataxia, fatigue 
Decrease appetite, weight loss, 
somnolence, dizziness, fatigue 
 
Burn  
 
Nausea, vomiting, drowsiness, 
somnolence, constipation 
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Figure 1.3: Schematic pathway of pain and sites of action of pain-relieving drugs. 
AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DRG, dorsal root 
ganglion; GABA, γ-amino butyric acid; 5-HT, serotonin; mGluR, metabotropic 
glutamate receptor; NMDA, N-methyly-D-aspartate; TCA, tricyclic antidepressant. 
(Modified from Vinik & Mehrabyan,  2004) 
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1.2.4.1 Pharmacological Therapies 
1.2.4.1.1 Antidepressants 
Tricyclic Antidepressant (TCA) 
The TCA amitriptyline has been the drug of first choice for neuropathic pain since 1970 
(Collins et al., 2000). Several studies have reported the significant relief of symptoms of 
neuropathic pain in diabetes patients using this drug (Nash, 1999; McQuay et al., 1996). 
TCAs relieve pain by inhibiting the reuptake of 5-HT and noradrenaline and blocking the 
sodium and calcium channels (Jensen et al., 2006). Side effects such as dry mouth, 
sweating, sedation and dizziness are mainly due to anti-cholinergic actions. The starting 
dose of Amitriptyline is 10 mg, and can gradually be titrated up to a maximum of 75 mg 
at night (NICE guidance on PDN, 2013)  
 Serotonin noradrenaline reuptake inhibitors (SNRI) 
The efficacy of the SNRI duloxetine in PDN has been investigated in several studies and 
found to be effective pain in relief at the doses of 60 and 120 mg/day (Jensen et al., 2006; 
Goldstein et al., 2005). SNRIs relieve the pain by increasing the availability of serotonin 
and noradrenaline in the descending pathways, which are inhibitory to pain impulses. The 
most frequently reported side effects are nausea, somnolence, dizziness and constipation 
(Goldstein et al., 2005; Raskin et al., 2005). Duloxetine is licensed for the treatment of 
painful diabetic neuropathy in UK (NICE guidance on PDN, 2013) 
Other studies have found that the SNRI venlafaxine is also effective for pain relief in 
painful diabetic neuropathy (Kadiroglu et al., 2008). Side effects of this drug included 
somnolence, nausea, hypertension and in some cases, ECG changes. Because arrhythmia 
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is a major concern, especially when diabetes patients have coexisting cardiovascular 
disease, venlafaxine is not licensed for PDN (Jensen et al., 2006).  
1.2.4.1.2 Anticonvulsants  
There are several old-fashioned and newer generation anticonvulsants that have been 
found to have beneficial effects in painful diabetic neuropathy. These include 
carbamazepine, phenytoin, sodium valproate, pregabalin, gabapentin, lamotrigine and 
topiramate. Anti-convulsants inhibit pain by either blocking sodium channels or binding 
to calcium ion channels, reducing the flux of sodium or calcium and thus reducing the 
release of neurotransmitter in hyperexcited neurones (Tesfaye, 2009). The common side 
effects from the use of anticonvulsants are somnolence, dizziness and in rare cases, liver 
derangements (Wong et al., 2007). 
Carbamzepine 
Carbamzepine stabilizes membranes by inhibiting sodium channels. Several double-blind 
placebo-controlled studies have demonstrated carbamazepine’s effectiveness in the 
management of painful diabetic neuropathy, finding that it is particularly useful for 
lightning-like or shooting pain (Vinik et al., 1992). Carbamazepine is known to be 
associated with bone marrow suppression and osteoporosis. Due to its toxic side effects, 
and the development of newer anticonvulsants, its use is limited in PDN (Chong and 
Hester, 2007).   
Phenytoin 
Phenytoin was one of the first sodium channel blockers and it has long been used in PDN. 
Two crossover studies with phenytoin conducted in 1970 showed some benefit at 5 weeks 
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of treatment compared to placebo, but no benefit at 20 weeks (Chadda and Mathur, 1978). 
The long-term use of phenytoin is also known to be associated with osteoporosis, 
peripheral neuropathy and cerebellar ataxia. It is known to be toxic to the liver and thus 
requires monitoring of liver function. For these reasons, phenytoin is not generally used 
in painful diabetic neuropathy (Chong and Hester, 2007).   
Sodium Valproate 
Sodium valproate potentiates the inhibitory neurotransmitter γ-Aminobutyric acid 
(GABA) in the brain. Its mechanism of action in neuropathic pain is still not fully 
understood. Double blind studies have shown modest benefits from sodium valproate 
treatment compared to placebo in PDN (Kochar et al., 2002; Sindrup et al., 2003). 
However, the long-term use of sodium valproate is associated with hair loss, weight gain, 
and in rare cases, liver toxicity. Because of the adverse effects and modest evidence of 
efficacy, sodium valproate is not widely used for PDN (Tesfaye, 2009; Chong and Hester, 
2007).   
Lamotrigine 
Lamotrigine is a new anticonvulsant sodium channel and presynaptic glutamate therapy, 
which may possess beneficial properties for pain relief. Studies have shown the possible 
benefits of lamotrigine in the treatment of PDN. However, these studies were small in 
sample size (n=10) and (n=59) (Eisenburge et al., 2001a; Eisenburge et al., 2001b). 
Lamotrigine is also known to be associated with Steven Johnson syndrome and 
bradycardia; therefore, careful titration of dose is needed (Fonseca, 2006). Due to limited 
evidence at present, lamotrigine is not widely used in painful diabetic neuropathy.  
48 
 
Gabapentin 
Gabapentin has been used since 1994 as an effective anticonvulsant that also has an 
analgesic effect in neuropathic pain (Gorson et al., 1999). Gabapentin inhibits voltage-
gated sodium and calcium channels and has an analgesic effect at spinal cord (Backonja, 
1999). Several studies have reported significant pain relief in PDN along with positives 
effect on mood and quality of life (Backonja, 1999; Vinik et al., 1998). A dosage of 1800 
mg to 3600 mg per day may be required (American Diabetes Association (ADA) guidance 
on PDN, 2013). Doses that high, however, may have untoward side effects, the most 
disconcerting being weight gain (Fonseca, 2006). Gabapentin is licensed in the US for 
the treatment of PDN (ADA guidance on PDN, 2013). 
Pregabalin 
Pregabalin is structurally related to gabapentin and has the same mode of action. Several 
studies have shown significant alleviation of pain in painful diabetic neuropathy 
(Rosenstock et al., 2004; Lesser et al., 2004; Richter et al., 2005; Freyhagen et al., 2005). 
While the doses used in these studies range from 150 mg/day to 600 mg/day, the drug 
was found to be significantly more effective at 300 mg/day to 600 mg/day. Rapid dose 
titration increases the risk of sedation and dizziness. High doses of pregabalin were 
reported to cause ankle edema and weight gain, and abrupt discontinuation could lead to 
cerebral edema (Oaklander and Buchbinder, 2005). In US and UK, pregabalin is licensed 
to treat PDN (NICE guidance on PDN, 2013; ADA guidance on PDN, 2013). 
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1.2.4.1.3 Opioids agonists 
Opioid agonists modulate pain by acting on peripheral nociceptors, presynaptic receptors, 
postsynaptic receptors, and on the descending system (Tesfaye, 2009). Tramadol has been 
found to show significant pain relief in PDN. In a randomised controlled study of 130 
patients, tramadol at an average dose of 200 mg/day for 6 weeks showed statistically 
significant pain relief compared to placebo (Harati et al., 1998). However, higher doses 
(300 to 400 mg/day) are associated with high incidence of adverse effects, such as 
drowsiness, headache, nausea and constipation. The other opioid reported to be beneficial 
in PDN is oxycodone. Studies on oxycodone have shown alleviation of pain compared 
with placebo (Gimbel et al., 2003; Watson et al., 2003). Physicians are generally reluctant 
to use opioids for the long term in PDN due to serious adverse effects, including opioid 
dependency, constipation and impaired cognitive function.  
1.2.4.1.4 Topical agents 
Capsaicin 0.075 % cream 
Capsaicin, a natural colloid extracted from red chilli peppers, works by depleting 
substance P from nerve terminals and has been found to be effective in neuropathic pain 
(Donofrio and Walker, 1991). Several studies have reported significant pain relief with 
topical application of capsaicin 0.075% in patients with PDN (Scheffler et al., 1991; Chad 
et al., 1990; Low et al., 1995). Sometimes, within the first 2 to 4 weeks of application, the 
treatment may actually cause worsening of neuropathic pain symptoms, including 
burning, tingling, stinging and erythema at application site. However, in general, when 
used sparingly 3 to 4 times a day on affected areas, it can provide effective relief of pain.  
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Lidocaine 5% Patch 
The lidocaine 5% patch acts as a local anaesthetic by blocking sodium channels and 
studies have reported significant improvements in the treatment of PDN (Devers and 
Galer, 2000; Barbano et al., 2004). One systematic review in 2010 compared lidocaine 
5% plaster with various other medications in PDN and that found it to be comparable to 
amitriptyline, capsaicin, gabapentin and pregabalin, with no significant adverse effects 
reported with topical application (Wolff et al., 2010). 
 Topical nitrate 
The impairment of nitric oxide synthesis contributes to the pathogenesis of diabetic 
neuropathy. Topical nitrate acts by producing nitric oxide and working locally at the 
nerve site. Several studies on patients with PDN have demonstrated significant 
improvement in pain relief upon topical application of isosorbide dinitrate spray or 
glyceryl trinitrate patches (Yuen et al., 2002; Rayman et al., 2003).  
 
1.2.4.1.5  Other Pharmacological Treatments 
Dextromethorphan 
Dextromethorphan is an NMDA receptor antagonist found to be effective in painful 
diabetic neuropathy. A randomized control trial comparing the drug to placebo reported 
significant pain relief in diabetic painful neuropathy using dextromethorphan (Nelson et 
al., 1970). However, the sample size was too small (n=13) to provide convincing evidence 
of efficacy. Further large studies are needed. 
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Lignocaine infusion 
Lignocaine is a sodium channel blocker first synthesized by Swedish chemist Nils 
Lofgren in 1943 (Lofgren et al., 1946). Lignocaine is widely used as a local anaesthetic 
and peripheral nerve blocker. It has been used intravenously for the treatment of 
arrhythmias and has also been found effective in chronic neuropathic pain (Tremont-
Lukats et al., 2006) and chronic pain disorders (Cahana et al., 1998; Wallace et al., 2000). 
Furthermore, it is not associated with any significant side effects (Challapalli et al., 2005). 
The potential use of lignocaine infusion as a treatment for PDN was first evaluated by 
Kastrup in 1986 (Kastrup et al., 1987). Since then, several studies have reported pain 
relief in PDN. The duration of pain relief post lignocaine transfusion was variable among 
studies, from 3 days to 28 days (Bach et al., 1990; Kastrup et al., 1987; Viola et al., 2006). 
Lignocaine infusion is often reserved only for patients with persistent excruciating pain 
and for whom other medications are not beneficial. Due to practicalities of lignocaine 
infusion, including intravenous mode of administration the need for cardiac monitoring, 
its use is very limited.  
Mexiletine 
Mexiletine, the structurally-similar, oral analogue of lidocaine, has the same mechanism 
of action, the blockade of sodium channels. The evidence thus far has shown variable 
pain relief in PDN (Jarvis and Couked, 1998). Two studies have reported significant pain 
reduction compared to placebo (Dejgard et al., 1988; Oskarsson et al., 1997), while two 
others reported no pain reduction compared to placebo (Stracke et al., 1992; Wright et al., 
1997). Since it is an analogue of lidocaine, it could therefore be a drug of choice for those 
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people who respond well to IV lignocaine. However, further studies are needed to assess 
the efficacy of mexiletine.   
 
1.2.4.2 Non- Pharmacological Therapies 
1.2.4.2.1 Transcutaneous electrical nerve stimulation (TENS) 
TENS has been used in variety of pain syndromes and has been found to be beneficial in 
PDN (Meyler et al., 1994). Its mode of action is thought to be the stimulation of nerves 
causing release of endogenous opioids and induction of the gate principle to prevent pain 
mediation (Shafter and Kitay, 1988). Several studies on TENS treatment have reported 
amelioration of pain perception in painful diabetic neuropathy (Alvero et al., 1999; 
Kumar and Marshall, 1997; Kumar et al., 1998; Julka et al., 1998). The advantage of 
TENS treatment is that it is portable and can be done by the patient, the current is low 
frequency, and it is safe to use (apart from someone who has pacemaker, in which case it 
is contraindicated).   
1.2.4.2.2 Acupuncture 
Acupuncture works on the same principle of TENS. It is a well-known non-
pharmacological method of treatment for a variety of pain syndromes. Several studies 
have shown that acupuncture significantly reduces pain perception in patients with PDN 
(Ahn et al., 2007; Kasuya, 2012; Abuaisha et al., 1998; Ewins et al., 1995). There are, 
however, limitations to the use of acupuncture, as it requires specialized skills and there 
is a lack of trained specialists in this field.  Further research is needed to determine 
whether it is cost effective to provide acupuncture as a treatment under NHS. 
53 
 
1.2.4.2.3 Electrical spinal cord stimulation 
Electrical spinal cord stimulation is an invasive treatment for PDN. An electrode is fitted 
into the spinal cord epidural space in the thoracic or lumbar region, and on stimulation it 
causes the release of endogenous opioids. Thus, it works on the same principle as TENS 
or acupuncture. Tesfaye et al. (1996) used electrical spinal cord stimulation for the first 
time in 1996 on patients with PDN and found promising results: 8 out of 10 patients 
showed significant pain reduction. In another study performed on 9 patients with whom 
conventional treatment was ineffective, 8 out of 9 patients reported to have significant 
pain relief for up to 6 months. For 6 of these patients, it was their only pain treatment (de 
Vos et al., 2008). There was another large multicentre prospective study on 36 patients 
with PDN resistant to conventional treatment used spinal cord stimulator and found 59% 
had adequate response till 6 months (Slangen et al, 2014). Electrical spinal cord 
stimulation has also been found to be safe overall, with the only side effects being peeling 
of the skin at the site of stimulator, and accidental damage of electrodes causing the need 
for replacement (Daousi et al., 2005).  
1.2.4.2.4 Psychological therapy  
Painful diabetic neuropathy has a huge psychological impact on patients, causing both 
physical and mental distress. The unremitting pain with contact hypersensitivity 
(allodynia) causes disturbances in sleep and withdrawal from social activity. Some 
patients may enter into a depressive phase. Psychological treatment mainly involves 
learning how to tackle the thoughts, emotions and distress that come with chronic pain. 
The aim is to train the patients cognitively in order to influence their thoughts and 
perceptions of the pain response, thus leading to diminution of distress and improvement 
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in activity and performance (Pither and Nicholas, 1991). A randomized controlled study 
of patients with PDN compared cognitive behavioural therapy (CBT) to treatment as 
usual (TAU). Out of the 20 patients who participated, 12 received CBT and 8 received 
TAU. Participants receiving CBT showed a significant decrease in pain severity and 
interference compared to the TAU group (Otis et al., 2013). There exist several challenges 
to the success of psychological therapy, including patient commitment, compliance with 
therapy, and availability of resources, such as the ability to provide such a service within 
the diabetes neuropathy clinic.   
1.2.4.3 Combination treatment and National Guidance  
In March 2013, NICE (UK) issued their guidance regarding pharmacological treatment 
of neuropathic pain including PDN (NICE guidance on PDN, 2013). The first line 
treatment recommended by NICE is either duloxetine, amitriptyline, pregabalin or 
gabapentin. The choice of drug should be patient centred and consider tolerance of side 
effects and comorbidities. If one drug is not effective or not tolerated then switch over to 
one of the remaining 4 drugs. Tramadol to considered as a rescue drug for pain relief. The 
recommended starting duloxetine dose is 30 mg/day, with upward titration to a maximum 
of 120 mg/day. Amitriptyline starting dose at 10 mg/day with upward titration to a 
maximum of 75 mg/day. Pregabalin starting dose is 150 mg/day in divided dose to a 
maximum of 600 mg/day in divided dose and gabapentin starting dose is 300mg/day in 
divided dose to maximum 1800mg/day with upward titration. If first line treatment is 
unable to achieve satisfactory pain relief at the maximum tolerated dose, then NICE 
recommended, as a second line, to switch over to, or employ combinations of, other first-
line medications. For example, if the first-line medication was with duloxetine, then the 
patient would switch to amitriptyline or pregabalin or combine duloxetine with 
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pregabalin. If first-line treatment was amitriptyline, then the patient would switch to 
pregabalin or combine amitriptyline with pregabalin. The third-line treatment 
recommended is to switch over to or add tramadol from 50 to 100 mg, 4 hourly, to a 
maximum of 400 mg/day. If pain control is still not satisfactory, this will require referral 
to a specialist in painful neuropathy.  
For the US, the American Diabetes Association’s (ADA) 2013 clinical practice 
recommendation for the treatment of PDN (ADA guidance on PDN, 2013) recommends 
first-line treatment with Amitriptyline, at a dose of 25 mg to 150 mg at bed time. The 
second line of treatment is to add on gabapentin gradually titrated up to 1.8 gram /day in 
three divided doses. The third line is to add on tramadol or oxycodone, and if pain control 
is not achieved, then consider referral to the pain clinic.  
A large multinational double-blind study on 804 PDN patients evaluated 
duloxetine or pregabalin as a monotherapy at higher doses (duloxetine 120 mg/day and 
pregabalin 600mg/day) vs. combination therapy with standard doses of duloxetine (60 
mg/day) and pregabalin (300mg/day). The study found no difference between the 
higher-dose monotherapy and the standard-dose combination therapy. However, at 
standard doses duloxetine was found to be superior in monotherapy compared to 
pregabalin (Tesfaye et al., 2013). The treatment algorithm flow chart, expressed as per 
National guidance NICE/ADA, is presented in Table 1.3 below. 
 
. 
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Table 1.3: Treatment Algorithm of Painful diabetic neuropathy 
TREATMENT ALGORITHM 
 
 
 
SNRI- Duloxetine (60mg daily to Max 120mg/day) 
OR 
TCA- Amitriptyline (10-25mg at night up to 75mg) 
OR 
Antiepileptics 
Pregabalin ( 75mg twice a day to maximum 150mg twice a day) 
OR 
Gabapentin (300 mg/day to maximum 1800 mg/day in three divided doses) 
 
  
Combination of SNRI-Duloxetine with Antiepileptics-Pregabalin OR Gabapentin 
OR 
Combination of TCA-Amitriptyline with Pregabalin OR Gabapentin 
 
 
Tramadol, Morphine Sulphate or Oxycodone 
AND/OR 
Topical Lidocaine 
 
 
TENS 
Psychological therapy 
Acupuncture 
Spinal cord stimulation 
 
Step 2 Combination Therapy 
Step 1 Monotherapy 
Step 3 Add on or Switch over 
Step 4 Add on or Switch over to Non pharmacological Therapies 
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1.2.5 Prognosis 
Patients with PDN usually suffer from constant and unremitting neuropathic pain, causing 
disturbances to sleep and having a huge impact on daily life. Social withdrawal and 
constant pain causes lowered mood and depression (Archer et al., 1983).  
Acute painful neuropathy is usually observed in newly diagnosed diabetes or in 
patients with poor control of diabetes after starting insulin or other hypoglycaemic agents, 
termed in the literature as insulin neuritis (Larsen and Kronenberg, 2002; Caravati, 1933). 
Several case studies have reported the acute symptoms of painful neuropathy, including 
weight loss termed diabetic cachexia (Ellenberg, 1974; Larsen and Kronenberg, 2002; 
Archer et al.,1983; Caravati, 1933; Dabbya et al., 2009; Wilson et al., 2003). In all the 
cases studied, symptoms completely resolved and patients regained weight under 
neuropathic treatment within 6 months.   
Despite advances in treatment, the chronic symptoms of PDN are challenging for 
clinicians and distressing to patients. Boulton et al. (1983) followed 39 patients with PDN 
over a period of 4 years after treatment and found no significant difference in the intensity 
of pain. Another 5-year follow-up study on PDN with conventional treatment reported 
that symptoms were resolved in only 23% of patients (Daousi et al., 2006). There have 
been limited studies on the natural course and prognosis of painful neuropathy; thus, 
further studies are needed. However, clinicians should be aware of the negative 
symptoms. If pain has resolved, the feet need to be examined. Sensory neuropathy may 
have gotten worse, which would cause disappearance of pain.   
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(a) Working Hypothesis: 
Different aetiological factors are associated with painful diabetic neuropathy, including 
longer duration of diabetes, poor glycaemic control, increasing age, smoking, renal 
impairment and increased prevalence in Northwest England—all of which have 
significant impact on the quality of life for patients. In most cases, patients can be 
symptomatically treated with medications such as duloxetine, amitriptyline, and/or 
pregabalin, with lignocaine infusion used in challenging cases. 
(b) Main aim: 
The main aim of the project was to investigate the prevalence of PDN in the Chorley & 
Whiston towns of England, to identify the risk factors associated with the disorder, and 
to investigate the treatment and psychological impact of PDN. 
(c) Specific Aims of the Research: 
1. To identify prevalence of PDN in the Chorley and Whiston towns of England and 
identify the association of gender, age, duration of diabetes, smoking, alcohol, HbA1c, 
lipid profile and eGFR as risk factors for painful diabetic neuropathy as compared to 
diabetic neuropathy without pain.  
2. To evaluate the psychological and physical impact of PDN on patients’ lives.  
3. To evaluate the effectiveness of lignocaine infusion treatment for PDN in challenging 
cases.  
 
 
59 
 
Format of the thesis 
This MSc by Research thesis contains one review article (part of the Introduction in 
Chapter 1) and three original research papers (each including an abstract, introduction, 
materials and methods, results and discussion) that are presented in Chapters 2, 3 and 4. 
All references are provided at the end of the paper. In addition, a general discussion is 
presented in Chapter 5, with concluding remarks and suggestions for future study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
 
 
 
Prevalence and characteristics of painful diabetic neuropathy in 
the diabetic population of Northwest England. 
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Submitted to the Canadian Journal of Diabetes (under review) 
2.1 Abstract  
Objective: This study was conducted to assess the prevalence of painful diabetic 
neuropathy (PDN) and its relationship to various cardiovascular characteristics in 
diabetes subjects. 
Methods: This was an observational study conducted in Chorley & Whiston towns of 
England, UK (n =204).  The Self-completed Leeds Assessment of Neuropathic Symptoms 
and Signs (S-LANSS) questionnaire was used by post to diagnose PDN. Consent for 
participation and access to blood results were provided by the diabetes subjects and 
ethical approval was granted National Research Ethics Committee UK.   
Results: In this study, the crude prevalence of PDN was 30.3%. The prevalence of type 
2 DM in the subjects was higher (33.1%) than type 1 (14.1%).  We found a significant 
association of obesity, smoking and height in males to PDN, compared with the non-PDN 
group (P <0.05). We also saw a significant trend of increasing prevalence of PDN with 
duration of diabetes, increased HbA1c and increased BMI (P<0.05). A trend of increasing 
prevalence with age was also found (P>0.05); however, due to the small sample, the data 
was not statistically significant. There was no relationship between PDN and systolic or 
diastolic blood pressure, nephropathy, alcohol intake or blood cholesterol (P>0.05).  
Conclusion: In this study, about 1/3 of all diabetic subjects suffered from PDN diabetic 
neuropathy. PDN was twice as prevalent in type 2 DM than in type 1, and a significant 
correlation with smoking, weight and height were seen. Prevalence of PDN increased 
with age, duration of diabetes, poor glycaemic control and obesity. These results highlight 
the importance of achieving better control of modifiable factors such as smoking, 
glycaemic control (HbA1c) and obesity. 
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2.2 INTRODUCTION 
Diabetes mellitus (DM) affects about 382 million people worldwide and its prevalence is 
expected to increase to 592 million by the year 2035 (International Diabetes Federation 
(IDF), 2013). Diabetic neuropathy (DN), a well-known, long-term complication of DM, 
may affect almost half of the diabetic population (Tapp and Shaw, 2009) and is associated 
with higher morbidity and mortality (Vinik et al., 1994). DN encompasses a variety of 
clinical and sub-clinical presentations. Painful diabetic neuropathy (PDN) is a common 
type of diabetic neuropathy and the most common cause of neuropathic pain (Chong and 
Hester, 2007). The reported prevalence of PDN has varied from 11% in Rochester, 
Minnesota, USA, (Dyck et al., 1993) to 53.7 % in the Middle East (Jambart et al., 2011). 
One UK study published in 2011 reported the prevalence of PDN to be 21.5% in type 2 
(T2) DM patients and 13.4% in type 1 (T1) DM patients, resulting in an overall prevalence 
of 21% (Abbott et al., 2011). Several studies have observed that that duration of DM and 
increased age are directly related to PDN (Jambart et al., 2011; Abbott et al., 2011; 
Tesfaye et al., 1996, Partanen et al., 1995). In a large, prospective EURODIAB study 
conducted in 16 European countries, almost one-quarter of type 1 DM patients developed 
new-onset PDN over a seven-year period (Tesfaye et al., 1996). A prospective study in 
Finland followed newly diagnosed diabetes patients between the ages of 45 and 64 years 
for 10 years and found a 6% prevalence of PDN at the time of DM diagnosis and a 26.4% 
prevalence at the 10-year follow-up (Partanen et al., 1995). Most studies found no 
significant difference in genders; However. Abbot et al. (2001), reported a slightly higher 
prevalence of painful symptoms of neuropathy in females (38%) than in males (31%). 
The same study also found a higher prevalence of painful symptoms in South Asians 
(38%) compared to Europeans (32%). 
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Several validated diagnostic questionnaires are available to aid in the diagnoses 
of neuropathic pain, including the  Neuropathic Symptom Score (NSS), the Douleur 
Neruopathicque en 4 Questions (DN4), the Leeds Assessment of Neuropathic Symptoms 
and Signs (LANSS) scale and the Self completed LANSS (S-LANSS). These 
questionnaires have all been used in various prevalence studies of PDN. Jambart et al. 
(2011) used the DN4 questionnaire in the Middle East and reported highest prevalence of 
PDN found to date, at 53.7%. Erbas et al. (2011) used the LANSS questionnaire and 
reported a PDN prevalence of 16% in the Turkish diabetic population. Abbot et al. (2011) 
used the NSS questionnaire and observed a 21% prevalence in United Kingdom diabetic 
population. S-LANSS is a self-completed version of LANSS. Bennett et al. (2005) 
compared the S-LANSS postal survey with the interview format and found that the S-
LANSS scale correctly identified 75% of pain types when self-completed and 80% when 
used in interview format. These findings support the use of the S-LANSS scale as a valid 
and reliable self-report instrument for identifying neuropathic pain that is also acceptable 
for use in postal survey research. As such, several studies have used the S-LANSS 
questionnaire to diagnose neuropathic pain including PDN (Yunus and Rajbhandari, 
2011; Cho et al., 2014, Torrance et al., 2013). Liberman et al. (2014), for example, used 
the S-LANSS questionnaire and observed a 46.5% prevalence of PDN in the Israel 
diabetic population, while Younis and Rajbhandari (2011) used the S-LANSS to confirm 
the presence of neuropathic discomfort in diabetic foot ulcers. 
The S-LANSS questionnaire is based on self-assessment performed by the patient 
and thus does not require healthcare professional input or examination to complete. It is 
a validated tool, is easy to use, and data can be collected easily from the targeted 
population via postal service. It is also routinely used in some diabetes neuropathy clinics. 
In contrast, the NSS questionnaire used by Abbot et al. (2011) in a PDN prevalence study 
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on 10,000 diabetic patients required assessment and examination by the healthcare 
professionals in order to complete the questionnaire. Although the S-LANSS 
questionnaire is comparatively easier to use, its completion depends on patient 
understanding of the questions. We chose the S-LANSS questionnaire for this study due 
to its ease of use and the fact that it is a validated tool that can be administered via postal 
survey (Bennett et al., 2005).  
The main aim of this study was to assess the prevalence of PDN using the postal 
self-administered S-LANSS questionnaire and to identify the associations of gender, age, 
duration of diabetes, smoking, alcohol, HbA1c, lipid profile and eGFR as risk factors for 
PDN in comparison to diabetic neuropathy without pain.  
2.3 SUBJECTS & METHODS 
Primary care subjects were identified from patients with the diagnosis of DM in the 
General Practice database of Aston Healthcare, Whiston, Merseyside. Secondary care 
subjects were identified from the Diabetes Alliance for Research in England (DARE) 
database at Lancashire Teaching Hospitals NHS Trust. Patients under 16 and over 80 
years of age were excluded. All patients were mailed a Modified S-LANSS questionnaire 
through the postal service. An information leaflet, consent form for participation and 
access to blood results, and a self-addressed return envelope were included in the mailing. 
In the modified S-LANSS questionnaire, a score of 12 or more and a bilateral stockings, 
or stockings and gloves distribution of pain were the criteria for the diagnosis of PDN in 
this study. The laboratory data and medical records held at Lancashire hospitals NHS 
Trust and Aston Health Care, Whiston were used for this study. Ethical approval was 
granted by the National Research Ethics Service, UK, and institutional approvals were 
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obtained from Lancashire Hospitals NHS Trust, Aston Health Care, Whiston, and the 
University of Central Lancashire. 
2.3.1 Statistical Analysis 
Data were analysed using Graph Pad software (Graphpad Inc USA, 2013). The 
continuous variable were normally distributed and expressed as means, +/- standard 
deviation (SD), median, 95% confidence interval and P value. The means were analysed 
by unpaired Student’s t-test. Categorical data were expressed as frequency distribution 
and percentage of subjects groups along with p value. The categorical data were also 
analysed by 2x2 table using Fischer’s exact test.  The continuous variable descriptive 
statistics and trend in groups were calculated with the chi-square test using Minitab 
statistical software (Minitab statistical software, 2013). 
2.4 RESULTS 
A total of 205 patients with diabetes were identified from primary care and 266 from 
secondary care and sent the pre-paid postal questionnaire. The total of 204 (43.3%) 
returned the postal modified S-LANSS questionnaire with the signed consent form. The 
number of secondary care subjects that responded was 48.7% (n=130) compared to 36% 
(n=74) from the primary care group. The mean age (+/-SD) of subject was 64.1 +/- 12.11 
years. There was a total of 125 males (61.2%) with mean age (+/-SD) of 64.5 +/- 11.5 
years, and 79 females (38.7%) with mean age (+/-SD) of 63.7 +/- 13.2 years. The ages in 
both genders were similarly distributed (P > 0.05). A total of 123 (60.2%) subjects with 
diabetes reported pain in the questionnaire. Further S-LANSS questionnaire assessment 
was done on all 123 of the subjects who reported pain.  A total of 62 (50.4%) of the 
subjects who had complained of pain fulfilled the criteria of PDN with the mean (+/-SD) 
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S-LANSS score of 18.1 (+/- 4.0). The overall prevalence of PDN in the population studied 
was 30.3% (n = 62, confidence interval (CI) = 24.4 – 37.0), and fairly comparable for 
males (30.4%, n=38, CI 23.0 – 38.9) and females (30.3 %, n= 24, CI 21.3 – 41.2) (P = 
1.0). The prevalence of PDN among  T2DM patients was 33.1% (n= 57, CI 26.5 – 40.4), 
which was significantly (P < 0.05) higher than in T1DM (14.2% (n= 4, CI 5.0 – 32.1) (P 
= 0.048) (see Table 2.1). 
 
Table 2.1:  Prevalence of PDN in the study population. Data expressed as percentages. 
 
Groups        Subjects with PDN                              Prevalence of PDN                                                                                                                              
(n)                                (n)           (Age)               (Duration of DM)                       (%)                  (95% CI) 
                                                       Yrs +/- SD                   Yrs +/-SD 
Total study group (n=204)              62        62+/- 10                      12.9+/-8.8                                   30.3                     24.4 – 37.0 
     Males     (n=125)                       38        63.7+/- 13.2                                                                    30.4                    23.0 – 38.9 
     Females (n=79)                         24        60+/- 12.1                                                                        30.3                    21.3 – 41.2    
     TIDM (n=28)                              4        55.5+/- 9.11                  31.75+/-13.2                              14.2                     5.0 – 32.1 
     T2DM (n=172)                          57       62.93+/- 10.94              11.79+/-6.82                              33.1                     26.5 – 40.4 
     Unknown type (n=4)                 1                                                                                                   25                       3.4 – 71 
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The overall prevalence of PDN in the secondary care group was 33% (n=43). This 
was statistically no different from the primary care group (25.6%; n=19) (P= 0.34). 
Details are provided in Table 2.2.  
 
 
 
 
 
Table 2.2:  Prevalence of PDN in Hospital and GP groups. Data expressed as percentages.                          
                                
                                                         Prevalence of PDN 
Group (n)                        Hospital Group (n)        GP Group (n)                      P value 
(n = Total )                                      (n = subjects with PDN) 
Male (125)                          34.5%  (28)                      22.7% (10)                      0.222 
Female (79)                          30.6% (15)                       30.0% (9)                       1.000                               
Type 1 Diabetes (28)             11.5% (3)                        50% (1)                          0.269            
Type 2 Diabetes (172)          39.0% (39)                        25.0% (18)                    0.070                          
 
 The clinical and biochemical characteristics of the study groups, either with or 
without PDN, are shown in Table 2.3. Taller height in males, increasing body weight and 
BMI, and smoking history, were associated with the presence of PDN (p<0.05). 
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Table 2.3:  Demographic and clinical variables and characteristics comparing subjects 
between PDN and non- PDN groups. Data are mean +_SD; * p<0.05 statistical significant 
 
              (Non PDN group)                            (PDN group) 
Variables                                            (n = 142)                                      (n = 62)                                           P value 
        Mean +/- SD                                  Mean +/- SD 
Age (years)                                            64 +/- 12                                    62 +/- 10                                                   0.179 
Males (n=125)                                       64.5 +/- 11.5                              63.7 +/- 13.2                                             0.634 
Females (n=79)                                      65.0 +/- 13.5                               60+/- 12.1                                                0.177 
Height (cm) 168.96+/- 8.94                          170.36+/-11.07            0.423  
Male                                                     173.3 +/- 6.4                              176 +/- 6.7                                                0.023* 
Female                                                 160.2 +/- 6.3                            159.1 +/- 7.61                                               0.591 
Weight (Kg)                                        90.1 +/- 23                                   106.6 +/- 27                                           0.0001* 
˃ 80 Kg                                               99.9 +/- 20.8                              110.4 +/- 26.3                                            0.015* 
˂ 80 Kg                                                 67.4 +/- 8.3                                68.0 +/- 4.24                                              0.894 
Body mass index (Kg/m2)                     31.8 +/- 8.1                                 37.1 +/- 9.0                                          0.0005* 
Systolic BP (mm Hg)                           135.8 +/- 19.1                              138 +/- 16.8                                              0.473 
Diastolic BP (mm Hg)                           75.5 +/- 12.0                              76.8 +/- 9.1                                               0.453 
Duration of diabetes (years)                  13.5 +/- 9.8                                  12.9 +/- 8.8                                             0.725 
HbA1c (mmol/mol)                              59.2 +/- 15.4                                60.5 +/- 14.8                                            0.588 
Urine ACR (mg/mmol)                          4.8 +/- 21.6                                   9.6 +/- 32.6                                            0.233 
eGFR (mls/min/1.732)                           70.8 +/- 19.3                                 71.2 +/- 18.3                                          0.889 
Creatinine (umol/L)                               92.4 +/- 69.5                                90.3 +/- 39                                              0.826 
Total Cholesterol (mmol/L)                    4.0 +/- 0.9                                    4.1 +/- 1.2                                              0.672 
Smoking % (n)                                        47.1 (67)                                       74.1 (46)                                           0.0004* 
Alcohol n (%)                                          85 (59.8)                                       36 (58.0)                                              0.877 
Management n (%) 
Diet only                                                 11 (7.7)                                         5 (8.0)                                                   1.000 
OGLA                                                     68 (47.8)                                       33 (53.2)                                               0.540 
Insulin                                                     31 (21.8)                                        9 (14.5)                                                  0.25 
OGLA + Insulin                                     32 (22.5)                                      15 (24.1)                                                 0.857 
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The results also show a significant (P < 0.0001) linear trend in the prevalence of 
PDN with the duration of DM in years overall (<5years: 8%; 5-9: 24.1%; ≥ 10: 40.3%, 
trend X2: 99.38, P<0.0001) (Figure 2.1), in type 1 DM (<5years:<1%; 5-9: <1%; ≥ 10: 
100%, trend X2: 23.58, P<0.0001) (Figure 2.2), in type 2 DM (<5years:10%; 5-9: 26%; ≥ 
10: 64%, trend X2: 60.49, P<0.0001) (Figure 2.3), increasing HbA1c (HbA1c < 6.5% (48 
mmol/mol): 20%; 6.6% – 7.4% (49-57 mmol/mol): 34%; ≥ 7.5% (58 mmol/mol): 53.1%; 
trend X2: 107.83, P<0001) (Figure 2.4) and increasing BMI (BMI <28: 12.7%; 28-34: 
34%; ≥ 35: 53.1%; trend X2: 16.27, P<0.023 (Figure 2.5). There was also a linear trend 
in the prevalence of PDN observed with increasing age (age < 40: 3.2%; 40-49: 6.4%; 
50-59: 17.7%; 60-69: 32.3%; > 65: 40.3%; trend X2: 14.38, P=0.109) (Figure 2.6). 
However, these data were not statistically significant. 
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Figure 2.1: Prevalence of PDN in relation to duration of DM in years. Trend X2: 99.38; *P<0.0001.  
 
 
 
 
 
 
Figure 2.2: prevalence of PDN in relation to duration of diabetes in type 1 DM in years. Trend X2: 23.58; 
*P<0.0001 
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Figure 2.3: prevalence of PDN in relation to duration of diabetes in type 2 DM in years. Trend X2: 60.49; 
*P<0.0001 
 
 
 
 
 
 
Figure 2.4: Prevalence of PDN in relation to HbA1c in mmol/mol. Trend X2: 107.83;* P<0.0001.  
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Figure 2.5: Prevalence of PDN in relation to body mass index (BMI) kg/m2. Trend X2: 16.27;* P = 0.023 
 
 
 
 
 
 
Figure 2.6: Prevalence of PDN in relation to age in years. Trend X2: 14.38, P > 0.109 
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2.5 Discussion: 
Painful diabetic neuropathy (PDN) is a common type of diabetic neuropathy and the most 
common cause of neuropathic pain (Chong and Hester, 2007). It has a huge impact on 
people’s quality of life, both physically and mentally. In this investigation, the crude 
prevalence of PDN in the study population in Chorley & Whiston towns of  England, UK 
was 30.3%. The prevalence of T2DM among subjects was higher (33.1 %) compared to 
T1DM subjects (14.1%). There was a significant association of obesity (increasing weight 
and BMI), smoking and height in males to PDN, compared with the non-PDN group. 
There was also a significant trend of increasing prevalence of PDN with duration of DM, 
increasing HbA1c and increasing BMI. There was also a trend of increasing prevalence 
with age; however, due to the small sample size, the data were not statically significant. 
2.5.1 Comparison with existing data 
Numerous studies have reported the prevalence of PDN in diabetes with varied results, 
reporting levels from 11% in Rochester, USA (Dyck et al., 1993) to 53% in the Middle 
East (Jambart et al., 2011). The variation in PDN prevalence numbers is likely due to the 
different diagnostic criteria used in the studies. Likewise, there are some actual 
geographical and population contributions to these findings. Jambart et al. (2011) 
reported the highest prevalence of PDN seen to date, in the Middle East (53%) using the 
DN4 score. Similarly, using the S-LANSS questionnaire, Liberman et al. (2014) observed 
46.5% prevalence of PDN in the Israel diabetic population.  Erbas et al. (2011) used the 
LANSS questionnaire in Turkey and reported 16%. The present study used the S-LANSS 
questionnaire in Northwest England and found a crude prevalence of 30.3%, which is 
comparable to a study by Abbot et al. (2011) in the Northwest England that used the NSS 
questionnaire and reported a prevalence of painful symptoms of 34%. Similarly, a study 
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by Davies et al. (2006) in the Wales population in the UK used neurological history and 
examination with the Toronto clinical scoring system and reported a 26.4% prevalence of 
PDN in diabetes sufferers. 
Type 1 vs. type 2 diabetes 
In the present study, the prevalence of PDN in T1DM was 14.1% and 33.1% in T2DM. 
These results are more or less similar to the study of Abbot et al. (2011), who reported a 
prevalence of 22.7% and 35% for painful symptoms in T1DM and T2DM, respectively. 
Gender 
In present study, there was no difference in prevalence by gender (males: 30.4% and 
females 30.3%). This is similar to other studies, but differs from Abbot et al. (2011) who 
reported higher prevalence of in females (38%) compared to males (31%).   
Height 
The present study also found that increasing height among males was significantly 
associated with PDN. This is similar to the results of a EURODIAB study (Tesfaye et al, 
1996) in which the authors found an association between increasing height and PDN.  
Obesity 
Jambart et al. (2011) reported that obesity with BMI greater than 30 was significantly 
associated with PDN. Similarly, the present study found a strong association of obesity, 
with weight above 80 Kg (P<0.0001) and increasing BMI (P<0.0005) showing a linear 
trend of increasing prevalence of PDN (BMI <28: 12.7%; 28-34: 34%; and ≥ 35: 53.1%; 
trend X2: 16.27, P <0.05) (Figure 3).  
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Smoking 
In the EURODIAB study, Tesfaye et al. (1996) reported smoking to be significantly 
associated with PDN, similar to the results from this study where PDN was significantly 
associated with smoking (P<0.0004). In contrast, Abbott et al. (2011) found no 
correlation between PDN and smoking. 
Alcohol 
The present study shows no significant association between PDN and alcohol 
consumption. These findings are similarly to the studies by Abbot et al. (2011) and 
Tesfaye et al. (1996), who reported no significant correlation between PDN and alcohol 
consumption. 
Cholesterol 
The present study demonstrated no correlation between PDN and increasing levels of 
cholesterol. This is similar to Tsuji et al.’s (2013) study, in which the authors found no 
correlation between PDN and cholesterol. In contrast, the EURODIAB study by Tesfaye 
et al. (1996) found a significant correlation between PDN and increasing levels of 
cholesterol. 
Blood pressure 
The present study found no correlation between systolic or diastolic blood pressure and 
PDN. These data are similar to those obtained by Tsuji et al. (2013). In contrast, Tesfaye 
et al. (1996) found significant correlation between diastolic blood pressure and PDN in 
their EURODIAB study.  
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Nephropathy 
The present study demonstrated no correlation between renal function and PDN. These 
data are similar to those obtained by Tsuji et al. (2013) but in contrast to the findings of 
Jambart et al. (2011) of significant correlation between nephropathy with PDN. In the 
present study, urine ACR was higher in the PDN group (mean 9.6 +/- 32.6) compared to 
the non-PDN group (mean 4.8 +/- 21.6). However, due to the small sample size, the data 
were not statistically significant.  
Duration of diabetes  
The present study also found a statistically significant linear trend of increasing 
prevalence with duration of DM—8% in those with DM for less than 5 years, 24.1% with 
up to 9 years and almost double, and 40.3% with 10 years. The present data are in close 
agreement with those obtained by Jambart et al. (2011) and Tesfaye et al. (1996).  
Poor Glycaemic control 
Similarly, the present study found a linear trend of increasing prevalence with poor 
glycaemic control (HbA1c < 6.5% (48 mmol/mol): 20%; 6.6% - 7.4% (49-57 mmol/mol): 
33.3%; and HbA1c ≥ 7.5% (58 mmol/mol): 46.6%; trend X2: 107.83, P<0.0001). In their 
study, Tesfaye et al. (1996) found significant correlation between PDN and poor 
metabolic control.  
Age 
The present study also found a linear trend of increasing prevalence of PDN with 
increasing age (age < 40: 3.2%; 40-49: 6.4%; 50-59: 17.7%; 60-69: 32.3%; > 65: 40.3%; 
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trend X2: 14.38, P=0.109. This was similar to the findings of Abbot et al. (2011), who 
demonstrated a significant increase in PDN prevalence with increasing age. The age-wise 
prevalence data in this study, however, were not statistically significant due to a small 
sample. 
2.5.2 Strengths and limitations of the study 
The study population was well defined for both the Hospital and General Practice groups. 
All subjects with diabetes between the ages of 16 to 80 registered at GP practice and all 
subjects with diabetes in the DARE database had previously agreed to participate in future 
research at Lancashire Hospitals NHS Trust, and were invited to participate in our study 
by post. Because we aimed to minimize the Berkson selection bias, participants were 
recruited from both hospital/secondary care and general practice/primary care. Regarding 
responses, both groups of participants responded to the study, but with less than 50% of 
the total invited. Of this percentage, 48.7% came from hospital group and 36% from GP 
practice group. Both groups completed the S-LANSS questionnaire and provided 
demographic data. Both groups were also similar in age and had a similar ratio of males 
to females.  
A major limitation of the study was related to the selection bias of both Hospital group 
and GP group patients. Hospital group patients were selected from the DARE database 
where patients were already volunteered for future diabetes research. Secondary care 
enrolment suggests severity of the disease with multiple comorbidities. Furthermore 
primary care group lies in the low socioeconomic community status area. Poor 
socioeconomic areas are known to have higher cardiovascular risks and comorbidities. 
Cardiovascular risks and comorbidities are known to have direct association with PDN.  
These discrepancies and lack of randomisation in the study, could have led to selection 
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bias, which could have an impact on outcome. Recall bias could exist during completion 
of the questionnaire. Questions on the S-LANSS questionnaire were based on current or 
recent characteristics of pain; hence, recall bias in the best scenario is expected to be 
minimal. However it requires ability to read, understanding of the questions and 
physically able to write the response and post it to the researcher. The outcome was based 
only on those patients who responded with their understanding of the questions hence 
recall bias could not be ruled out.   
2.6 Conclusion 
The study found that about 1/3 of all diabetic subjects in the study suffered from painful 
diabetic neuropathy. It was twice as prevalent in type 2 diabetes than in type 1. There was 
a significant correlation of PDN with smoking & height. Prevalence of PDN also 
increased with age, duration of diabetes, poor glycaemic control and obesity. As painful 
diabetic neuropathy has a huge impact on quality of life (Quattrini and Tesfaye, 1996), 
this study highlights the importance of better control of modifiable factors such as 
smoking, glycaemic control (HbA1c) and obesity. Controlling these factors may not only 
prevent cardiovascular disease but also prevent the occurrence of painful diabetic 
neuropathy. 
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Chapter 3 
 
 
 
 
 
The impact of painful diabetic neuropathy on quality of life 
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Currently in press in the journal Diabetes and Primary Care  
3.1 Abstract 
Diabetes is a common disorder affecting over 380 million people worldwide. It is 
associated with several long-term complications, one of which is painful diabetic 
neuropathy (PDN). About a third of diabetes subjects experience PDN, a distressing 
condition that affects patients both physically and emotionally. This aim of this study was 
to assess the quality of life (QoL), mood and anxiety in diabetic patients with PDN using 
the Short form (SF36) and Hospital Anxiety and Depression Scale (HADS Scale) 
questionnaires. When PDN patients were compared with diabetic patients without PDN 
(Control group), the results revealed that PDN was significantly associated with impaired 
QoL, both physically (p<0.0001) and mentally (p<0.026). Anxiety also was significantly 
associated with the PDN group compared to control (p<0.018), and depression was 16% 
more prevalent in the PDN group than in control. 
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3.2 Introduction  
There are currently about 382 million people worldwide living with diabetes mellitus 
(DM) and it is estimated that this figure will rise to 592 million by the year 2035 
(International Diabetes Federation, 2013). The prevalence of DM-related complications 
are also rising. PDN is a common complication of DM, affecting about 1/3rd of all patients 
with diabetes (Tesfaye and Boulton, 2009). PDN is characterized by bilateral symmetrical 
distal neuropathic pain in the lower extremities with varied symptoms from mild pins and 
needles, tingling sensations, shooting pain similar to electric shock, constant burning 
sensation with nocturnal exacerbation, and contact hyper-sensitivity-allodynia (Larsen 
and Kronenberg, 2002). Relentless pain and allodynia affect patients both physically and 
mentally, causing disturbances in sleep, lowered mood, sexual impotence and social 
withdrawal. In extreme cases, the patient is unable to walk (Galer et al., 2000; Quattrini 
and Tesfaye, 1996; Gardner and Shoback, 2007). PDN can thus significantly alter a 
patient’s quality of life. Currently, there are only few studies that have specifically 
measured the physical and mental impacts of PDN on patients’ quality of life. This study 
was designed to assess the quality of life (QoL), mood and anxiety in patients with PDN 
(PDN group) compared to patients with diabetes not known to have PDN (Control group). 
There are several health related questionnaires available to assess QoL, and 
physical and mental wellbeing (Healthmeasurement.org, 2014). Most researchers 
typically use the short form health survey (SF36) for the assessment of QoL and hospital 
anxiety and depression scale (HADS) for the assessment of mood and anxiety. Ware and 
Sherbourne (1992) introduced the 36-item short form health survey (SF36) in 1992. It 
was designed for use in clinical practice and research, health policy evaluations, and 
general population surveys.  
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The SF36 includes 36 subjective questions that assess eight health concepts of 
QoL from the patient’s point of view. These include: 
1) Limitations on physical activities due to health problems. 
2) Limitations on social activities due to physical or emotional problems 
3) Limitations on usual roles and associated activities due to physical health problems 
4) Bodily pain 
5) General mental health (psychological distress or well-being) 
6) Limitations on usual roles and associated activities due to emotional problems 
7) Vitality (energy or fatigue) 
8) General health perceptions 
  SF36 is practical, reliable and valid measure of physical and mental health and 
has been used in a variety of chronic health conditions, including diabetic neuropathic 
pain (Ware et al., 1994; Garratt, 1993; Vinik et al. 2013; Rosenstock, 2004) and published 
in more than 4,000 documents (Turner-Bowker et al., 2002).  
The HADS questionnaire was originally developed by Zigmond and Snaith (1983) 
for use in psychometric evaluation. Since then, it has been widely used worldwide by 
health professionals, both in the community and hospital settings and has been found to 
be both a reliable and a valid measure of anxiety and depression (El-Rufaie and Absood, 
1987; Nortvedt and Riise, 2006). The HADS questionnaire contains 14 questions, seven 
for the assessment of anxiety assessment and seven for depression. HADS provides clear 
cut-off scores for the severity of anxiety and depression. Since HADS is believed to be 
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an ideal tool for screening and an index measuring clinical change, it was decided to 
employ this questionnaire to measure the QoL in diabetic patients along with the SF-36. 
 
3.3 Methods 
3.3.1 Participants 
This was an observational study conducted to assess quality of life, mood and anxiety in 
patients with PDN attending the Diabetic Neuropathic Pain Clinic at Chorley District 
General Hospital (CDGH). The PDN group was compared to diabetic patients not 
known to have neuropathic pain (Control group), who attended the Aston Healthcare 
General Practice (GP) Surgery for diabetes review at Whiston in Merseyside, UK. 
Institutional approvals were obtained at both centres for the study.  A total of 25 
consecutive patients with PDN were selected at Chorley DGH during their follow-up 
visit at the diabetic neuropathy pain clinic. The mean age (+/- SD) of subject was 56.4 
+/- 11.4 years. There was a total of 15 males (60%) with mean age (+/- SD) of 55 +/- 
10.2 years, and 10 females (40%) with mean age (+/- SD) of 58.6 +/- 13.4 years. The 
ages in both genders were similarly distributed (P >0.05). Another 25 consecutive 
patients with diabetes but without PDN were selected on their routine visits at GP 
surgery. There was a total of 14 males (56%) with mean age (+/- SD) of 57.7 +/- 14.5 
years, and 9 females (44%) with mean age (+/- SD) of 55 +/- 15.8 years. The ages in 
both genders were similarly distributed (P >0.05). Patients under 16 and over 80 years 
of age were excluded from participation. All patients gave consent for participation. 
3.3.2 Study Design 
The SF36 and HADS (Hospital Anxiety and Depression Score) questionnaires were used 
for data collection, based on the rationale described above. The SF36 requires about 15 
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minutes to complete, and HADS 5 minutes, which meant that participants were able to 
complete the questionnaires while waiting for their appointments. Alternatively, they 
were given the choice to send it through post after completing it at home. 
3.3.3 Assessment of quality of life, anxiety and mood. 
SF36 used for QoL assessment  
The SF36 questionnaire consisted of 36 questions that were scored from 0 (worse possible 
functioning) to 100 (highest level of function). Aggregate scores were compiled as a 
percentage of the total points possible using the RAND scoring system (Rand.org, 2013). 
The average scores from those questions that addressed a specific functional health 
domain were the final score of the domain. There were eight domains: four for physical 
health (physical function, role limitation due to physical health, pain and general health) 
and four for mental health (role limitations due to emotional problems, low 
energy/fatigue, emotional well-being and social functioning).  The scores for each 
individual domain and the average aggregate scores for the physical and mental health 
domains were expressed as a percentage, with 0 representing the worse possible health 
state and 100 representing highest level of functioning and health.  
 
HADS questionnaire used for the assessment of anxiety and mood  
The HADS questionnaire contained a total of fourteen questions, seven questions for 
anxiety and seven for depression. Each question was scored from 0 (excellent mental 
health) to 3 (poor mental health). The sum of all seven questions score was the final score 
for either anxiety or depression, which ranged from 0 to a maximum of 21 (worst possible 
mental health). Scores between 0 to 7 were normal HADS scores for both anxiety and 
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depression assessment. Scores 8 and above were considered to be significant for the 
diagnosis of both anxiety and depression (El-Rufaie and Absood, 1987; Nortvedt and 
Riise, 2006). 
 
3.3.4 Statistical Analysis 
Data were analysed using Graph Pad software (Graph pad software Inc. USA, 2013). The 
continuous variable of SF36 and HADS were normally distributed and expressed as 
means, +/- standard deviation (SD), median, 95% confidence interval and P value. The 
means were analysed using an unpaired Student’s t-test. Categorical data were expressed 
as frequency distribution and percentage of subjects groups and p value. The categorical 
data from the HADS were also analysed by 2x2 table using Fischer’s exact test.  Boxplots 
were created with descriptive statistics using Minitab statistical software (2013). The 
plots display the median (horizontal band) along with minimum and maximum, and the 
boxes represent the lower (Q1=25%) and upper (Q3=75%) quartile range. 
 
3.4 Results  
Both groups were similarly distributed (P > 0.05) in age and gender. Subjects in the PDN 
group had significantly (p<0.05) lower scores in seven out of eight domains of SF36 
compared to the control group (Table 3.1). These included physical functioning 
(p<0.0001), physical health limitations (p<0.0002), pain (p<0.0005), general health 
(p<0.0034), emotional problem limitations (p<0.0188), fatigue (p<0.0073) and social 
functioning (p<0.0292). The only exception was emotional well-being, in which the PDN 
group was not significantly different from control (p>0.05). Both physical health 
(p<0.0001) and mental health (p< 0.026) summary scores were significantly lower in the 
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PDN group compared to the control group. The summary of physical health and mental 
health aggregate scores from the SF36 is given in Figure 3.1.  
 
 
Table 3.1: SF36 eight domains data in PDN and control group.  
SF36 Domains                PDN Mean        Control Mean      95% Confidence interval                P value 
 
Physical Functioning  
  
 
                 
28.38                 65.2                   18.91 to 54.71                            <0.0001* 
Physical Health  
Limitation     
 
                      
17.0                   61.0                    21.94 to 66.06                             <0.0002*    
Pain                                             
 
29.3               59.9                   14.21 to 46.98                               <0.0005* 
General Health                      
 
31.06                  52.0                    7.27 to 34.59                                 <0.0034* 
Social Functioning                    
 
48.8                      68.0                     2.03 to 36.36                               < 0.0292*              
Emotional well-being  
                
61.44                    69.28                  -6.96 to 22.64                                 0.292 
 
Fatigue                                      
 
25.36                     42.4                     4.8 to 29.26                                   <0.0073* 
Emotional Limitation           
 
41.33                   71.99                    5.30 to 56.02                                 <0.0188*      
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Table 3.1 gives the SF36 eight domain score means, 95% confidence interval and 
P values for the PDN and control groups. The subjects in PDN group had significantly 
lower scores compared to control group in physical functioning domain (p < 0.0001), 
physical health limitation domain (p < 0.0002), pain domain (p <0.0005), general health 
domain (p<0.0034), social functioning domain (P=0.0292), fatigue domain (p<0.0073) 
and emotional problem limitation domain (p<0.0188). The data for emotional wellbeing 
domain was not statistically significant (P<0.292; not significant). 
 
Subjects in PDN group had significantly (p<0.001) higher HADS anxiety scores 
in comparison to the C group. However, HADS depression scores were not statistically 
significant (Figure 3.2).  
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Figure 3.1: The box plot analysis shows the overall physical and mental health domain 
aggregate scores from the SF36 in the PDN and C groups. Data are mean +/_ SD; n=25. 
In the physical health aggregate domain, the PDN group’s mean score was 27.26 (SD 
23.15, median 17.5) and the C group’s mean score was 59.52 (SD 29.71, median 60.62) 
(P<0.0001). In the mental health aggregate domain, the PDN group’s mean score was 
44.43 (SD 27.52, median 35.16) and the C group’s mean score was 62.31 (SD 27.59, 
median 72.25) (P<0.0262). The plot shows the median score (horizontal band) along with 
the minimum and maximum score. The box represents the lower (Q1=25%) and upper 
(Q3=75%) quartile range of the score. 
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Figure 3.2: The box plot analysis shows the HADS anxiety and depression scores for the 
PDN and C groups. Data are mean +/- SD; n=25. For the HADS anxiety score, the PDN 
group’s mean score was 7.32 (SD +/- 3.42, median 8) and the C group’s mean score was 
4.72 (SD +/- 4.34, median 4) (P= 0.023). For the HADS depression score, the PDN 
group’s mean score was 8.36 (SD +/- 4.05, median10) and the C group’s mean score was 
6.6 (SD +/- 4.16, median 7) (p= 0.136). The plot shows the median score (horizontal 
band) along with the minimum and maximum score. The box represents the lower 
(Q1=25%) and upper (Q3=75%) quartile range of the score. 
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 Fourteen (56%) subjects out of 25 had anxiety in the PDN group, mean score was 
7.32 +/- 3.42 SD. In the C group, 5 (20%) had anxiety, mean score 4.72 +/- 4.34 SD. P 
value calculated by both continuous data of means by unpaired t test (p< 0.023) and 
categorical 2x2 table analysis with frequency of anxiety diagnoses (P=0.018).  Fifteen 
(60%) out of 25 were diagnosed with depression in the PDN group, mean score 8.36 +/- 
4.05 SD. In the C group, 11 (44%) were diagnosed with depression, mean score 6.6 +/- 
4.16 SD. P value calculated by both continuous data of comparison of means by unpaired 
t test (p= 0.136) and categorical 2x2 table analysis with frequency of depression diagnoses 
(P= 0.396). 
 
3.5 Discussion  
Painful diabetic neuropathy (PDN) is one of the most common complications of diabetes 
mellitus, with about 1/3 of all DM patients suffering from diabetic neuropathic pain 
(Tesfaye and Boulton, 2009). Although it has a huge impact on quality of life (QoL) 
(Galer et al., 2000; Quattrini and Tesfaye, 1996; Gardner and Shoback, 2007), few studies 
have specifically reported the impact of DPN on QoL and or looked specifically at the 
psychological well-being of diabetes patients (Galer et al., 2000; Quattrini and Tesfaye, 
1996; Van Acker, 2009; Benbow et al., 1998; Gore et al., 2005; Argoff et al. 2006). Our 
data shows a significant association of PDN with poor QoL and anxiety symptoms, but 
not with depression. This could be because a number of patients with PDN are treated 
with antidepressants for their neuropathic pain. Hence, the underlying symptoms of 
depression could have been minimized to some extent. Also, the control group data, 
which were collected from the GP surgery, belong to a low socioeconomic area of 
Northwest England. It is known that low socioeconomic community status is associated 
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with higher prevalence of depression (Murali and Oyebode, 2004). These are possible 
reasons for the lack of statistical significance in the depression data.   
3.5.1 Comparison with existing data 
The data from this study showed significant impairment of QoL with lower SF36 scores 
for both physical and mental health in the PDN group compared to control. The results 
are consistent with a similar study that used  the short version 12-item (SF12) 
questionnaire. In that study, Van Acker (2009) found significant impairment in both 
physical and mental health components of QoL. Another study by Benbow et al. (2000), 
used the Nottingham health profile questionnaire and found significant impairment in 
QoL for PDN patients in 5 out of 6 domains, including emotional reaction, energy, pain, 
physical mobility, and sleep. The only exception was the social isolation domain. 
Similarly, in the present study, the data showed significant impairment in 7 our of 8 
domains, including physical functioning, physical health limitation, pain, general health, 
emotional problem limitation, fatigue and social functioning. The only exception was 
emotional well-being. In cases of severe PDN, patients have reported experiencing 
constant unrelenting neuropathic pain, disturbance of sleep, and even inability to walk 
due to the severity of the pain (Galer et al., 2000; Quattrini and Tesfaye, 1996; Gardner 
and Shoback, 2007). Such an experience, in turn, causes withdrawal from routine 
activities of life, including employment, and also affects the emotional well-being of a 
patient and causes social isolation. The data for the emotional well-being domain in this 
study and social isolation domain of Benbow et al. (2000) study were not significant, 
perhaps due to a lower number of severe PDN cases with extreme symptoms in the study 
groups. However, both studies showed a significant overall impairment of QoL in both 
physical and mental components. 
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The HADS score data in the present study showed that more than half of the patients 
(56%) in the PDN had anxiety symptoms (HADS A score > 7), significantly higher than 
the control group. The data were consistent with those reported by Gore et al. (2005), who 
used the HADS questionnaire and found that 35% of their PDN patients showed anxiety 
symptoms. However, they used a threshold HADS score of 11 or above (moderate to 
severe symptoms). The data for depression symptoms in this study showed that more than 
half of the PDN patients (60%) had symptoms of depression (HADS-D score > 7). 
However, the results were not statically significant compared to the control group, which 
had 44% with depression classification. In contrast, Gore et al. (2005) showed a 
significant association between depression and PDN. In their study, the prevalence of 
depression was 28% in painful diabetic neuropathy (HADS score 11 or above).  A large 
of systematic review and meta analysis reported that the prevalence of depression in the 
diabetic population is around 17.5% (Ali et al., 2006). In the current study, the random 
control group of non-PDN diabetes patients were found to have unusually high prevalence 
of depression (44%), which is inconsistent with baseline prevalence previously reported. 
Since the control cohort of patients belongs to a poor socioeconomic area, the higher 
prevalence of depression in control group could be a confounding factor. The data, 
therefore, were not statically significant.   
3.5.2 Strengths and limitations of the study 
The study population was well-defined for both groups and was assembled with minimal 
selection bias since all participants were selected randomly using snowball sampling. 
Moreover, both groups of participants completed 100% of both questionnaires (SF36 and 
HADS). Both groups were similar in age had a similar ratio of males to females (PDN 
group: male 60%, female 40%; C group; male 56%, female 44%). Hence, selection bias 
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was minimal. Recall bias could exist during completion of the questionnaire. However, 
most questions from both the HADS and SF36 questionnaires were based on the current 
or recent physical and mental well-being of person; hence, recall bias is expected to be 
minimal.  
A major limitation of the study relates to the selection of the control group. As mentioned 
above, the GP surgery from which the control group data were taken lies in an area of 
Northwest England with low socioeconomic status. It is known that low socioeconomic 
community status is positively associated with prevalence of depression (Murali and 
Oyebode, 2004). Furthermore, the two groups were selected from healthcare settings of 
different nature. These discrepancies, and the lack of randomisation in the study, could 
have led to selection bias, which in turn could have had an impact on outcomes. Data 
other than age and sex were not collected for comparison (duration of diabetes, presence 
of other complications, and treatment with antidepressants are among the other potential 
confounding factors). As with any non-randomised study, it is not possible to infer a 
causal relationship and thus our conclusions are tentative at best.  
3.5.3 Conclusion 
Overall, this study supports past findings that painful diabetic neuropathy has a huge 
impact on quality of life and moreover, has a strong association with symptoms of anxiety 
and depression. When encountering patients with PDN, clinicians must thus consider 
exploring more about the psychosocial and mental well-being of patients and the overall 
impact of the condition on patients’ quality of life.   
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Treatment of painful diabetic neuropathy vs. chronic pain with 
intravenous lignocaine infusion. 
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Submitted to the journal, Pain Medicine (under review) 
4.1 ABSTRACT  
 
Objective:  
This study assessed the efficacy of lignocaine infusion as a treatment for chronic 
refractory pain where conventional treatment has proven unsatisfactory. We also assessed 
the difference in responses between painful diabetic neuropathy (PDN) and chronic pain 
(non-PDN). 
Methods:   
A total of 11 patients participated in the study, with 7 patients referred from pain clinic 
(non-PDN group) and 4 patients referred from the diabetes foot clinic (PDN group) for 
lignocaine infusion as a treatment for chronic refractory pain. Both groups of participants 
were on a combination of pain medications with inadequate response. All the subjects 
filled out a McGill short form (SF) questionnaire prior to and after lignocaine infusion to 
evaluate the response.      
Results:  
The mean duration of chronic pain (+/- SD) was 7.1 +/- 4.4 years. The mean somatic pain 
score on the McGill SF questionnaire dropped from 20.1 +/- 7.2 to 16.5 +/- 9.5 after 
lignocaine infusion (P<0.05). Similarly, the mean affective score dropped from 5.5 +/- 
3.1 to 4.0 +/- 3.1 (P<0.05). The results showed a 33% reduction in visual analogue pain 
score after lignocaine infusion in the PDN group compared to an 11% reduction in the 
non-PDN group. These data were statistically significant (P<0.05). Similarly, there was 
a significant (p<0.05) reduction in affective pain score of 41% after lignocaine infusion 
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in the PDN group compared to 21% in the non-PDN group.  In contrast, the somatic pain 
score reduction after lignocaine infusion was 23% in the PDN group compared to 17% in 
non-PDN group. These data were statistically not significant (P>0.05).  All 11 patients 
reported no adverse effects and their observations were within the normal limits 
throughout the lignocaine infusion.  
 Conclusion:  
Overall, the study showed that lignocaine infusion is both effective and safe in reducing 
chronic intractable pain when conventional treatments are intolerable or unhelpful. The 
treatment was more effective in PDN patients compared to other causes of chronic pain.   
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4.2 INTRODUCTION  
The International Association for the Study of Pain (IASP) defines neuropathic pain as 
“pain caused by a lesion or disease of the somatosensory nervous system.” Neuropathic 
pain is caused by direct injury or damage to, or pathological changes in, the peripheral or 
central nervous system. In contrast, nociceptive pain is caused by direct injury or disease 
(Treede et al., 2008). Chronic pain is generally defined as pain that lasts for more than 3 
to 6 months (Debono et al., 2013). Chronic neuropathic pain is very common around the 
world, with almost 6% to 8% of world’s population estimated to suffer from chronic 
neuropathic pain (Torrance et al., 2006; Bouhassira et al., 2008). Diabetic neuropathic 
pain (aka painful diabetic neuropathy, PDN) is the most common type of chronic 
neuropathic pain. Despite advances in treatment options, chronic symptoms of PDN are 
challenging for clinicians and distressing for patients. Boulton et al. (1983) followed 39 
patients with PDN over the period of 4 years and found no significant decreases in 
intensity of pain over time. Another 5-year follow-up study on PDN with conventional 
treatment reported that symptoms resolved in only 23% patients (Daousi et al., 2006).  
Despite advanced treatments and multiple drug regimes, up to 50% of chronic 
neuropathic pain patients are resistant to conventional treatment. One study of chronic 
neuropathic pain patients taking combination conventional neuropathic medications 
showed poor response (Tesfaye et al., 2013). Furthermore, some treatment-resistant 
patients are in intractable pain. These patients have always been a challenge for 
physicians.  Lignocaine infusion has been reported to show satisfactory response in some 
of these challenging, conventional-treatment-resistant patients (Kastrup et al., 1987; 
Viola et al., 2006; Bach et al., 1990).    
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Lignocaine is a sodium channel blocker first synthesized by the Swedish chemist 
Nils Lofgren in 1943 (Löfgren and Lundqvist, 1946). Lignocaine is widely used as a 
local anaesthetic and peripheral nerve blocker. It has been used intravenously for the 
treatment of arrhythmias and is not associated with any significant side effects 
(Challapalli et al., 2005). It has also been found to be effective in chronic neuropathic 
pain (Tremont et al., 2006) and chronic pain disorders (Cahana et al., 1998; Wallace et 
al., 2000). Lignocaine is metabolized in the liver and its elimination half-life following 
intravenous bolus injection is typically 1.5 to 2 hours. However, when chronic liver 
disease and congestive heart failure is present, its half-life may be prolonged.  
The potential use of lignocaine infusion as a treatment for PDN was first 
evaluated by Kastrup in 1986 (Kastrup et al., 1987). Since then, several studies have 
reported pain relief in PDN with lignocaine infusion (Kastrup et al., 1987; Viola et al., 
2006; Bach et al., 1990). Despite its rapid half-life, the duration of pain relief reported 
post lignocaine transfusion was up to 28 days (Kastrup et al., 1987; Viola et al., 2006). 
This could be due to the central de-sensitization effect of the lignocaine along with its 
peripheral action. The side effects in high doses of intravenous (IV) lignocaine can be 
sedation, hypotension and arrhythmia. Severe toxicity is rare, but when it does occur, 
requires cardio-pulmonary resuscitation using the standard protocol along with 
Intralipid infusion via peripheral vein. It expands the intravascular lipid phase that acts 
to absorb the unbound circulatory lipophilic lignocaine (Weinberg, 2012). Overall, 
studies have found that IV lignocaine infusion is very well-tolerated and safe (Kastrup 
et al., 1987; Viola et al., 2006; Wallace et al., 2000). However, because of its practical 
limitations, it is often reserved only for patients who have persistent excruciating pain 
and where other medications are not beneficial. 
99 
 
 There are several pain assessment questionnaires available for the assessment of 
pain. This study used the McGill short form (SF) questionnaire, which was developed 
by Melzack in 1987 (Melzack, 1987). The McGill SF questionnaire is an easy, quick, 
and reliable tool to measure the quality of pain in three different aspects, including 
somatic, affective and visual analogue scores. It has been used as a measure of pain in a 
variety of pain conditions, including PDN (Viola et al., 2006). 
The aim of this study was to assess the efficacy of lignocaine infusion in patients 
with chronic refractory pain and compare the responses between painful diabetic 
neuropathy patients (PDN group) and chronic pain patients (non-PDN group).  
 
4.3 SUBJECTS AND METHODS 
A total of 11 subjects participated and completed the McGill SF questionnaire before and 
after lignocaine infusion. The mean age (+/- SD) of subjects was 52 +/- 13.96 years. There 
were total of 4 males (36%) in PDN group with mean age (+/- SD) 58.7 +/- 15 years and 
7 females (64%) in chronic pain group (non-PDN) with mean age (+/- SD) of 49 +/- 13 
years. All 4 patients in PDN group had type 2 DM with mean duration of diabetes (+/- 
SD) 6.0 +/- 2.4 years. PDN subjects with chronic refractory pain for (+/- SD) 6.5 +/- 3.42 
years, who had not responded to standard oral and topical treatments, were identified from 
the Foot Clinic at Chorley District General Hospital (CDGH). Chronic pain subjects (non-
PDN) with chronic refractory pain for (+/- SD) 7.75 +/- 4.77 years, who had not 
responded to standard oral and topical treatment, were referred for lignocaine infusion 
from the Pain Clinic, Lancashire Hospitals NHS Trust. Both groups of patients had 
already tried and were currently taking a combination of pain medications without relief. 
All subjects attended the study treatment individually and were admitted to the CDGH 
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coronary care unit (CCU) as day cases for 3 hours and given lignocaine infusion 0.2% (2 
mg/ml) at 5 mg/kg body weight over 2 hours with throughout monitoring of 
electrocardiogram, blood pressure, pulse and oxygen saturations. Nurses administered the 
McGill pain short form (SF) questionnaire before and after the infusion for each subject. 
All patients returned to the “pain clinic” after 6 weeks for follow-up.  
The McGill SF consisted of 15 representative words from the somatic (n=11) and 
affective (n=4) pain, as well as visual analogue score (VAS). Each word descriptor was 
ranked by the patient on an intensity scale of 0 – none; 1 – mild; 2 – moderate; and 3 – 
severe. Somatic pain score ranged from 0 to 33, affective pain score ranged from 0 to 12, 
and VAS range from 0 to maximum 10 (Melzack, 1987).  
4.3.1 Statistical Analysis 
Data were analysed using Graph Pad software (Graphpad Inc USA, 2013). The 
continuous variables were normally distributed and expressed as means, +/- standard 
deviation (SD), median and P value. The means of the McGill pain scores were analysed 
by paired Student’s t-test comparing the before- and after-lignocaine infusion results. 
Categorical data were expressed as frequency distribution, percentage of subjects groups, 
and p value. The categorical data were analysed by a 2x2 table using Fischer’s exact test.  
The boxplots were created with descriptive statistics using Minitab statistical software 
(2013). The plots show the median (horizontal band) along with minimum and maximum. 
The box represents the lower (Q1=25%) and upper (Q3=75%) quartile range. 
4.4 RESULTS 
Table 4.1 shows the demographics and baseline characteristics of patients who 
participated in the study. The mean duration of chronic pain (+/- SD) was 7.09 +/- 4.37 
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years. The mean somatic score before lignocaine infusion was (+/-SD) 20.14 +/- 7.16 
compared to a mean somatic score after lignocaine infusion of (+/-SD) 16.5 +/- 9.52. 
There was significant reduction in somatic pain score after lignocaine infusion (P<0.05). 
The mean affective score before lignocaine infusion was (+/-SD) 5.5 +/- 3.09 compared 
to a mean affective score after lignocaine infusion of (+/- SD) 4.0 +/- 3.13. This represents 
a significant reduction in affective pain score after lignocaine infusion (P<0.05). The 
mean visual analogue score (VAS) before lignocaine infusion was (+/- SD) 7.72 +/- 1.75 
compared to mean a VAS score after lignocaine infusion of (+/- SD) 6.13 +/- 2.53. This 
showed a trend for reduction of VAS pain score after lignocaine infusion (P= 0.053). 
(See Figure 4.1) 
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Table 4.1: Demographics and baseline characteristics of patients who participated in the study 
Patient 
No 
Age 
Yrs 
Gender Diagnosis of 
pain  
Duration 
of pain 
Yrs 
Medication tried not helped Current pain medications Before Lignocaine infusion After Lignocaine infusion 
VAS Somatic Affective VAS Somatic Affective 
1 79 Male PDN 11 Amitriptyline , Imipramine, 
Carbamazepine, Capsaicin cream, 
Tramadol, Pregabalin , Mexiletine, GTN 
patch, Duloxetine, MST, Acupuncture, 
Alphalipoic acid, Lignocaine patch 
Gabapentin, Oxycontin  
 
7.5 8 1 3.5 3 3.5 
2 60 Male PDN 3 Pregabalin, Amitriptyline Duloxetine, 
Clonazepam, Durogesic patch,  Oramorph 
PRN. 
Pregabalin, Amitriptyline 
Duloxetine, Clonazepam, 
Durogesic patch,  
Oramorph PRN. 
9 32 7 9 29 9 
3 44 Male PDN 5 Gabapentin, Butrans patch, capsaicin 
cream, colnazepam 
Pregabalin, Amitriptyline, 
Topiramate 
9 12 6 3 4 3 
4 52 Male PDN 7 Pregabalin, Gabapentin, topical Capsaicin, 
Duloxetine, BuTrans patch, Tramadol, 
Oxycontin,  
Morphine Sulphate, 
Amitriptyline, Sodium 
Valproate 
10 22 3 8 21 8 
5 41 Female Back pain 5 Carbamazepine, Duloxetine, 
Amitriptyline, Pregabalin, Ropinerole. 
SI joint injections, Facet joint injections, 
Butrans patch, TENS machine 
Carbamazepine, 
Duloxetine, Amitriptyline, 
Pregabalin, Ropinerole. 
8 30 9 8 29 8 
6 66 Female Fibromyalgia  
3 
TENS, acupuncture, physiotherapy, 
Gabapentin, amitriptyline, Naproxen, 
Codeine, Butrans patch 
Ibuprofen 400mg prn 
  
 
4 20 5 3 11 3 
7 53 Female Back pain  
 
9 Epidural steroid injection, Gabapentin Oxycontin, Pregabalin, 
Amitriptyline 
7 19 4 3 7 3 
8 59 Female Angiolipomata 
 
7 Gabapentin, Cocodamol 30/500, SI joint 
injection, Facet joint injections, TENS  
Carbamazepine, 
Duloxetine, Amitriptyline, 
Pregabalin, Ropinirole 
9 18 4 6 15 6 
9 26 Female Fibromyalgia 
 
18 Amitriptyline 50 mg, Pregabalin, 
Gabapentin, Tramadol, psychotherapy 
OxyContin, Ibuprofen, 
Amitriptyline, Duloxetine. 
6 16 3 8 18 8 
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10 45 Female Demyelination 
of nerves 
6 Gabapentin, Pregabalin, Nabilone, 
Ketamine, Butranspatch, codeine, 
Capsaicin cream, Lidocaine patch, 
Fentanyl patch, Duloxetine, Topiramate, 
Carbamazepine, TENS 
Amitriptyline 50 mg 
Codeine 60 mg at night 
 
6.5 21.5 6.5 7 17.5 7 
11 54 Female Stump pain 4 Paracetamol , Oramorph prn, Oxycodone 
MR, Pregabalin, Lidocaine patches, 
Acupuncture, TENS, carbamazepine 
Paracetamol , Oramorph 
prn, Oxycodone MR, 
Pregabalin, Lidocaine 
patches  
9 26 12 9 27 9 
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Figure 4.1:  Box plot showing the McGill SF somatic score, affective score and visual 
analogue score (VAS), before (B) and after (A) lignocaine infusion in chronic pain 
subjects. Data are mean +/_ SD; n=11, * p<0.05 for somatic score and affective score. * 
p=0.053 for VAS score. 
The box plot in figure 4.1 shows the McGill pain scores in all 3 sub-categories, including 
somatic score, affective score and visual analogue scores (VAS), before  (A)  and  after  
(B) lignocaine infusion in all subjects.  Before lignocaine infusion, the mean somatic 
score was 20.4 +/- 7.16 SD (median 20) compared to a mean somatic score after 
lignocaine infusion of 16.5 +/- 9.52 SD (median 17.5) (P< 0.014). Before lignocaine 
infusion, the mean affective score was 5.5 +/- 3.09 SD (median 5) compared to a mean 
affective score after lignocaine infusion of 4.0 +/- 3.13 SD (median 3.0) (P< 0.013). 
Before lignocaine infusion, the mean VAS score was 7.72 +/- 1.75 SD (median 8) 
compared to a mean VAS score after lignocaine infusion was 6.13 +/- 2.53 SD (median 
7) (P= 0.053). The plot also shows the median score (dark band) along with minimum 
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and maximum score. The box represents the lower (Q1=25%) and upper (Q3=75%) 
quartile range of score.  
All PDN patients were male and all non-PDN patients were female. The ages in 
both genders were similarly distributed (P >0.05). The mean duration of pain (+/- SD) in 
the PDN group was 6.5 +/- 3.42 years compared to 7.75 +/- 4.77 years in non-PDN group. 
The duration of pain in both groups were similarly distributed (P>0.05). All participants 
had tried a combination of medications including antidepressants, antiepileptic 
medications, and opioid agonists, and moreover, were currently on a combination of 
medications with unsatisfactory response.  
The results show a 33% reduction of visual analogue pain score after lignocaine 
infusion in the PDN group compared to an 11% reduction in non-PDN group. The data 
were statistically significant (P<0.05; see Figure 4.2). Similarly, there was a significant 
(p<0.05) reduction in affective pain score (41%) after lignocaine infusion in the PDN 
group compared to 21% in the non-PDN group (see Figure 4.3).  In contrast, the somatic 
pain score reduction after lignocaine infusion was similar between groups, with 23% 
reduction in the PDN group and 17% in non-PDN group. These data were not statistically 
significant (P>0.05; see Figure 4.4) 
All 11 patients reported no adverse effects and their observations, including 
electrocardiograms, pulse, blood pressure and oxygen saturation, were within normal 
limits throughout the lignocaine infusion.  
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Figure 4.2:  Box plot showing visual analogue scores before (B) and after (A) lidocaine 
infusion in the PDN and non-PDN groups. Data are mean +/-SD; n=4 for PDN and n=7 
for non-PDN. * p<0.05 for PDN group compared to non-PDN group. In this and 
subsequent figures, PDN(B) = Painful diabetic neuropathy group score before lignocaine 
infusion; PDN(A) = Painful diabetic neuropathy group score after lignocaine infusion; 
Non-PDN(B) = Non-PDN group score before lignocaine infusion; Non-PDN(A) = Non-
PDN group score after lignocaine infusion; VAS = Visual analogue score 
The box plot analysis in Figure 4.2 shows the visual analogue score (VAS) before  
(A)  and  after  (B) the lignocaine infusion in PDN and non-PDN groups., In the PDN 
group, the VAS mean score before lignocaine infusion was 8.87 +/- 1.03 SD (median 9.0) 
compared to a VAS mean score of 5.87 +/- 3.06 SD (median 5.75) after lignocaine 
infusion (33% pain reduction). In the Non-PDN group (n=7), the mean VAS score before 
lignocaine infusion was 7.07 +/- 1.7 SD (median 7) compared to a VAS mean score of 
6.28 +/- 2.43 SD (median 7) after lignocaine infusion (11% pain reduction). The pain 
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reduction in the PDN group compared to the non-PDN group was statically significant 
(P<0.0015). The plot also shows the median score (horizontal band) along with the 
minimum and maximum score. The box represents the lower (Q1=25%) and upper 
(Q3=75%) quartile range of the score.  
 
 
Figure 4.3:  Box plot showing affective score before (B) and after (A) lidocaine infusion. 
Data are mean +/_ SD; n=4 PDN group and n=7 for non-PDN group. * p<0.05 for PDN 
group compared to non-PDN group. 
The box plot analysis in Figure 4.3 shows the McGill SF affective score before 
(B) and after (A) the lignocaine infusion in the PDN and non-PDN groups. The results 
show that in the in PDN group, the affective mean score was 4.25 +/- 2.75 SD (median 
4.5) before lignocaine infusion compared to an affective mean score of 2.50 +/- 3.11 SD 
(median 1.5) (41% pain reduction) after lignocaine infusion. In the non-PDN group (n=7), 
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before lignocaine infusion, the mean affective score was 6.17 +/- 3.54 SD (median 4.5) 
compared to an affective mean score of 4.83 +/- 3.31 SD (median 3.5) (21% pain 
reduction) after lignocaine infusion was. The pain reduction in the PDN group compared 
to the non-PDN group was statistically significant (P<0.0036). The plot shows the 
median score (horizontal band) along with the minimum and maximum score. The box 
represents the lower (Q1=25%) and upper (Q3=75%) quartile range of the score.  
 
Figure 4.4: Box plot showing McGill SF somatic score before (B) and after (A) lidocaine 
infusion. Data are mean +/_ SD; n=4 for PDN group and n=7 for non-PDN group.* p<0.05 
for PDN group compared to non-PDN group. 
The box plot analysis in Figure 4.4 shows the McGill SF somatic score before (B) 
and after (A) lignocaine infusion in the PDN and non-PDN groups. In PDN group, the 
somatic mean score was 18.5 +/- 10.75 SD (median 17.0) before lignocaine infusion 
compared to a somatic mean score of 14.25 +/- 12.84 SD (median 12.5) (23% pain 
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reduction) after lignocaine infusion. In the non-PDN group, before lignocaine infusion, 
the mean somatic score was 21.50 +/- 5.36 SD (median 19.5) compared to a somatic mean 
score of 17.83 +/- 8.73 SD (median 16.5) (17% pain reduction) after lignocaine infusion. 
The pain reduction in PDN group compared to the non-PDN group was not statically 
significant (P=0.3769). The plot shows the median score (horizontal band) along with the 
minimum and maximum score. The box represents the lower (Q1=25%) and upper 
(Q3=75%) quartile range of the score. 
4.5 Discussion  
Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus (DM), 
with about 1/3 of all DM patients suffering from diabetic neuropathic pain (Tesfaye, 
2009). Moreover, the condition has a huge impact on the quality of life (QoL) of the 
patient (Galer et al., 2000; Gardner and Shoback, 2007; Quattrini and Tesfaye, 1996). 
Several trials have reported some improvement of PDN symptoms with various 
antidepressants, anticonvulsants, opioids and topical medications (Kaur et al., 2011; 
Goldstein et al., 2005; Kadiroglu et al., 2008, Rosenstock et al., 2004; Lesser et al., 2004; 
Richter et al., 2005; Freyhagen et al., 2005; Backonja, 1999; Vinik et al., 1998; Badran et 
al., 1975; Edwards et al., 2000; Donofrio et al., 2005; Harati et al., 1998; Rudroju et al., 
2013; Vinik et al., 2014; Low et al., 1995; Yuen et al., 2002). However, follow-up studies 
have revealed that only 23% of patients show satisfactory improvement of PDN 
symptoms after conventional treatment (Boulton et al., 1983; Daousi et al., 2006). Most 
patients learn to tolerate the residual pain and live with it; however, severe cases of PDN 
can include constant unrelenting neuropathic pain, disturbance of sleep, and even inability 
to walk due to the severity of the pain (Galer et al., 2000; Gardner and Shoback, 2007; 
Quattrini and Tesfaye, 1996). Lignocaine infusion has been used as a treatment in various 
challenging cases of chronic pain, including chronic pain syndrome, (Wallace et al., 2000; 
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Challapalli et al., 2005), chronic neuropathic pain (Tremont-Lukats et al., 2006) and PDN 
(Kastrup et al., 1987; Viola et al., 2006; Bach et al., 1990), when conventional treatments 
proved ineffective or intolerable. 
The present data have shown a reduction in all 3 domains of the McGill SF 
questionnaire pain scores for the PDN group, including visual analogue score (33% 
reduction), affective score (41% reduction) and somatic scores of (23% reduction) after 
lignocaine infusion, compared to 11%, 21% and 17%, respectively, in the non-PDN 
group. The differences between groups were statistically significant for the VAS and 
affective scores, but not for the somatic scores. This could be due to the statistically 
significant response of lignocaine infusion on somatic scores in both groups of patients 
(see Figure 4.1).  
 
4.5.1 Comparison with existing data 
The data from this study have clearly shown significant reduction of McGill SF affective 
pain score and visual analogue score after lignocaine infusion in patients with PDN 
compared to patients with non-PDN chronic pain. These results are consistent with the 
findings of Viola et al. (2006) and Kastrup et al. (1987), who demonstrated significant 
reduction in both affective scores and visual analogue scores after lignocaine infusion. 
The present study measured the effectiveness of lignocaine infusion as a treatment in 
PDN patients compared to patients with chronic pain from other causes. Viola et al. 
(2006) and Kastrup et al. (1987), on the other hand, measured the effectiveness of 
lignocaine infusion compared to saline infusion in patients with PDN. In our study, the 
reduction of the McGill SF somatic pain score was 23% in PDN group compared to 17% 
in the non-PDN group. Despite the higher reduction of somatic pain score in the PDN 
group, the data were not statistically significant. In contrast, Viola et al. (2006) and 
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Kastrup et al. (1987) showed a significant reduction of McGill somatic pain score in the 
PDN group compared to control. This discrepancy could be due to the fact that the 
lignocaine infusion response was nearly the same level in both the PDN and non-PDN 
groups, making the difference insignificant. The present study was similar to that of Viola 
et al. (2006) in that all participants had intractable pain and failure to respond to or tolerate 
conventional treatment.  It is particularly noteworthy that in this study and the studies 
done by Viola et al. (2006) and Kastrup et al. (1987), no participants reported any adverse 
effects with lignocaine infusion of 5 m/kg bodyweight. This observation clearly suggests 
that this dosage of lidocaine is safe for the treatment of PDN. However, one investigation 
(Raphael et al., 2003) has reported that lignocaine infusion caused marked adverse effects 
resulting in hypotension and arrhythmia. The study was performed on fibromyalgia 
patients and lignocaine infusion was given consecutively for 6 days. Also, the dose was 
increased incrementally every day to maximum of 5 mg/kg bodyweight plus 150 mg or 
total maximum 550 mg (Raphael et al., 2003).  
There are several studies reporting significant reduction in pain after lignocaine 
infusion in PDN as well as in a variety of non-PDN conditions including fibromyalgia 
(Raphael et al., 2003), headache (Rosen et al., 2009), back pain (Park et al., 2012), 
trigeminal neuralgia (Arai et al., 2013) and chronic pain syndrome (Cahana et al., 1998; 
Wallace et al., 2000). As with previous investigations, the present study showed a 
beneficial effect of lignocaine infusion in treating both the PDN and non-PDN groups. 
However, in patients with PDN, lignocaine infusion was statistically more effective than 
for other causes of chronic pain. PDN pathogenesis involves peripheral and central 
sensitization with neural plasticity (Aslam et al., 2014). The half-life of lignocaine 
infusion is only 2 hours; however, the effect of analgesia is reported for up to 28 days 
(Kastrup et al., 1987; Viola et al., 2006). This suggests that lignocaine infusion may affect 
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not only peripheral, but perhaps central neural plasticity as well. The possible central 
effect of lignocaine could have caused the increased effectiveness in the PDN group.  
4.5.2 Strengths and limitations of the study 
The study population was well defined for both groups and assembled with minimal 
selection bias as the participants for the PDN and non-PDN groups were referred from 
the Foot Clinic or Pain Clinic, respectively. Moreover, both groups of participants 
completed the McGill SF pain questionnaires 100%. Both groups were similar in age; 
however, all participants in the PDN group were males and all in the non-PDN group 
were females. Recall bias could exist when participants completed the questionnaire. 
However, most questions from the McGill SF questionnaire were based on current or 
recent physical and mental well-being of person; hence, recall bias can be assumed to be 
minimal. The results also showed that lignocaine infusion had no significant effect on the 
ECG, BP, pulse rate or oxygen saturation in the both groups of patients. This was an 
observational study and all patients were well aware that they were having treatment with 
lignocaine infusion. Therefore, possible placebo effect cannot be ruled out. Also, the 
sample size was very small with only 4 in the PDN group and 7 in the non-PDN group. 
A further randomized controlled trial on a large sample is needed in order to verify the 
results.   
4.6 Conclusion 
Overall, the study has shown that lignocaine infusion is both effective and safe in reducing 
chronic intractable pain in both PDN and non-PDN patients when conventional 
treatments are intolerable or unhelpful. The study found that the treatment is more 
effective in PDN patients compared to patients with other causes of chronic pain.  There 
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is a need for a multicentre randomized controlled trial to verify the effect of lignocaine 
infusion, especially in PDN. Chronic neuropathic pain, including PDN, causes the 
modulation of pain signalling at the spinal level and plasticity in the brain. As a result, it 
is more difficult to treat the refractory pain (Aslam et al., 2014). Perhaps clinicians need 
to consider introducing lignocaine infusion in the early stages when conventional 
treatments are not helpful.   
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Chapter 5 
 
 
 
General discussion, conclusions and future scope of research  
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5.1 General discussion 
It was a wonderful experience to complete research projects as a part of MSc by 
Research degree. During my academic tenure at University of Central Lancashire 
(UCLAN), I learnt several new generic academic skills including academic writing, 
research methods, research designing, process of ethical clearance, statistics analyses 
and how to write a paper and get it published. During my MSc tenure at UCLAN, I was 
able to publish papers in leading journals. It was only possible with the help and support 
provided to me from my supervisors and excellent research environment provided by 
UCLAN and Lancashire hospitals NHS trust. Apart from generic skills, I have learnt 
enormously in the field of diabetes and in particularly PDN.  
During my MSc by research, I contributed knowledge in the academic arena and 
completed three pilot research projects. The data was either published or is under review 
by leading journals. The prevalence and characteristics of PDN study under review in 
Canadian journal of diabetes, impact of PDN on quality of life study published in 
diabetes & primary care journal and lignocaine infusion as a treatment of PDN under 
review in journal of pain medicine.  
The study found that about 1/3 of the diabetic subjects tested in Chorley and 
Whiston towns of Northwest England suffer from PDN, and that it was twice as prevalent 
in type 2 DM than in type 1. These results are similar to other prevalence studies in UK 
(Abbot et al., 2011; Davies et al., 2006). There was a significant correlation of PDN with 
various cardiovascular risk factors, including smoking, increasing age, duration of 
diabetes, poor glycaemic control and obesity. We used S-LANSS questionnaire in postal 
survey to diagnose PDN. A major limitation of the study was related to the selection bias 
of both Hospital group and GP group patients. Hospital group patients were selected from 
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the DARE database where patients had already volunteered for future diabetes research. 
Secondary care enrolment suggests severity of the disease with multiple comorbidities. 
Furthermore primary care group lies in the low socioeconomic community status area. 
Poor socioeconomic areas are known to have higher cardiovascular risks and 
comorbidities. Cardiovascular risks and comorbidities are known to have direct 
association with PDN.  These discrepancies and lack of randomisation in the study could 
have led to selection bias which could have an impact on outcome. Recall bias could exist 
during completion of the questionnaire. Questions on the S-LANSS questionnaire were 
based on current or recent characteristics of pain; hence, recall bias in the best scenario is 
expected to be minimal. However it requires ability to read, understand the questions and 
physically able to write the response and post it to the researcher. The outcome was based 
only on those patients who responded with their best understanding of the questions hence 
recall bias could not be ruled out.  There is a need of a large multicentre randomized 
controlled study to verify these results.   
 
The study suggests PDN has a huge impact on quality of life of the patients, and 
moreover, it has strong association with symptoms of anxiety and depression. When 
encountering patients with PDN, clinicians should consider exploring more about the 
psychosocial and mental well-being of the patients and the overall impact of the condition 
on the patient’s quality of life.  A major limitation of the study relates to the selection of 
the control group. As mentioned above, the GP surgery from which the control group data 
were taken lies in an area of low socioeconomic status. It is known that low 
socioeconomic community status is positively associated with prevalence of depression 
(Murali and Oyebode, 2004). Furthermore, the two groups were selected from healthcare 
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settings of different nature. These discrepancies and the lack of randomisation in the study 
could have led to selection bias, which in turn could have had an impact on outcomes. 
Data other than age and sex were not collected for comparison (duration of diabetes, 
presence of other complications, and treatment with antidepressants are among the other 
potential confounding factors). As with any non-randomised study, it is not possible to 
infer a causal relationship and thus our conclusions are tentative at best.  
 
Treatment of PDN is often challenging for physicians and distressing for patients. 
Studies have found up to a 50% response rate with combination of treatment (Tesfaye et 
al., 2013; Boulton et al., 1983; Daousi et al., 2006).  The results of this study has shown 
that lignocaine infusion is both effective and safe in reducing chronic intractable pain in 
PDN and non-PDN patients when conventional treatments are intolerable or not helpful. 
Lignocaine infusion is more effective in PDN patients than in those with other causes of 
chronic pain.  This was an observational study and all patients were well aware that they 
were having treatment with lignocaine infusion. Therefore, possible placebo effect cannot 
be ruled out. Also, the sample size was very small with only 4 in the PDN group and 7 in 
the non-PDN group. A further multicentre randomized controlled trial on a large sample 
is needed in order to verify the results.  Chronic neuropathic pain, including PDN, causes 
modulation of pain at the spinal level and plasticity of brain; as a result, it is more difficult 
to treat the refractory pain (Aslam et al., 2014). Physicians may thus need to consider 
introducing lignocaine infusion in early stages when conventional treatments are not 
helpful.  
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5.2 Conclusion 
 The study found that about 1/3 of all diabetic subjects in the study suffered 
from PDN. It was twice as prevalent in type 2 DM as in type 1 DM. There was a 
significant correlation of PDN with smoking & height. Prevalence of PDN also increased 
with age, duration of diabetes, poor glycaemic control and obesity. The study also 
supports past findings that PDN has a huge impact on quality of life and moreover has a 
strong association with symptoms of anxiety and depression. The study has shown that 
lignocaine infusion is both effective and safe in reducing chronic intractable pain in both 
PDN and non-PDN patients when conventional treatments are intolerable or unhelpful. 
The study found that the treatment is more effective in PDN patients compared to patients 
with other causes of chronic pain. There is a need for a multicentre randomized controlled 
study on larger sample to verify these results.  
 
 
5.3 Scope for future studies 
About 1/3 of all diabetes patients suffer from PDN, a distressing condition and has a huge 
impact on the patient’s quality of life. Despite the development of newer medications, the 
treatment of this distressing condition is frequently challenging for physicians. This may 
be because we have a poor understanding of pathogenesis of PDN. In this thesis research, 
similar to several others, it was shown that various cardiovascular risk factors are 
associated with PDN including smoking, increasing age, increasing duration of diabetes, 
obesity and poor glycaemic control. So far there is no direct evidence linking the 
pathogenesis of PDN with these risk factors. It is assumed that these individual risk 
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factors alone or collectively damage the nerves but our understanding of the pathogenesis 
of PDN remains poor. This is an area worthy of extensive study. 
The present study found that PDN patients infused with lignocaine responded 
better compared to patients suffering from other forms of chronic pain. Although the 
half-life of lignocaine infusion is only 2 hours, studies have reported an analgesic effect 
of up to 28 days, suggesting that lignocaine may act centrally as well as peripherally. 
The studies undertaken in this thesis were observational studies with small samples and 
lack of randomization which could have led to selection bias. This in turn could have 
had an impact on the outcome. As with any non-randomized study, it is not possible to 
infer a causal relationship accurately and, thus, the present conclusions remain tentative. 
There is a need for multicentre randomized study on large sample to verify these results.  
Also, there is a space for further research in exploring the pathogenesis of PDN. This 
may help us to understand the modes of action of current PDN treatments including 
lignocaine infusion and may help in creating newer treatments to help in this 
debilitating condition. 
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Appendix 1: S-LANSS Questionnaire 
 
Name: __________________________             
 
Date of Birth: __________________ 
 
Post Code:______________________ 
Sex:      Male ____ Female: _______ ,   
Smoker:   Yes_____   No____  
Ex smoker______(Which year did you stop________)  
 
Do you drink Alcohol: Yes_____   No____,  
If you drink alcohol how much do you drink in an average week? 
Cider/Lager/ Bitter______ pints per week 
Wine:_________ Glasses per week 
Spirit:_________ measures per week 
Other (Please specify) ____________________ per week 
               _____________________ per week 
 
How long you have had diabetes for?  ______  (yrs)    
 
Do you know your diabetes type: Type 1____    Type 2____  Don’t know ______ 
 
Ethnicity: (Please tick one)   1. White____ 2. Asian _____ (Pakistan___, Bangladesh____, 
Indian__, other_____)     3. Black______ 4. Other_______  
 
Are you experiencing any pain in feet/legs or hands? Yes ______   No_________ 
 
If yes, kindly fill out the form below. It will help us to know more about diabetes related nerve 
problem. If not you can send back this page along with the empty form. 
 
If you do not want us to access your blood results from Lancashire hospitals NHS trust database 
please indicate below:  
__________________________________________ 
 
If for any reason you wish to withdraw from our list to receive information about future research 
projects please indicate below.  
__________________________________________ 
What treatment do you 
take for diabetes: 
1…………………………… 
2…………………………… 
3…………………………… 
4…………………………… 
5…………………………… 
6…………………………… 
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This questionnaire can tell us about the type of pain that you may be experiencing. Please 
draw on the diagram below where you feel your pain. If you have pain in more than one area, 
only shade in the one main area where your worst pain is. 
 
 
 
 
 
On the line below, please put a cross across or circle a number to indicate how bad your pain 
(that you have shown on the above diagram) has been in the last week. 
 
 
 
NONE                    SEVERE PAIN 
(0 1 2 3 4 5 6 7 8 9 10)  
 
 
 
On an average day how many hours do you have very bad pain?  __________ Hours
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Below are 7 questions about your pain (the one in the diagram). Think about how your pain 
that you showed in the diagram has felt over the last week. Put a tick against the 
descriptions that best match your pain. These descriptions may, or may not, match your pain 
no matter how severe it feels. Only tick the responses that describe your pain in any 
question. 
 
1. In the area where you have pain, do you also have 'pins and needles', tingling or prickling 
sensations? 
------a) NO - I don't get these sensations      
  
------b) YES - I get these sensations often       
 
2. Does the painful area change colour (perhaps looks mottled or more red) when the pain is 
particularly bad? 
------a) NO - The pain does not affect the colour of my skin      
------b) YES - I have noticed that the pain does make my skin look different from normal
  
3. Does your pain make the affected skin abnormally sensitive to touch? Getting unpleasant 
sensations or pain when lightly stroking the skin might describe this. 
------a) NO - The pain does not make my skin in that area abnormally sensitive to touch
  
------b) YES - My skin in that area is particularly sensitive to touch    
  
4. Does your pain come on suddenly and in bursts for no apparent reason when you are 
completely still? Words like 'electric shocks', jumping and bursting might describe this. 
------a) NO - My pain doesn't really feel like this       
------b) YES - I get these sensations often       
  
5. In the area where you have pain, does your skin feel unusually hot like a burning pain? 
------a) NO - I don't have burning pain       
  
------b) YES - I get burning pain often       
  
 
6. Gently rub the painful area with your index finger and then rub a non-painful area (for 
example, an area of skin further away or on the opposite side from the painful area). How 
does this rubbing feel in the painful area? 
------a) The painful area feels no different from the non-painful area   
  
------b) I feel discomfort, like pins and needles, tingling or burning in the painful area that 
is different from the non-painful area  
       
7. Gently press on the painful area with your finger tip then gently press in the same way 
onto a non-painful area (the same non-painful area that you chose in the last question). How 
does this feel in the painful area? 
------a) The painful area does not feel different from the non-painful area    
------b) I feel numbness or tenderness in the painful area that is different from the non-
painful area.   
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Appendix 2. SHORT FORM-36 (SF36) SURVEY 
 
Please answer the following questions about your health. Select ONLY ONE ANSWER for each 
question 
 
1. In general, would you say your health is: 
1. Excellent 
2. Very Good 
3. Good 
4. Fair 
5. Poor 
 
2. Compared to one year ago, how would you rate your health in general now?  
1. Much better now than one year ago 
2. Somewhat better now than one year ago 
3. About the same as one year ago 
4. Somewhat worse now than one year ago 
5. Much worse than one year ago 
 
3. Does your health now limit you in this activity? If so, how much? Vigorous activities, such as 
running, lifting heavy objects, participating in strenuous sports.  
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
4. Does your health now limit you in this activity? If so, how much? Moderate activities, such 
as moving a table, pushing a vacuum cleaner, bowling or playing golf.  
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
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5. Does your health now limit you in this activity? If so, how much? Lifting or carrying 
groceries.  
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
6. Does your health now limit you in this activity? If so, how much? Climbing several flights of 
stairs. 
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
7. Does your health now limit you in this activity? If so, how much? Climbing one flight of 
stairs.  
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
8. Does your health now limit you in this activity? If so, how much? Bending, kneeling, or 
stooping. 
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
 
 
 
 
9. Does your health now limit you in this activity? If so, how much? Walking more than a mile. 
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
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10. Does your health now limit you in this activity? If so, how much? Walking several blocks.  
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
11. Does your health now limit you in this activity? If so, how much? Walking one block. 
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
12. Does your health now limit you in this activity? If so, how much? Bathing or dressing 
yourself. 
1. Yes, limited a lot 
2. Yes, limited a little 
3. No, not limited at all 
 
13. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of your physical health? Cut down the amount of time you 
spent on work or other activities.  
1. Yes 
2. No 
 
14. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of your physical health? Accomplished less than you would 
like. 
1. Yes 
2. No 
 
15. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of your physical health? Were limited in the kind of work or 
other activities.  
1. Yes 
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2. No 
 
16. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of your physical health? Had difficulty performing the work or 
other activities (for example, it took extra effort). 
1. Yes 
2. No 
 
17. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious). ?Cut down the amount of time you spent on work or other activities.  
1. Yes 
2. No 
 
18. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious) ?Accomplished less than you would like.  
1. Yes 
2. No 
 
19. During the past 4 weeks, have you had the following problem with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)?Didn't do work or other activities as carefully as usual.  
1. Yes 
2. No 
 
20. During the past 4 weeks, to what extent has your physical health OR emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
1. Not at all 
2. Slightly 
3. Moderately 
4. Quite a bit 
5. Extremely 
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21. How much bodily pain have you had during the past 4 weeks?  
1. None 
2. Very mild 
3. Mild 
4. Moderate 
5. Severe 
6. Very severe 
 
22. During the past 4 weeks how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
1. Not at all 
2. A little bit 
3. Moderately 
4. Quite a bit 
5. Extremely 
 
23. How much of the time during the past 4 weeks: Did you feel full of pep?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
24. How much of the time during the past 4 weeks: Have you been a very nervous person?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
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6. None of the time 
 
25. How much of the time during the past 4 weeks: Have you felt so down in the dumps that 
nothing could cheer you up?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
26. How much of the time during the past 4 weeks: Have you felt calm and peaceful?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
27. How much of the time during the past 4 weeks: Did you have a lot of energy?  
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
28. How much of the time during the past 4 weeks: Have you felt downhearted and blue? 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
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4. Some of the time 
5. A little of the time 
6. None of the time 
 
 
 
 
29. How much of the time during the past 4 weeks: Did you feel worn out? 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
30. How much of the time during the past 4 weeks: Have you been a happy person? 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
 
31. How much of the time during the past 4 weeks: Did you feel tired? 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. None of the time 
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32. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
1. All of the time 
2. Most of the time 
3. Some of the time 
4. A little of the time 
5. None of the time 
 
33. How true or false is the following statement? I seem to get sick a little easier than other 
people. 
1. Definitely true 
2. Mostly true 
3. Don't know 
4. Mostly false 
5. Definitely false 
 
34. How true or false is the following statement? I am as healthy as anybody I know. 
1. Definitely true 
2. Mostly true 
3. Don't know 
4. Mostly false 
5. Definitely false 
 
35. How true or false is the following statement? I expect my health to get worse. 
1. Definitely true 
2. Mostly true 
3. Don't know 
4. Mostly false 
5. Definitely false 
 
36. How true or false is the following statement? My health is excellent. 
1. Definitely true 
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2. Mostly true 
3. Don't know 
4. Mostly false 
5. Definitely false 
 
37. Are you ...? 
1. Male 
2. Female 
 
38. How old were you on your last birthday? 
Age:  
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Appendix 3: Hospital Anxiety and Depression Scale Scoring Sheet                            
 
                                                                                   Yes              Yes                  No                   No 
                                                                                                 definitely     sometimes     not much          not at all 
1) I wake early and then sleep badly for the rest  
of the night                                                                                                3                         2                        1                          0 
 
2) I get very frightened or have panic feelings for                                         3                        2                        1                          0 
apparently no reason       
 
3) I feel miserable and sad                                                                              3                        2                         1                         0 
 
4) I feel anxious when I go out of the house on my own                                3                          2                        1                         0 
 
5) I have lost interest in things                                                                         3                         2                       1                           0 
  
6) I get palpitations, or sensations of ‘butterflies’ in my                                  3                         2                      1                           0 
stomachor chest    
 
7) I have a good appetite                                                                                   0                         1                      2                         3 
 
8) I feel scared or frightened                                                                              3                         2                     1                        0 
 
 
 
9)  feel life is not worth living                                                                          3                           2                     1                       0 
 
10) I still enjoy the things I used to                                                                     0                          1                      2                       3 
 
11) I am restless and can’t keep still                                                                   3                          2                      1                       0 
 
12) I am more irritable than usual                                                                       3                         2                        1                       0 
 
13) I feel as I have slowed down                                                                        3                          2                       1                       0 
       
14) Worrying thoughts constantly go through my mind                                      3                           2                     1                       0 
 
 
     
  
Anxiety    2,4,6,8,11,12,14 
Depression     1,3,5,7,9,10,13 
Scoring       3,2,1,0 (for item 7 & 10 the scoring is reversed) 
GRADING: 0-7 =Non-case   8 and above +ve  
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Appendix 4: McGill (SF) Pain Assessment Form 
Name: 
Hospital No: 
DOB: 
Tick the level of pain for each word or tick none if it does not apply to you. 
No Type of pain None Mild Moderate Severe 
1 Throbbing     
2 Shooting     
3 Stabbing     
4 Sharp     
5 Cramping     
6 Gnawing     
7 Hot-burning     
8 Aching     
9 Heavy     
10 Tender     
11 Splitting     
12 Tiring-Exhausting     
13 Sickening     
14 Fearful     
15 Cruel-punishing     
Put a cross on this line to show how bad your pain is. At the left end of line means no pain at all, at right 
end means worst-pain possible. 
 ……………………………………………………… 
 
 
 
 
Date:…………… 
No 
Pain 
Worst Possible 
Pain Please do not write in this box: 
S  -------- / 33                          A  -------- / 12                                  VAS  -------------- /10 
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Abstract 
Diabetes is very common and its global prevalence is rising day by day. As a result we 
are seeing more complications related to diabetes. In order to prevent micro vascular and 
macro vascular complications such as retinopathy, nephropathy, erectile dysfunction, 
neuropathy, myocardial infarction and stroke health care professionals are keen to have 
better glycaemic control. When dealing with newly diagnosed or poorly controlled 
diabetes patients are encouraged to bring down glycated haemoglobin (HbA1c). Diabetic 
painful neuropathy (DPN) is one of the well-known complications associated with long- 
term poor glycaemic control. However, on the other hand rapid control of high blood 
sugar can precipitate painful neuropathy known as “insulin neuritis”. The rapid tight 
glycaemic control with either insulin or oral hypoglycaemic agents on poorly controlled 
diabetic patients cause flux of blood glucose and metabolic shift resulting in structural 
changes at nerve endings (endoneural blood vessels) which resemble the retinopathy 
changes in retina. It causes steal effect and hypoxia in the nerves and hence precipitates 
neuropathic pain. It lasts for about 6 months and responds well to standard treatment of 
painful neuropathy. Health professionals need to be aware of this condition and consider 
gentle glycaemic control when aiming for Target HbA1c. This review outlines the 
disease, the symptoms, the types and treatment. 
 
 
Words for index: insulin neuritis, diabetes mellitus, glycaemic control, neuropathy, 
retinopathy, blood glucose 
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Introduction 
Diabetes mellitus (DM) is the commonest metabolic disease currently affecting more that 
250 million people worldwide and it costs the Governments of the world more than £800 
billion to diagnose, treat and care for diabetic patients. DM is associated with numerous 
long-term complications including cardiomyopathy, nephropathy, neuropathy and 
retinopathy. This review addresses diabetic painful neuropathy (DPN) which is one of the 
well-known complications of diabetes and it affects up to 53% of diabetic population1. It 
is the most common form of painful neuropathy2. It manifests with varying description 
from mild pins and needle sensation to the stabbing pain, burning, unremitting or even 
described as electric shock. The most common feature is cutaneous hypersensitivity 
leading to acute distress on contact with an external stimulus, such as clothing3. The 
pathogenesis of DPN is mainly caused by inflammatory process4 and strongly correlates 
with longer duration of the diabetes and poor glycaemic control5-18 
Treatment induces acute neuropathy due to rapid glycaemic control has been reported in 
literature as ‘insulin neuritis’ that usually manifests with severe excruciating neuropathic 
pain in the first month of initiation of insulin or oral hypoglycaemic agents. Symptoms 
usually last up to 6 months and respond to treatment that is usually needed up to 6 
months3. Insulin neuritis was first described by Caravati in 1933. He reported a diabetic 
woman with numbness, tingling, and shooting pains in the lower extremities that appeared 
four weeks after the initiation of insulin. The pain increased despite the use of analgesics 
and sedatives, but resolved within 3 days of stopping insulin concurrent with severe 
hyperglycaemia. Further attempts at the use of insulin resulted in similar levels of pain. 
He called the condition “insulin neuritis”19. The word insulin neuritis is a misnomer, as it 
can also be induced by oral hypoglycaemic agent20. The cause is not directly by insulin 
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but mainly due to the change in flux of blood glucose caused by rapid change in blood 
glucose level following pharmacological treatment21.  
Symptoms 
There are several studies and case reports in the literature about insulin neuritis with 
varying presentation after starting insulin or oral hypoglycaemic agents. These reports 
described the most common features as generalized pain bilaterally mainly distally in feet 
with burning sensation, hypersensitivity and contact discomfort of the skin within 2 to 4 
weeks20,22,23. It may present with truncal neuropathy24,25,26,27, autonomic neuropathy28, 
worsening of retinopathy29 and even with profound weight loss22,30,31,32  
Generalize pain mainly distally. 
The most common presentation of Insulin neuritis is symmetrical and bilateral distal 
neuropathic pain mainly involving feets3. In one observational study on 6 patients with 
diabetes, all experienced severe excruciating bilateral neuropathic pain mainly in feet 
after 2-4 weeks of insulin treatment with rapid reduction of blood glucose up to one fifth 
of initial levels. This improved in all cases with symptomatic treatment allowing 
discontinuation of therapy in 3-8 months20. A case report on a newly diagnosed type 1 
diabetes patient described development of severe pain in his feet, which prevented him 
from walking, after initiation of insulin. The HbA1c of that patient dropped from 14.1 to 
7.6%, and 3 months after presentation, the patient showed dramatic improvement and 
regained his ability to walk33. There is another similar case report of painful neuropathy 
on 15th day of treatment with intense insulin therapy following poor glycaemic control 
period of 8 years. He responded well on symptomatic treatment on day 3 on venlafaxine.34  
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Diabetic neuropathic cachexia  
Painful neuropathy is sometimes associated with profound weight loss and called 
“Diabetic neuropathic cachexia”. This has also been reported with insulin neuritis that 
could last up to a year. The exact mechanism and cause is unknown3. It is observed that 
constant pain and discomfort can cause loss of appetite and low mood which results in 
patients not eating enough and start losing weight. Most patients respond well with 
neuropathic pain treatment which gives pain relief and regain weight. In one observational 
study, 9 diabetic patients experienced painful neuropathy with constant burning pain 
mainly in the legs, especially distally. There was marked troublesome allodynia 
associated with profound weight loss along with depression with impotence. These severe 
manifestations subsided in most cases in 6 months and in all cases in 10 months 22. There 
is another case report in which patient presented with painful neuropathy, profound 
weight loss after initiation of insulin therapy within 3 months31 
 
Truncal neuropathy 
Insulin neuritis may precipitate focal neuropathic pain called “Truncal neuropathy” on 
specific dermatome region. Truncal neuropathy in diabetes presents with neuropathic 
pain such as a hypoesthesia, regional hyperalgesia, allodynia and sometime focal 
weakness in specific dermatome region.  It usually presents with unilateral abdominal or 
thoracic wall pain.3,25 There was one case of insulin neuritis which presented with painful 
neuropathy with paraesthesia and hyperesthesia restricted to the abdomen and this was 
associated with profound weight loss. The haemoglobin A (1c) had dropped from 12% to 
7.5% within 5 months, following rapid improvement in glycaemic control.  On 
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investigation, there was no indication of disease in intra-abdominal area. The symptoms 
improved dramatically within 4 months after symptomatic treatment30 
It is not uncommon that these patients have to undergo a number of investigations to 
determine the cause of pain before having the diagnosis of truncal neuropathy24-27,30. 
There are several cases of truncal neuropathy that were misdiagnosed initially as for 
example hernia due to focal weakness on abdominal wall26,  angina due to left sided chest 
wall pain25 and painless gall stones due to focal sensory deficit complicated with painless 
jaundice secondary gall stone27. The diagnosis of truncal neuropathy is essentially clinical 
and positive recognition of neuropathic element of pain is the key factor. Most people 
respond well on neuropathic treatment and usually settle in 3 to 12 months.  
 
Autonomic neuropathy 
Autonomic dysfunction is one of the complications of diabetes3. It manifests with one or 
more of the following: erectile dysfunction, gatsroparesis, neurogenic bladder, dry feet, 
depressed cough reflex, postural hypotension or high blood flow to foot35,36 . Insulin 
neuritis has been reported to precipitate autonomic neuropathy. In one prospective study 
on 16 diabetic patients followed up for 18 months, all the patients develop severe painful 
neuropathy in 8 weeks of intense glycaemic treatment. All individuals with treatment for 
induced neuropathy had evidence of autonomic dysfunction on testing and exhibited 
symptoms of autonomic impairment. Approximately, 69% of cohort had systolic blood 
pressure falls > 20 mmHg. Symptoms of autonomic dysfunction were more prevalent and 
more severe in subjects with type 1 diabetes, particularly with respect to symptoms of 
orthostatic intolerance and gastrointestinal function. Urinary frequency, nocturia and 
anhidrosis were reported more frequently in individuals with type 2 diabetes28. 
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Retinopathy 
Retinopathy is a well-known complication of diabetes and directly related with poor 
glycaemia and duration of diabetes37. It is also proven that better glycaemic control 
prevent worsening of retinopathy38. Insulin neuritis with rapid flux of blood glucose 
causes structural changes at endoneural blood vessels of nerves which resemble with 
retinopathic changes in retina39. Rapid drop in blood glucose in poorly controlled diabetes 
may exert the same changes in retina, thus worsening the retinopathy. In one large 
observational study, 87 patients were divided in 3 groups of varying glycaemic control. 
These included a group of poor glycaemic control corrected rapidly, poor glycaemic 
control not corrected and good control group. The progression rate of diabetic 
maculopathy was significantly higher in the group that underwent rapid control than in 
the other 2 groups (P <02). Patients with moderate to severe non-proliferative diabetic 
retinopathy preoperatively in the rapid control group had significantly higher progression 
rates of diabetic retinopathy and maculopathy (P <002 and p<008, respectively) 40. 
Pathogenesis 
In 1992 Boulton first described the observation that acute painful neuropathy might 
follow sudden change in glycaemia control suggesting that blood glucose flux could 
precipitate pain. Sudden changes in glycaemia may contribute to the generation of 
impulses or even induce relative hypoxia in nerve fibres, indicating that it is the 
combination of structural and functional changes in peripheral nerves which cause the 
pain21. This observation was experimentally tested by Kihara et al in 1994 on rats. In their 
study, they infused insulin under non- hypoglycaemic conditions and evaluated its effect 
on endoneurial oxygen tension, nerve blood flow, and the oxy-haemoglobin dissociation 
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curve of peripheral nerves in normal and diabetic rats. Their results showed that insulin 
administration could cause a reduction in nerve nutritive blood flow and an increase in 
arterio-venous shunt flow. When the latter was eliminated by the closure of arterio-venous 
shunts (infusion of 5-hydroxytryptamine), endoneurial oxygen reverted to normal. These 
findings clearly indicate a deleterious vasoactive effect of insulin and may explain the 
development of insulin neuritis41.   
In 1996 Tesfaye et al observed neurovascular changes in vivo in five human diabetic 
patients with insulin neuritis. These patients presented with severe sensory symptoms 
but clinical examination and electrophysiological tests were normal except with one 
subject who had severe autonomic neuropathy and all tests were abnormal. On sural 
nerve exposure in vivo, epineural blood vessels showed severe structural abnormalities 
resembling the retinopathy changes normally seen in the retina, including arteriolar 
attenuation, tortuosity and aterio-venous shunting and proliferating new vessels 
formation. They hypothesized that the structural abnormalities with new vessels 
formation in epineural blood vessels cause steal effect and hence results in hypoxia and 
neuropathic pain39.  It can now be postulated that sudden change in glycaemic control 
can cause flux effect resulting in structural and functional changes at the epineural blood 
vessels of nerves which in turn can lead to neuropathic pain “Insulin neuritis (see figure 
1)”21,39. 
Treatment 
Management of neuropathic pain in “insulin neuritis” is symptomatic including first line 
medication tricyclic antidepressants (Amitriptyline) or selective serotonin uptake 
inhibitor (Duloxetine). Second line medications include anti-epileptic medications 
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(Gabapentin, Pregabalin, Carbamazepine and Topiramate) and Opioids. Most patients 
recover within 6 months of onset of insulin neuritis3     
Conclusion 
The flow diagram in Figure 2 summarises the pathogenesis of insulin neuritis. With 
increasing prevalence of diabetes and its complications, both health professional and 
patients are keen to have good glycaemic control in order to prevent long term 
complications42. Most of the time it is not a problem but on several occasions intense 
treatment for rapid glycaemic control may cause insulin neuritis. This is presumed to be 
caused by change in glucose flux which can result in structural and functional changes 
at the nerves leading to hypoxia. This in turn can precipitate neuropathic pain and the 
whole phenomenon is called “insulin neuritis”. It usually manifests distally in feet and is 
bilateral with burning sensation, hypersensitivity and allodynia. It could affect focally – 
truncal neuritis and may present with neuropathic pain and/or weakness in dermatomal 
region. Similarly, it may present with autonomic symptoms. Constant pain may cause 
cachexia and loss of appetite which can result in significant weight loss. Most patients 
respond well with neuropathic treatment and recover within 6 months. It is very 
important to be aware that treatment induced insulin neuritis can have significant impact 
on the quality of the life of the diabetic patient. This can be easily prevented by gradual 
glycaemic control and by symptomatic treatment as necessary.  Healthcare professionals 
need to be aware of this condition when managing poorly controlled diabetic patients 
and should consider gradual titration of the pharmacological agents employed to treat 
the patients. 
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PATHOGENESIS OF INSULIN NEURITIS 
Poorly control diabetes patient  
 
Intense hypoglycaemic treatment 
 with insulin or oral hypoglycaemic medication 
 
Rapid flux of blood glucose 
 
Structural changes at nerve endings (endoneural blood vessels) 
resembles changes in retina 
(Aterio-venous shunting, Attenuation, tortuosity and proliferating new vessels formation) 
 
 
Steal effect and Hypoxia at Nerve endings 
 
Neuropathic Pain (Insulin Neuritis) 
 
Figure 1: A flow diagram showing the pathogenesis of insulin neuritis 
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Figure 2:  Arteriolar attenuation, tortuosity and aterio-venous shunting and proliferating 
new vessels formation of vasanervosum seen in sural nerve of patient with insulin 
neuritis (photo courtesy of  Tesfaye and Boulton 9) 
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1.  Painful diabetic neuropathy 
(PDN) is a common and 
potentially very serious 
complication of diabetes.
2. There is relatively little research 
aimed at quantifying the 
impact of PDN on quality of 
life (QoL) and mental health.
3. Here the authors report data 
from north-west England 
suggesting that PDN is 
associated with a negative 
impact on QoL and anxiety.
Key words
– Anxiety
– Depression
– Painful diabetic neuropathy
– Quality of life
Authors
Amir Aslam is a Clinical Research 
Fellow, Lancashire Hospitals 
NHS Trust, Chorley and South 
Ribble District General Hospital, 
Chorley. Jaipaul Singh is a 
Professor of Physiology, School 
of Pharmacy and Biomedical 
Sciences and School of Forensic 
and Investigative Sciences, 
University of Central Lancashire, 
Preston Satyan M Rajbhandari 
is a Consultant in Diabetology 
and Endocrinology, Lancashire 
Hospitals NHS Trust, Chorley and 
South Ribble District General 
Hospital, Chorley, and a Clinical 
Professor, University of Central 
Lancashire, Preston.
About a third of people with diabetes experience PDN at some point in their lives, and it 
is a distressing condition affecting individuals both physically and emotionally. The aim of 
the study reported here was to assess quality of life, anxiety and depression in people with 
PDN using the 36-item Short Form Health Survey and the Hospital Anxiety and Depression 
Scale questionnaires, comparing these results against those in with people with diabetes 
who did not have PDN. The findings are presented in this article.
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Currently, over 380 million people worldwide are living with diabetes and it is estimated that this figure will rise 
up to 592 million in the year 2035 (International 
Diabetes Federation, 2013). The prevalence of 
diabetes-related complications is also rising. 
Painful diabetic neuropathy (PDN) is a common 
complication of diabetes, affecting about a third 
of all people with diabetes (Tesfaye, 2009). 
It is characterised by bilateral symmetrical 
distal neuropathic pain in the lower extremities 
with varied symptoms including mild pins and 
needles, a tingling sensation, a shooting pain 
similar to electric shock, a constant burning 
sensation with nocturnal exacerbation, and 
contact hyper-sensitivity (allodynia; Larsen et 
al, 2002). Relentless pain and allodynia can 
affect people both physically and mentally 
and can cause disturbance in sleep, low mood, 
impotence and social withdrawal. In some 
extreme cases, the affected individual is unable 
to walk (Quattrini and Tesfaye, 1996; Galer et 
al, 2000; Gardner and Shoback, 2007). PDN 
can significantly alter – and, moreover, has a 
huge impact on – individuals’ quality of life 
(QoL).
Currently, there are only a few studies that 
have been performed specifically to measure 
the physical and mental impact of PDN on 
QoL. The study reported here was designed to 
assess QoL, anxiety and depression in people 
with PDN (PDN group) compared with those 
with diabetes not known to have PDN (control 
group).
There are several health-related questionnaires 
available to assess QoL and physical and 
mental wellbeing (Healthmeasurement.org, 
2014). Typically, researchers use the 36-item 
Short Form Health Survey (SF-36®) for the 
assessment of QoL and the Hospital Anxiety and 
Depression Scale (HADS) for the assessment of 
mood and anxiety. Ware and Sherbourne (1992) 
introduced SF-36, which was designed for use 
in clinical practice and research, health policy 
evaluations and general population surveys. 
SF-36 includes 36 subjective questions that 
assess eight health concepts of QoL from the 
patient’s point of view:
1 Limitations in physical activities because of 
health problems.
2 Limitations in social activities because of 
physical or emotional problems.
3 Limitations in usual role activities because of 
physical health problems.
4 Bodily pain.
5 General mental health (psychological distress 
and wellbeing).
6 Limitations in usual role activities because of 
emotional problems.
7 Vitality (energy and fatigue). 
8 General health perceptions.
SF-36 is a practical, reliable and valid measure 
of physical and mental health and has been 
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used in a variety of chronic health conditions 
including diabetic neuropathic pain (Garratt, 
1993; Ware et al, 1994; Rosenstock et al, 2004; 
Vinik et al, 2013) and published in more than 
4000 documents, as of 2002 (Turner-Bowker et 
al, 2002).
The HADS questionnaire was originally 
developed by Zigmond and Snaith (1983) for 
psychometric evaluation. Since then, it has been 
widely used worldwide by health professionals, in 
both the community and hospital settings, and it 
has been found to be both a reliable and a valid 
measure of anxiety and depression (el-Rufaie 
and Absood, 1987; Nortvedt et al, 2006). The 
HADS questionnaire is based on a total of 14 
questions, seven for anxiety assessment and 
seven for depression. HADS provides clear cut-
off scores for severity of anxiety and depression. 
We felt that HADS would serve as an ideal tool 
for screening and thus adopted it in our study.
Methods
Study design
This was an observational study. The SF-36 
and HADS questionnaires were used for data 
collection, based on the rationale described 
above. It takes approximately 15 minutes to fill 
in the SF-36 questionnaire and 5 minutes to 
fill in the HADS questionnaire, which meant 
that participants were able to fill these in while 
waiting for their appointment or to post them 
back to the research team after completing them 
at home.
Participants
The PDN group was formed from attendees  at 
the diabetic neuropathic pain clinic at Chorley 
and South Ribble District General Hospital, 
while the control group (comprising people with 
diabetes not known to have neuropathic pain) 
was formed from individuals visiting the Aston 
Healthcare GP surgery at Whiston (Merseyside) 
for diabetes review. Each group consisted of 25 
consecutive consenting patients at the respective 
sites. Individuals under 16 or over 80 years 
of age were excluded from participation. All 
individuals gave consent for participation. 
Institutional approvals were obtained at both 
centres for the study.
Assessment of QoL, anxiety and depression
SF-36 (used for QoL assessment)
The SF-36 questions were scored from 0 (worst 
possible functioning) to 100 (highest level 
of function). The average scores from those 
questions that addressed each specific area of 
a functional health domain provided the final 
score for the domain. Aggregate scores were 
compiled as a percentage of the total points 
possible, using the RAND scoring system 
(RAND Health, 2014). 
Of the eight domains (described earlier), four 
relate to physical health (physical functioning, 
physical health limitation, pain and general 
health) and four to mental health (social 
functioning, emotional wellbeing, fatigue and 
emotional problem limitation). Aggregate scores 
for physical health domains and for mental 
health domains were also calculated.
HADS questionnaire (used for the 
assessment of anxiety and depression)
Each HADS question was scored from 0 
(excellent mental health) to 3 (worst mental 
health). Aggregate scores (with a maximum 
of 21) were calculated for the seven anxiety 
questions and the seven depression questions. 
Scores between 0 to 7 were considered “normal”, 
for both anxiety and depression assessment. 
Scores of 8 and above were considered to 
be significant for the diagnosis of anxiety 
or depression (el-Rufaie and Absood, 1987; 
Nortvedt et al, 2006).
Statistical analysis
Data were analysed using GraphPad software 
(GraphPad Software Inc, 2014). For the 
normally distributed continuous variables from 
SF-36 and HADS, means (± standard deviation 
[SD]) were calculated and analysed using the 
unpaired Student’s t-test. Categorical data were 
also calculated, as a percentage of participants. 
The categorical data from HADS were analysed 
as a 2x2 table using Fisher’s exact test.
For the purpose of visually summarising 
the data, box-plots were also created, using 
Minitab (2014) statistical software, and these 
represented median, minimum and maximum 
values, as well as  the lower and upper quartiles.
Page points
1. In this observational study, the 
36-item Short Form Health 
Survey was used the assessment 
of quality, while the Hospital 
Anxiety and Depression Scale 
was employed to explore 
specific aspects of mental 
health.
2. The painful diabetic neuropathy 
group was formed from 
attendees at the diabetic 
neuropathic pain clinic at 
Chorley and South Ribble 
District General Hospital, while 
the control group (comprising 
people with diabetes not known 
to have neuropathic pain) was 
formed from individuals visiting 
the Aston Healthcare GP 
surgery at Whiston (Merseyside) 
for diabetes review.
3. Each group consisted of 25 
consecutive consenting patients 
at the respective sites.
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Results
The two groups were similarly distributed 
(P>0.05) in age and also in sex (PDN group,  60% 
male; control group, 56% male). Participants in 
the PDN group had significantly (P<0.05) lower 
scores in seven out of eight domains of SF-36 
compared with the control group (Table 1). The 
exception was emotional wellbeing. Both physical 
health and mental health summary scores were 
significantly lower in the PDN group than the 
control group (Figure 1).
Individuals in the PDN group had 
significantly higher HADS anxiety scores, but 
HADS depression scores were not statistically 
significantly different from those in the control 
group (Figure 2).
Fourteen individuals (56%) out of 25 had 
anxiety in the PDN group (the mean score was 
7.32 ± 3.42). In the control group, five individuals 
(20%) met the criterion for a diagnosis of anxiety 
(the mean score was 4.72 ± 4.34). The P-values 
calculated from comparisons of the continuous 
data and of the categorical data were 0.023 and 
0.018, respectively (both statistically significant).
Fifteen people (60%) out of 25 had depression 
in PDN group (the mean score was 8.36 ± 4.05). 
In the control group, 11 people (44%) met the 
criterion for a diagnosis of depression (the mean 
score was 6.6 ± 4.16). The P-values calculated 
from comparisons of the continuous data and 
of the categorical data were 0.136 and 0.396, 
respectively (neither being statistically significant).
Discussion 
Few studies have specifically reported the impact 
of PDN on QoL and psychological wellbeing 
of people with diabetes (Benbow et al, 1998; 
Quattrini and Tesfaye, 1996; Galer et al, 2000; 
Gore et al, 2005; Argoff et al, 2006; Van Acker et 
al, 2009). Our data reveal a significant association 
of PDN with poor QoL and anxiety symptoms but 
not with depression. This last observation could 
be because a number of people with PDN were 
treated with antidepressants for their neuropathic 
pain, and the underlying symptoms of depression 
might have thus been reduced to some extent, or 
it could be down to insufficient power.
Comparison with existing data
The data from our study hint at a significant 
impairment of QoL associated with PDN within 
both the physical and mental health areas of the 
SF-36 questionnaire. The results are consistent with 
similar research reported using a shorter (12-item) 
version of the questionnaire. Van Acker et al (2009) 
found significant impairment in both the physical 
and mental health components of QoL. In another 
study, by Benbow et al (1998), the Nottingham 
Health Profile questionnaire was used, and it was 
found that there were significant impairments in QoL 
in five of the six domains (emotional reaction, energy, 
pain, physical mobility and sleep). The exception was 
the social isolation domain. Similarly, in the present 
study, the data showed significant impairment in all 
of the domains but one (emotional wellbeing).
Page points
1. Few studies have specifically 
reported the impact of painful 
diabetic neuropathy (PDN) 
on quality of life (QoL) and 
psychological wellbeing of 
people with diabetes
2. The authors’ data hint at an 
association of PDN with poor 
QoL and anxiety symptoms.
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SF-36 domain
Mean score in
PDN group
Mean score in 
control group
95% confidence 
interval
P-value
Physical functioning 28.4 65.2 18.9 to 54.7 <0.0001*
Physical health limitation 17.0 61.0 22.0 to 66.1 <0.0002*
Pain 29.3 59.9 14.2 to 47.0 <0.0005*
General health 31.1 52.0 7.3 to 34.6 0.0034*
Social functioning 48.8 68.0 2.0 to 36.4 0.0292*
Emotional wellbeing 61.4 69.3 -7.0 to 22.6 0.292
Fatigue 25.4 42.4 4.8 to 29.3 0.0073*
Emotional problem limitation 41.3 72.0 5.3 to 56.0 0.0188*
*P<0.05.
PDN=painful diabetic neuropathy.
Table 1. Data for the eight domains of the 36-item Short Form Health Survey (SF-36®) in the 
study groups.
As mentioned earlier, there are reports of severe 
PDN with constant unrelenting neuropathic 
pain, disturbance of sleep and even the loss 
of the ability to walk, owing to the severity of 
pain (Quattrini and Tesfaye, 1996; Galer et al, 
2000; Gardner and Shoback, 2007). This can in 
turn lead to withdrawal from routine activity of 
life, including employment, and can also affect 
emotional wellbeing and contribute to social 
isolation. The data for the emotional wellbeing 
domain in our study and the social isolation 
domain of Benbow et al (2000) study were not 
significant, perhaps owing to the presence of only 
a small number of the severe type of PDN case 
associated with extreme symptoms.
HADS data in the present study showed that 
more than half (56%) of the participants in the 
PDN group had anxiety symptoms, with this 
proportion (and the summarised continuous 
data) being statistically significantly different 
from those of the control group. The data were 
broadly consistent with those reported by Gore 
et al (2005), using the HADS questionnaire. 
They reported that 35% of their participants 
had anxiety symptoms. However, they used 
a threshold score on HADS of 11 or above 
(moderate-to-severe symptoms), while we used 
a threshold score of 8 and above. Our data for 
depression symptoms showed that more than 
half (60%) of the individuals in the PDN group 
had symptoms of depression (a score above 7). 
However, comparisons of the differences from the 
control group were not statistically significant. In 
contrast, Gore et al (2005) showed a significant 
association between PDN and depression. In 
their study, the prevalence of depression in people 
with PDN was 28% (a score of 11 or above).
A large systematic review and meta-analysis 
reported the prevalence of depression in people 
with diabetes to be around 17.5% (Ali et al, 
2006). In our study, the control group of people 
with diabetes was found to have an unusually 
high prevalence of depression (44%). This may be 
down to random  factors or could have resulted 
from the control group having been taken from 
an area of relatively low socioeconomic status.
Strengths and limitations of the study
The study population was well defined, and both 
groups of participants had a 100% response in 
completing the two questionnaires. The groups 
were similar in age and in the ratio of males to 
females.
Recall bias could potentially exist when 
participants are completing questionnaire. 
However, most questions from both 
questionnaires used were based on current or 
recent physical and mental wellbeing of the 
person, and hence recall bias is considered to 
have been minimal.
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Figure 1. A box-plot of the overall physical and mental health scores from the 36-item Short Form 
Health Survey in the painful diabetic neuropathy (PDN) and control (C) groups (boxes for median 
and lower and upper quartile values [with bars for minimum and  maximum score]; n=25). 
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Figure 2. A box-plot of the Hospital Anxiety and Depression Scale (HADS) scores in the painful 
diabetic neuropathy (PDN) and control (C) groups (boxes for median and lower and upper 
quartile values [with bars for minimum and  maximum score]; n=25).
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A major limitation of the study relates to the 
selection of the control group. As mentioned 
above, the GP surgery from which the control 
group data were taken lies in an area of north-
west England with a low socioeconomic status. 
It is known that low socioeconomic community 
status has a positive association with prevalence 
of depression (Murali and Oyebode, 2004). 
Furthermore, the two groups were selected from 
healthcare settings of a different nature. These 
discrepancies, and the lack of randomisation in 
the study, could thus have led to selection bias, 
which in turn could have had an impact on 
outcomes. Data were not collected to compare 
factors other than age and sex (duration of 
diabetes and the presence of other complications 
are among the other potential confounding 
factors). As with any non-randomised study, 
it is not possible to infer a causal relationship 
and thus our conclusions can only be tentative 
at most.
Conclusion
Overall, we believe our study tentatively suggests 
that, in a population in north-west England, 
PDN has a clinically significant impact on 
QoL and is also associated with symptoms of 
anxiety. Further research would be needed to 
shed more light on depression and to draw firmer 
conclusions on the potential causal nature of the 
association observed.
In light of our findings, we suggest that, when 
caring for people with PDN, clinicians should 
consider exploring psychosocial wellbeing and 
the overall impact of the condition on QoL. n
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The prevalence of diabetes is rising globally and, as a result, its associated complications are also rising. Painful diabetic neuropathy
(PDN) is a well-known complication of diabetes and themost common cause of all neuropathic pain. About one-third of all diabetes
patients suffer fromPDN. It has a huge effect on a person’s daily life, both physically andmentally. Despite huge advances in diabetes
and neurology, the exact mechanism of pain causation in PDN is still not clear.The origin of pain could be in the peripheral nerves
of the central nervous system. In this review, we discuss various possible mechanisms of the pathogenesis of pain in PDN. We
discuss the role of hyperglycaemia in altering the physiology of peripheral nerves. We also describe central mechanisms of pain.
1. Introduction
Diabetes affects 382 million people wordlwide and its preva-
lence is expected to increase to 592 million by the year
2035 [1]. Diabetic neuropathy, a well-known, long-term
complication of diabetes, can affect almost half of the diabetic
population [2] and is associated with higher morbidity and
mortality [3]. Diabetic neuropathy encompasses a variety of
clinical or subclinical presentations. Painful diabetic neu-
ropathy (PDN) is a common type of diabetic neuropathy
and the most common cause of neuropathic pain [4]. The
reported prevalence of PDN varied from 11% in Rochester,
Minnesota, USA [5], to 53.7% in the Middle East [6]. One
UK study published in 2011 reported that the prevalence of
PDNwas 21.5% in type 2 diabetes patients and 13.4% in type 1
diabetes patients, resulting in an overall prevalence of 21% [7].
In the large, prospective EURODIAB study in 16 European
countries, almost one-quarter of type 1 patients developed
new onset painful diabetic neuropathy over a seven-year
period [8]. A prospective study in Finland followed newly
diagnosed diabetes patients between the ages of 45 and 64
years for 10 years. It found a 6% prevalence at the time
of diagnosis of diabetes and a 26.4% prevalence at the 10-
year follow-up [9]. In a large UK-based community diabetic
population, Abbot et al. [7] observed that increasing age was
directly related to painful symptoms of neuropathy. Most
studies found no significant difference in gender; however,
Abbot et al. [7] reported a slightly higher prevalence of
painful symptoms of neuropathy in females (38%) than
males (31%). The same study also found a higher prevalence
of painful symptoms in South Asians (38%) compared to
Europeans (32%).
Painful diabetic neuropathy (PDN) symptoms exhibit a
symmetrical “stocking and gloves” distribution and are often
associated with nocturnal exacerbation. It can be presented
from a mild pins and needle sensation to stabbing, burning,
unremitting, or even unpleasant electric shock sensation.
There can be allodynia in the form of cutaneous hypersen-
sitivity leading to acute distress on contact with an external
stimulus, such as clothing [10]. The pain is often worse
at night and often disturbs sleep, causing tiredness during
the day. Some patients present with distressing allodynia
and severe pain in the legs. This may be so painful that it
prevents them from performing their daily activities, thereby
impacting their employment and social life. The constant,
unremitting pain and withdrawal from social life often result
in depression [11]. In extreme cases, patients lose their
appetite and experience significant weight loss, which is
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reported in the literature as “diabetic neuropathic cachexia”
[10].
2. Physiology of Pain
Pain is the body’s perception of actual or potential damage to
the nerve or tissue by noxious stimuli. The sensory afferent
nerves carry sensations from the skin, joints, and viscera
via large and small fibres. Large fibres, such as A-alpha, are
responsible for limb proprioception and A-beta fibres carry
sensations of limb proprioception, pressure, and vibration.
Large A-delta myelinated fibres and small C unmyelinated
fibres are mainly responsible for carrying nociceptive sen-
sations. Superficial pain is often a sharp or pricking sen-
sation and is transmitted by A-delta fibres. A deep-seated,
burning, itching, aching type of pain is often accompa-
nied with hyperalgesia and allodynia and is transmitted via
slow, unmyelinated C fibres. Tissue damage results in the
release of inflammatory chemicals, such as prostaglandins,
bradykinins, and histamines, at the site of inflammation,
which triggers the depolarization of nociceptors, thereby
generating an action potential.The action potential transmits
the nociceptive sensation, via the dorsal root ganglion (DRG),
to the dorsal horn of the spinal cord.The release of glutamate
and substance P results in the relay of nociceptive sensations
to the spinothalamic tract, thalamus, and, subsequently, the
cortex, where pain is interpreted and perceived [12].
Nociceptive pain is the normal response to noxious insult
or injury of tissues such as skin, muscles, visceral organs, and
joints. Nociceptive pain usually subsides upon the healing of
the tissue injury. On the other hand, neuropathic pain arises
as a direct consequence of a lesion or disease affecting the
somatosensory system without any noxious stimuli. Neuro-
pathic pain is caused by damage or pathological change and
is characterised by the activation of abnormal pathways of
pain at the peripheral nerves and posterior roots (peripheral
neuropathic pain) or spinal cord and brain (central pain) [13].
Neuropathic pain manifestation can be focal, multifocal, or
generalized depending on the involvement of peripheral or
central origin and cause of the disease. A few examples of
neuropathic pain are listed in Table 1.
3. Neuropathic Pain Generation Pathogenesis
Theorigin of pain in PDN is not fully understood.The abnor-
malities in the peripheral or central nervous system could
be related to hyperglycaemia, as this is the key metabolic
abnormality of diabetes.There aremany other conditions that
produce pain similar to that of PDNand theymay also aid our
understanding of the pathophysiology of PDN.
3.1. Ectopic Electrical Impulses. Chronic hyperglycemic dam-
age to the nerves can cause regeneration of nerve sprouts,
called neuromas, at the stump. The sprouting of the new
nerves in all directions causes collateral damage of otherwise
undamaged nerves and expands the sensitized area [14].
Hyperexcitability in the neuroma generates ectopic impulses
that affect neighbouring intact afferents and the cell bodies
Table 1: Examples of neuropathic pain.
Origin of pain Structure Example
Peripheral nervous
system
Central nervous system
Nerve
Dorsal root
Spinal cord
Thalamus
Diabetic painful
neuropathy
Neuroma
Phantom limb pain
Trigeminal neuralgia
Lumbosacral plexopathy
Postherpetic neuralgia
Brachial plexus avulsion
Spinal cord injury
Spinal cord infarction
Multiple sclerosis
Infarct
Tumour
Parkinson’s disease
of the DRG. It leads to spontaneous, exaggerated, abnormal
hyperexcited responses, along with increased sensitivity to
a given stimulus [15]. This phenomenon is called peripheral
sensitization. Electrical impulses from the axon of small fibres
at the dorsal horn of the spinal cord are increased and, hence,
it alters the “gate” (described below) and causes the release of
substance P and glutamate.This causes a relay of the impulses
to the ascending track, which is perceived as pain [16].
3.2. Change in Glucose Flux and Pain. Treatment of induced
acute neuropathy due to rapid glycemic control in the first
month of the initiation of insulin or oral hypoglycemic
agents has been reported in the literature as “insulin neuritis.”
In 1992, Boulton [17] first described the observation that
acute painful neuropathy might follow a sudden change in
glycaemia control, suggesting that blood glucose flux could
precipitate pain. This observation was experimentally tested
in rats by Kihara et al. in 1994 [18]. In their study, they infused
insulin under nonhypoglycemic conditions and evaluated its
effect on endoneurial oxygen tension, nerve blood flow, and
the oxyhaemoglobin dissociation curve of peripheral nerves
in normal and diabetic rats. Their results showed that insulin
administration caused a reduction in nerve nutritive blood
flow and an increase in arteriovenous shunt flow. When the
arteriovenous shunts were obliterated by the infusion of 5-
hydroxytryptamine, endoneurial oxygen reverted to normal.
Sudden changes in glycaemia may induce relative hypoxia in
nerve fibres, which contributes to the generation of impulses,
thereby indicating that it is the combination of structural and
functional changes in peripheral nerves that cause the pain.
In 1996, Tesfaye et al. [19] observed neurovascular
changes in vivo in five human diabetic patients with insulin
neuritis. These patients presented with severe sensory symp-
toms but clinical examination and electrophysiological tests
were normal, except in one subject who had severe autonomic
neuropathy. On sural nerve exposure in vivo, epineural
blood vessels showed severe structural abnormalities resem-
bling the retinopathy changes normally seen in the retina,
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Figure 1: Arteriolar attenuation (A), tortuosity (B), arteriovenous
shunting (C), and proliferation of newly formed vessels (D) of the
vasa nervosum seen in the sural nerve of a patient with insulin
neuritis (photo courtesy of Tesfaye).
including arteriolar attenuation, tortuosity, arteriovenous
shunting, and the proliferation of newly formed vessels.They
hypothesized that the structural abnormalities in epineural
blood vessels, together with the formation of new vessels,
caused a steal effect and, hence, resulted in hypoxia and
neuropathic pain. It can now be postulated that a sudden
change in glycemic control can cause flux effects that result
in structural and functional changes in the epineural blood
vessels of nerves, which, in turn, can lead to neuropathic
pain or “insulin neuritis” [17, 19] (Figure 1). Symptoms can be
mild and often go unreported but may present with severe,
excruciating neuropathic pain. Symptoms usually last up to
six months and respond to treatment that is usually needed
for up to six months [10].
3.3. Role of the Dorsal Root Ganglion in Neuropathic Pain.
The expression of voltage-gated sodium and calcium chan-
nels and voltage-independent potassium channels in the
DRG has a significant role in the generation of nociceptive
sensation and peripheral sensitization that leads to central
sensitization. Hyperexcited ectopic impulses are generated
by the expression of various voltage-gated sodium channels,
such as Nav1.3, Nav1.7, and Nav1.8 [20]. The voltage-gated
sodium channel Nav1.3 probably plays a key role in the
development of neuropathic pain [21]. Amir et al. described
after nerve injury, in theDRG, the fact that there is a sustained
phasic discharge that results in repeated firing [22]. The
voltage-dependent sodium channel alternates with a voltage-
independent potassium leak to oscillate membrane poten-
tials. When these oscillations reach the threshold amplitude,
they result in the generation of ectopic impulses and, hence,
lead to sustained peripheral sensitization [23]. In addition to
the voltage-gated sodium channels, the expression of voltage-
gated calcium channels was also found in neuropathic pain
[24]; specifically subtype Cav 3.2 is highly expressed in
DRG neurons and showed strong correlation with allodynia
[25]. Calcium entry through voltage-gated calcium channels
causes the release of substance P and glutamate, which results
in the modulation of pain at the dorsal horn [26]. The
upregulation of transient receptor potential expression is also
found to be associated with neuropathic pain. Studies found
a direct relationship between TRPV1 (transient receptor
potential vanilloid 1) and neuropathic pain. A few animal
studies suggest that hyperalgesia does not develop in TRPV1-
deficient mice and TRPV1 antagonists reduce pain behaviour
in mice [27, 28].
3.4. Methylglyoxal and Pain. Methylglyoxal (MG) is a reac-
tive intracellular by-product of several metabolic pathways.
However, the most important source of MG is glycolysis and
hyperglycaemia [29]. Studies found that PDN patients had
significantly higher concentration of plasma MG (>600 nM)
compared to healthy control or diabetes patients without pain
[30, 31]. MG depolarizes the sensory neuron by activating
TRPV1 in the DRG [32] and also induces posttranslational
modification of the voltage-gated sodium channel Nav1.8
[30]. These changes are associated with increased electrical
excitability and facilitate firing of nociceptive neurons.
3.5. Sympathetic Modulation of Pain. Nociceptive A-delta
and C fibres are normally not directly connected to
sympathetic nervous system. Several experiments using
𝛼-adrenoreceptor agonists found that it did not activate
sympathetic neurons at nociceptor fibres under normal con-
ditions [33, 34]. It is widely accepted that the sympathetic
nervous system does not activate the sensory nervous system
under normal conditions.
Neuropathy causes hypersensitivity in nerves as a result
of an abnormal epinephrine-mediated transmission from
one axon to another. This unusual connection is called
ephaptic transmission or cross-talk [35]. It was also noted
that damaged nerves in the periphery also cause basket
formation, called sympathetic sprouting in the DRG, which
results in the release of noradrenaline [36]. Both sympathetic
sprouting and ephaptic transmission release adrenaline and
cause sympathetic-sensory coupling.This leads to an increase
in ectopic and spontaneous firing.This unusual connection is
called sympathetically maintained pain.
Several studies proved this hypothesis and showed dra-
matic improvement in pain relief after sympathetic block-
age [37], sympathectomy [38], or temporary blockage with
𝛼-adrenergic antagonists with intravenous phentolamine
[39].
3.6. Gate Control Theory. In 1965, Melzak and Wall [40]
described, for the first time, the fact that nervous connections
from the peripheral to central nervous system and to the
brain are not a seamless transmission of information. They
described the gate mechanism at the dorsal horn of the spinal
cord, which inhibits or facilitates the flow of afferent impulses
fromperipheral nerves to the spinal cord before it evokes pain
perception.The activity at the gate is primarily dependent on
the transmission of impulses along small or large nerve fibres.
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Small nerve fibres, unmyelinated C fibres, and myelinated A-
delta fibres tend to open the gate and large A-beta fibres tend
to close the gate. Opening and closing of the gate depend on
the number of input impulses.Thus, if nociceptive input from
C- and A-delta fibres exceeds A-beta fibre input, then the gate
is open and nociceptive impulses ascend to the spinal cord.
On the other hand, if A-beta fibre input (touch, vibration,
and pressure) exceeds that of C- and A-delta fibre input
(pain), then the gate is closed; nociceptive impulses only pass
through when the gate is open. The classic example of this
phenomenon is the rubbing of an injured site immediately
after suffering from trauma, which results in gate closure.
3.7. Central Sensitization. Central sensitization was first
described by Woolf in 1983. Nonnoxious stimuli transmitted
from the periphery with A-beta fibres (touch) were perceived
as painful by patients with allodynia [41]. A-delta fibres and
C fibres are innervated in laminae I-II and A-delta fibres also
are innervated in laminaV of the dorsal horn.Themajority of
spinal cord neurons that express the substance P receptor are
located in lamina I or have their cell bodies in laminae III-IV
but extend their dendrites to lamina I. The pain mediation
of noxious stimuli occurs by releasing substance P, mainly
in lamina I of the dorsal horn. A-beta fibres are innervated
deep in laminae III to V and are responsible for touch
mediation [42–44]. Peripheral sensitization and sustained
hyperexcited impulses at the dorsal horn cause an increase in
responsiveness to noxious and nonnoxious stimulation. This
was believed to be due to the structural plasticity of sprouting
of A-beta fibres, which leads to “rewiring” of the dorsal horn
laminae in the central nervous system (CNS) [44]. As a result,
the CNS pathway, which is responsible for transmitting only
nonnoxious stimuli (touch), was replaced by sprouting A-
beta fibres that transmit nonnoxious impulses and release
substance P in the dorsal horn, thereby mediating allodynia
[45]. This hypothesis was mainly based on experiments
that showed that the uptake of the cholera toxin B (CTB)
subunit, which is a selective tracer for large myelinated A-
fibres, terminated in lamina II [46]. The selectivity of this
toxin after peripheral nerve injury is somewhat controversial.
Experiments demonstrated that uptake of the CTB tracer
was not selective, that CTB was found in axons of all types,
including A-delta fibres and C fibres, and that the CTB
tracer incorporated in C fibres that terminated in lamina II
[47]. This contradicts the hypothesis of structural plasticity
and A-beta fibres sprouting in lamina II. However, studies
with immunostaining and electrophysiological recordings
have clearly established that peripheral nerve injury causes
large myelinated fibres to begin to drive nociceptive neu-
rons in superficial lamina [48, 49]. The persistent incoming
nerve impulses lead to activation of N-methyl-D-aspartate
(NMDA) receptors on postsynaptic membranes in the dorsal
horn of the spinal cord. This leads to the release and binding
of glutamate (an excitatory neurotransmitter), which causes
an influx of sodium and calcium and an efflux of potassium.
This generates a larger postsynaptic action potential and
augments the perception of normal stimuli, thereby resulting
in allodynia [50].
3.8. Central Inhibition. Impulses from the brainstem nuclei
descend to the spinal cord and influence the transmission
of pain signals at the dorsal horn. The periaqueductal grey
matter (PAG), locus coeruleus, the nucleus raphe magnus,
and several bulbar nuclei of reticular formation give rise to
descending modulatory pathways. These pathways dampen
or enhance the pain signal. The projections from the nucleus
raphe magnus to the spinal cord are the major source of
serotonin in the spinal cord. Exogenous opioids imitate the
endogenous opioids and induce analgesia by acting upon the
PAG, reticular formation, and the spinal dorsal horn [12].
The antidepressant serotonin and norepinephrine reuptake
inhibitors (SNRIs) [51] and opioids [52] have been found to
be beneficial in the treatment of neuropathic pain as these
medications increase the availability of these neurotrans-
mitters and, hence, increase inhibition at the spinal cord.
Psychological factors, such as fear and anxiety, can influence
the inhibitory mechanism through the modulatory system.
Cognitive behavioural therapies are thought to be beneficial
in modulating the pain by reducing the fear and anxiety [53].
3.9. Thalamic Abnormalities. The nociceptive hyperexcited
impulse generated within primary afferent nerves is modu-
lated and amplified not only at the DRG-spinal cord level but
also at the thalamic ventral posterolateral (VPL) level, before
being relayed to the cerebral cortex. This was experimentally
proved in streptozosin rat model with PDN. The experiment
demonstrated hyperexcitability in thalamic VPL neurons,
with increased responses to phasic brush, press, and pinch
stimuli applied to peripheral receptive fields. VPL neurons
from diabetic rats also displayed enhanced spontaneous
activity, independent of ascending afferent impulses, and
enlarged receptive fields [54]. Selvarajah et al. [55] investi-
gated this further in humans using a magnetic resonance
(MR) perfusion scan in patients with PDN. This study
demonstrated increased thalamic vascularity and sluggish
blood flow. Similar vascular perfusion findings were also
observed at the sural nerve in patients with PDN [56]. It was
suggested that increased perfusion at thalamus VPL neurons
in PDN patients causes an increase in neuronal activity and,
hence, further modulates pain and central sensitization.
3.10. Chronic Neuropathic Pain and Plasticity of Brain. Neu-
roplasticity or plasticity of the brain is the term used to
describe the adaptive change in structure, chemical bal-
ance, and function of the brain in response to changes
within the body or in the external environment. In response
to chronic neuropathic pain, neuroplasticity is associated
with somatosensory cortex remodelling, reorganization, and
hyperexcitability in the absence of external stimuli. A study of
patients with chronic neuropathic and nonneuropathic pain
using functional and anatomicalmagnetic resonance imaging
found cortical reorganization and changes in somatosensory
cortex activity only in the neuropathic pain group [57].
Provoked pain and spontaneous stimuli may reverse the
remodelling and reorganization at the somatosensory cortex.
Studies have shown a beneficial effect of pain relief with
transcranial magnetic stimulation (TMS) and transcranial
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direct current stimulation (tDCS), which suggests a reversal
of plasticity [58, 59].
4. Conclusion
In summary, the exact mechanism of pain in PDN is far
from being clear. The source of pain could be anywhere in
the pathway from the damaged nerves to the somatosensory
cortex or it could be due to a combination of pathologies.
PDN is a distressing condition and, as a result, adversely
affects a patient’s quality of life, both physically and mentally.
Despite significant advances in therapeutics, the treatment
of chronic symptoms of pain in PDN is still suboptimal
and challenging for clinicians [11, 60]. This may be due to
a poor understanding of the pathogenesis of PDN. There is
an increasing body of evidence that suggests that the central
nervous system is primarily responsible for maintaining
painful symptoms. In recent years, there have been significant
advances in the neuroimaging of pain. Further research is
needed to have a better understanding of the disease process
of PDN, which will help to tackle this enormous challenge.
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Abdominal Pain and Weight Loss in New-Onset 
Type 1 Diabetes
Amir Aslam, MBBS, MRCP, MRCGP, Joanne Byrne, BSc, DSN,  
and Satyan M. Rajbhandari, MBBS, MD, FRCP London, FRCP Edin
Patients who are newly diag-nosed with type 1 diabetes are routinely counseled by their 
health care professionals to make 
lifestyle changes and take other 
measures to improve their glyce-
mic control and prevent long-term 
complications. However, the rapid 
achievement of metabolic control 
can lead to unforeseen consequences. 
We recently identified one such 
case, in which rapid improvement in 
metabolic control precipitated insulin 
neuritis with associated weight loss, 
resulting in extensive and unnecessary 
investigations. 
PRESENTATION 
A 31-year-old man presented to our 
hospital emergency department with 
new-onset type 1 diabetes compli-
cated by ketoacidosis. He responded 
to intravenous fluids and insulin and 
was discharge on day 2 on a basal-
bolus insulin regimen using premeal 
insulin aspart three times daily and 
insulin detemir at bedtime.
Under the supervision of a diabetes 
specialist nurse, his metabolic control 
improved, with self-monitoring of 
blood glucose results between 90 and 
126 mg/dl. The patient did, how-
ever, develop severe right-side lower 
abdominal pain that was associated 
with weight loss and was accordingly 
referred to a gastroenterologist. Testing 
was performed to exclude celiac dis-
ease, and the patient also underwent 
numerous tests including urine culture, 
abdominal ultrasound, CT scan of the 
abdomen, colonoscopy, and barium 
meal follow-through, all of which 
yielded normal or negative results. 
The patient was seen in the diabe-
tes clinic 2 months after the episode 
of ketoacidosis and still complained 
of sharp pain over his right side. 
There was no aggravating factor, but 
he reported nocturnal exacerbation 
of pain that disturbed his sleep.
It transpired that his appetite had 
reduced, and he had lost ~ 15 lb in 
weight since his diagnosis, despite 
having good glycemic control. His 
A1C had fallen from 14.4 to 7.1% 
within that 2-month period. During 
the consultation, he denied body 
image problems or excessive exercise 
or self-induced vomiting. On further 
examination, he had mild tenderness 
over the right iliac fossa region and 
had altered sensation in the derma-
tome supplied by the right T12 and 
L1 nerve root. He was diagnosed with 
“truncal neuropthy” due to “insulin 
neuritis” causing pain and cachexia.
The patient was prescribed ami-
triptyline, 25 mg at night, with the 
dose gradually increasing to 75 mg. 
His pain and appetite improved, and 
he gained 13 lb within a month. 
QUESTIONS
1. Should blood glucose be lowered 
gradually in all cases to avoid 
“insulin neuritis?” 
2. Is there any association between 
weight loss and “truncal 
neuropathy?”
3. Could the patient in this case 
have had an underlying behavior 
disorder? 
4. Were all of the invasive investi-
gations performed in this case 
necessary for a 31-year-old man?
COMMENTARY
Acute neuropathy resulting from 
rapid glycemic control has been 
reported in literature as “insulin 
neuritis” that usually manifests with 
severe excruciating neuropathic pain 
in the first month of insulin therapy. 
Symptoms can last up to 6 months 
and respond to treatment, which is 
usually required for a similar period.1 
In one observational study,2 six 
patients with diabetes experienced 
severe neuropathic pain, mostly in 
their feet. The pain started within 
2–4 weeks of initiation of intensive 
diabetes therapy, during which blood 
glucose levels dropped up to one-fifth 
of initial levels.
The patient in this case developed 
localized pain in his abdominal wall 
within 4 weeks of rapid correction 
of blood glucose. Similar abdomi-
nal wall pain has been reported 
after rapid reduction of A1C from 
12 to 7.5% in a patient with type 2 
diabetes.3 
Development of acute painful 
neuropathy after rapid glycemic con-
trol suggests that blood glucose flux 
is responsible for the pain.4 Tesfaye 
et al.5 elegantly demonstrated several 
structural abnormalities in the sural 
nerve, including arteriolar attenua-
tion, tortuosity, and arterio-venous 
shunting with new vessel formation 
in patients with insulin neuritis. 
The combination of structural and 
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functional changes in the nerves is 
possibly the cause of neuropathic 
pain in insulin neuritis.4
Our patient experienced weight 
loss associated with neuropathic 
pain, which resulted in a number of 
clinical investigations. Weight loss 
associated with painful diabetic 
neuropathy has been reported in the 
literature as “diabetic neuropathic 
cachexia,” which can last up to 1 
year. Most patients respond well to 
neuropathic pain treatment, which 
provides pain relief and assists in 
increasing weight. The exact mecha-
nism and cause are unknown.1
In one observational study,6 nine 
patients with diabetes reported 
to have painful neuropathy with 
constant discomfort, and profound 
weight loss was noted, along with 
depression and impotence. The 
severe manifestation subsided in all 
cases within 10 months and in most 
cases within 6 months. One case has 
been reported7 in which the patient 
presented with profound weight loss 
associated with painful neuropathy 
in the abdomen, as was the case with 
our patient.
The abdominal pain in our case 
resulted from truncal neuropathy, a 
condition that manifests with neuro-
pathic pain such as a hypoesthesia, 
regional hyperalgesia, allodynia, and 
sometime focal weakness in a spe-
cific dermatome region.1,8 The onset 
is sub-acute, and symptoms are usu-
ally unilateral but can be bilateral.
There are many possible causes 
of pain in the abdominal or tho-
racic wall; thus, patients with such 
symptoms often undergo numerous 
investigations.8–10 There are several 
cases in which investigations led to 
a misdiagnosis of hernia, angina, or 
choledocholithiasis, with patients 
subsequently failing to respond to 
treatment for those conditions.8,9,11
The diagnosis of truncal neuropa-
thy is made on clinical grounds with 
a good history and physical exami-
nation. The pain is neuropathic in 
character (i.e., burning and stab-
bing), localized to a dermatome, and 
often associated with altered sensa-
tion.8 Most people respond well to 
neuropathic treatment within 3–12 
months. 
CLINICAL PEARLS
•	 Rapid correction of blood glucose 
can cause insulin neuritis that can 
presents as neuropathic pain. 
•	 Neuropathic pain can be associ-
ated with weight loss. 
•	 Neuropathic pain localized to the 
thoracic or abdominal wall on 
one side is due to truncal neuritis. 
This is often missed and leads to 
extensive investigations, the results 
of which are usually normal.
•	 Most patients with insulin neuritis 
and truncal neuropathy respond 
well to specific treatment for pain-
ful neuropathy.
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Depression is more common in subjects with diabetes 
amongst general practice attendees 
A Aslam1,2,3, J Singh2, SM Rajbhandari1,2
1Lancashire Hospitals NHS Trust, Chorley District General Hospital, Chorley, UK. 
2University of Central Lancashire, Preston, UK. 
3Aston Healthcare, Whiston Primary Care Resource Centre, Whiston, UK
Globally the mortality from heart attack and stroke has declined due to better treatments as a result we are living 
longer with chronic health conditions (CHC). 
Diabetes is a major chronic health condition currently affecting more than 350 million people worldwide and its 
prevalence is rising day by day. 
The main aim of this study was to compare the frequency of depression between subjects attending diabetes clinic 
(DM group) and other clinic (C group) in a busy general practice. 
This was a prospective audit to study prevalence of depression using Hospital Anxiety and Depression Scale 
(HADS) in general practice setting. 25 adult subjects with diabetes [mean age 51 +/-14 years standard deviation 
(SD); 56%: Males], who attended for diabetes review and 25 adult subjects who attended other clinic [mean Age 
49, +/- 13 years (SD); 52% Males] self-completed HADS questionnaire. 
The results were analysed using Fisher’s exact test. 
11 subjects (44%) out of the 25 were diagnosed with depression in DM group (mean score 6.60 and SD 4.16) 
compared to only 3 subjects (12%) in the C group (mean score 3.20 and SD 3.06 (P < 0.0255).  
It is estimated about 1/3rd of CHC people are suffering from underlying depression. 
The frequency of depression was significantly higher in DM group and found to be more than 3 times compared to 
C group. 
Clinicians should consider screening for underlying depression when diabetes patients attend surgery.  
Background and Aim:
Method:
Results:
Conclusions:
Comparison of frequency of depression HADS score comparison
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(n=25)
C Group
(n=25)
Percentage of subjects with depression
P < 0.0255
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SD 4.16
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SD 3.06
C Group  (n=25)DM Group  (n=25)
Mean age 51 +/- 14 years (SD)
Male 56%, Female 44%
Mean age 49 +/- 13 years (SD)
Male 52%, Female 48%
Mean Score
Lancashire Hospitals
NHS Trust
Other Clinic
(C group)
Diabetes Clinic
subject
(DM group)
44%
12%
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Case history
A 66-year-old woman with childhood
onset type 1 diabetes, complicated
by blindness due to retinopathy and
early vascular dementia following
cerebrovascular accident, had chal-
lenging behaviour towards health
care professionals. She lived alone
with family support and was inde-
pendently mobile. She managed her
own blood glucose testing and
insulin injections, but had an inap-
propriately fixed idea about the 
dose and type of insulin. She was
admitted to the hospital six times
with diabetic ketoacidosis (DKA) in
one year. On one occasion when
admitted due to  DKA, she needed
intensive treatment in the critical
care unit.
After one of her admissions for
DKA treatment she was discharged
with an increased package of care,
which included diabetes specialist
nurse input in the community and
district nurses administering long-
acting insulin on a daily basis.
Unfortunately, she was admitted
again with DKA because she refused
to open the door to district nurses
and so missed her insulin injections.
Following that episode, she was 
discharged to a care home for all
insulin to be administered by staff.
In the care home, she became ver-
bally abusive and screamed, wanting
to go home. She was assessed by a
psychiatrist and it was found that she
had some degree of dementia, with
no insight regarding diabetes, but
was deemed to have capacity to
make her own decision about going
home. She was therefore allowed
home, and it took only a few days
before she was readmitted with DKA.
After recovering, she wanted to go
home against medical advice.
On questioning, she was found to
have no capacity to understand
about the life-threatening conse-
quences of not taking insulin. In her
best interests, she had to be deprived
of her liberty and was started on
once-daily treatment with long-act-
ing insulin against her wishes. In
view of this, the treating team
applied to the local primary care
trust (PCT) for authorisation for
deprivation of liberty safeguards
(DoLS) assessment. She had the
Deprivation of liberty to safeguard
against recurrent ketoacidosis
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Advances in medical treatment have resulted in prolonged survival of people with diabetes,
with multiple complications. Vascular dementia is one of these and is increasingly seen due to
a reduction in mortality from cardiovascular causes. People suffering from dementia are often
not capable of weighing up the advantages and disadvantages of proposed treatment in order
to give an informed decision. In most cases, this incapacity does not cause problems as
patients and their carers agree with the recommendation made by their health care
professionals. However, we encountered a challenging case where we had to apply for
deprivation of liberty safeguards (DoLS) to treat in the patient’s best interests. 
We report the case of a patient with vascular dementia who had repeated admissions
with life-threatening diabetic ketoacidosis (DKA) as she refused to comply with the insulin
treatment because of her lack of insight regarding her diabetes care. In order to prevent harm
to her, an application was successfully made for DoLS. This allowed treatment with once-daily,
long-acting analogue insulin under supervision even against her wishes. This prevented further
admission to hospital with DKA. 
DoLS was introduced in the UK in April 2009 to safeguard some of the most vulnerable
people in our society for their own safety. People with type 1 diabetes are increasingly surviving
longer and may suffer from dementia. The majority will manage with some help from family or
health care worker, but in a small proportion DoLS may be needed, as in our case, to prevent
recurrent life-threatening complications. Copyright © 2013 John Wiley & Sons.
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DoLS assessment including mental
capacity and best interests assess-
ment, and, later on, a best interests
meeting with the medical team, the
nursing team, a family representa-
tive, PCT representative, social
worker, best interests assessor, and
general practitioner. It was agreed
that she had no capacity to make
decisions about her treatment and
care needs. The local authority
authorised the DoLS in the patient’s
best interests for once-daily, fixed-
dose, long-acting analogue insulin
along with finger prick blood test for
glucose even against her wishes. She
was transferred to a care home
where nursing staff injected daily
insulin which she could not refuse,
and she did not have any further
admissions with DKA. 
Deprivation of liberty
Depriving liberty from someone who
lacks the capacity to consent to the
arrangements made for their care or
treatment is a serious matter. The
DoLS makes it clear that a person
may only be deprived of their liberty:
in their own best interests to protect
them from harm if it is a propor-
tionate response to the likelihood
and seriousness of the harm; and if
there is no less restrictive alternative.
DoLS must not be used as a form of
punishment, or for the convenience
of professionals, carers or anyone
else. It should not be extended due
to delays in moving people between
care or treatment settings. DoLS
does not occur in every case where
an individual lacks capacity to make
decisions. In deciding whether or
not application is necessary, the
managing authority (hospital or
care home) should carefully con-
sider whether any restrictions that
will be needed to provide ongoing
care or treatment amount to a 
deprivation of liberty.1
DoLS was introduced to prevent
breaches of the ECHR (European
Convention on Human Rights) 
after a court case of HL vs United
Kingdom.2 HL, an autistic man with
learning disability, had no capacity to
make any decision about his treat-
ment or hospital admission. He was
admitted to a psychiatric hospital on
an informal basis under common law
but was prevented from leaving the
hospital with his carers. His carers
challenged this in the European
Court of Human Rights; the judge-
ment held that the informal hospital
admission constituted a deprivation
of HL’s liberty and, further, that the
deprivation of liberty had not been
in accordance with the procedure
prescribed by law, therefore in
breach of Article 5(1) of the ECHR.3
This led to the introduction of DoLS
in the UK in April 2009.4
Deprivation of liberty safeguards:
application process
The managing authority (hospital or
care home) has to apply to the super-
visory body (PCT, local authority or
Welsh minister) for the assessment to
get lawful authorisation to deprive 
liberty. A standard authorisation can
be applied for when the managing
authority feels that it is highly 
likely that the patient’s liberty will 
be deprived in the next 28 days.
However, in circumstances where
there is no time to wait for standard
authorisation, the managing author-
ity can issue urgent authorisation
themselves, which lasts for seven days,
and at the same time apply for 
standard authorisation. This should
be assessed within the timeframe of
urgent authorisation. Standard autho-
risation assessment must be com-
pleted by the supervisory body within
21 days of application, and urgent
authorisation assessment should be
completed before its expiry. The
supervisory body only authorises 
deprivation of liberty when they are
satisfied with the following:1
• The person should be at least 18
years of age or older.
• The person should have a mental
disorder – including dementia,
learning disability, or certain neuro-
logical brain disorders (e.g. as a
result of brain injury).
• The person lacks capacity to
decide treatment or residence.5
• It should be in the best interests of
the person to deprive liberty in order
to prevent the likelihood and serious-
ness of the harm. The best interests
assessor should seek the views of
those interested in the care and 
welfare of the person such as family
carers or close relatives; if no-one can
represent on the patient’s behalf,
then the managing authority should
apply for an Independent Mental
Capacity Advocate to represent and
provide help about continued use 
of safeguards.
• The person is not eligible for 
deprivation of liberty authorisation
if they need treatment for mental
health for which they should be
detained under the Mental Health
Act 1983.
• There is no existing authority for
decision making for that person
which would conflict with depriva-
tion of liberty authorisation such as
an advanced directive made by the
person for refusal of particular
treatment.
If all of the above assessments sup-
port the authorisation of DoLS, then
the best interests assessor recom-
mends authorisation to the person’s
appointed representative. If there is
any doubt or contradiction regard-
ing the decisions, there is the right
to apply for Court of Protection
which has the power to terminate
authorisation or vary conditions. If
there is no conflict, the managing
authority implements DoLS. The
maximum duration of authorisation
is 12 months. Reapplication by the
managing authority is necessary
before the authorisation expires if it
is still deemed to be necessary.1
Discussion
People with diabetes have a 2.5 times
higher risk of developing dementia.6
In one prospective study of 1262
patients followed up for 4.3 years,
the adjusted relative risk of stroke-
associated dementia in patients 
with diabetes was 3.4 times higher.7
Various neurophysiological and
structural changes have been
described in subjects with type 1 dia-
betes;8,9 however, there is a paucity
of literature regarding an associa-
tion between type 1 diabetes and
dementia. The Rotterdam study on
6330 participants found a 3.2 times
higher prevalence of dementia in
diabetes subjects treated with
insulin.10 This problem is likely to
increase as the survival of people
with type 1 diabetes is improv-
ing.11,12 Patients with dementia 
often fail to remember to take their
prescribed medications. One of the
consequences of missing insulin in
type 1 diabetes could be life-threat-
ening DKA. This can be prevented
by special reminders, supervision by
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family members or administration
by health care professionals. Most of
the time, dementia patients and
their families concur with the treat-
ment plan; however, if a situation
arises when either the patient or
their family disagree, the treating
team needs to consider applying
DoLS in order to prevent harm in
the best interests of the patient.
Therefore, health care professionals
managing type 1 diabetes need to 
be aware of DoLS and related 
legal issues.
We applied for DoLS in our
patient as she was neither taking her
insulin nor allowing anyone to give it
to her, which resulted in multiple
episodes of life-threatening DKA.
Due to vascular dementia, she did
not have any insight into the 
dangers of not taking insulin. Both
the treating team and her family
agreed on DoLS, and there were no
advanced directives. Consequently,
DoLS was authorised for the use of
long-acting insulin once a day along
with daily blood glucose monitoring,
which prevented further admissions
with diabetic ketoacidosis. 
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l Patients with type 1 diabetes are
increasingly surviving longer and
developing complications such as
vascular dementia
l Vascular dementia makes it difficult for
the patient to understand the need for
insulin to prevent diabetic ketoacidosis 
l Deprivation of liberty safeguards (DoLS)
can be applied for from the local
authority in order to ensure these
patients take insulin under supervision,
thus preventing diabetic ketoacidosis
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